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(-)-Agelastatin A (1) is a tetracyclic alkaloid recently isolated from the marine sponge 
Agelas dendromorpha. It has powerful antitumour properties in vitro and in vivo, and is a 
selective inhibitor of the ubiquitous enzyme, glycogen synthase kinase 3(3. It also exhibits 
insecticidal properties.
In this thesis, we describe an enantiospecific total synthesis of the cyclopentenone (-)- 
175, an advanced intermediate whose racemate had previously been converted into (±)- 
agelastatin A by Weinreb and co-workers. Our strategy exploited the chiral oxazolidinone 150 
as a key intermediate, and commenced from the Hough-Richardson aziridine 234 (which is 
itself obtainable from D-glucosamine hydrochloride). Noteworthy reactions in the route to 150 
include the regioselective trans-diaxial ring-opening of 234 with azide ion to set up the vicinal 
diamido functionality present in (-)-175, and the Grubbs-Hoveyda ring-closing metathesis 
reaction that is used to fashion its cyclopentene core.
We also describe a new synthetic endgame for converting (-)-150 to (-)-agelastatin A 
via cyclopentenone 307.
This new endgame has so far allowed 223 mg of (-)-agelastatin A to be prepared for 
detailed toxicological and biological evaluation. Some of the results of these studies are 
presented in this thesis.
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Chapter 1: The Agelastatins and Related Marine Alkaloids
Chapter 1: The Agelastatins and Related 
Marine Alkaloids
The utility of natural products as sources of novel structures for the discovery and the 
development of drug candidates is well established. A recent review by Newman and co­
workers indicates that, in the area of cancer, over 60% of the drugs approved by the Food and 
Drug Administration over the period 1981-2002 could be traced back to a source of natural 
origin.1 The diversity of the structures presented to us by Nature is well beyond the scope of 
the human mind, and this probably justifies the efforts made for the isolation and the structure 
elucidation of new compounds of natural origin.
1.1. Isolation of the Agelastatins
(-)-Agelastatin A (1, Figure 1) is an alkaloid of unprecedented structure, isolated by 
Pietra and co-workers from the marine sponge Agelas dendromorpha (order Axinellida, family 
Agelasidae), collected by dredging in the Coral Sea off New Caledonia.2 Its absolute 
configuration, deduced by a combination of NMFt and circular dichroism studies,3 was assigned 
to be (5aS, 5bS, 8aS, 9aR). In the crude extract, agelastatin A cannot be separated from its 
dibrominated analogue, (-)-agelastatin B (ca. 20% in weight) (2, Figure 1). More recenltly, 
Molinski and co-workers reported the isolation of two additional congeners of the agelastatin 
family, (-)-agelastatin C and (-)-agelastatin D (3 and 4, Figure 1), from the West Australian 
sponge Cymbastella sp.4 (-)-Agelastatin C features an additional 5b-hydroxyl group, whereas 
(-)-agelastatin D lacks the AAmethyl group.
>NH
NH
NH
NHNH
'NH5b 6
1 2 3 4
(-)-Ageiastatin A (-)-Agelastatin B (-)-Agelastatin C (-)-Agelastatm D
Figure 1. Structure of the agelastatin family members
1.2. Biological Properties of the Agelastatins
(-)-Agelastatin A has powerful cyotoxic effects against various tumour cell lines. 
Growth-inhibition tests for (-)-agelastatin A, and some of its semi-synthetic derivatives, were 
performed on an L1210 murine lymphocytic leukemia cell line and a subline that was resistant
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to doxorubicin (L1210/Dx) . 5 Similar assays were performed on a human KB nasopharyngeal 
cancer cell line. The results (Table 1) were expressed in terms of IC50 values (test compound 
dose causing 50% inhibition of cell growth in treated cultures relatively to untreated control).
Table 1. Cytotoxicity data (IC50, pg/mL) against L1210, L1210/Dx, and KB tumour cells in vitro for (-)-
agelastatin A and some of its derivatives
L1210
I C 5 0
L1210/DX
I C 5 0
Resistance Index
(ratio between IC50 
values for L1210/Dx 
cells vs. L1210 cells)
KB
I C 5 0
(-)-Agelastatin A 0.033 0.469 14.0 0.075
(-)-Agelastatin B > 1 > 1 - > 1 0
(-)-Debromo-agelastatin A 0.143 2 .1 1 14.7 -
Doxorubicin 0.014 0.548 38.8 -
The data obtained so far have demonstrated that the monobrominated pyrrole ring 
system is optimal for cytotoxic activity. Cytotoxicity declines on alkylating or acylating any one 
of the N(5), N(6 ), or C(8 a)-OH groups. Inversion of the C(5b)-C(8a) ring-junction 
stereochemistry also leads to a 3 to 4-fold decrease in antitumour activity, which suggest that 
there is a strict configurational requirement for the cytotoxicity.
In vivo toxicity of (-)-agelastatin A was evaluated by intraperitoneal (/.p.) and intra­
venous (i.v.) administration of the natural product in mice inoculated with L1210 murine 
leukemia. The activity was evaluated in terms of percentage increase in median survival times 
in comparison with untreated controls. Increase of survival time was 63% at the dose of 2.6 
mg/kg, after repeated /'.p. administration; no activity was found after single or repeated i.v. 
administration.
The arthropod toxicity of (-)-agelastatin A was evaluated by Molinski et a l*  They 
observed that it was highly toxic towards brine shrimp. Dose-response measurements against 
newly hatched brine shrimp gave an LC50 of 5.0 pM. (-)-Agelastatin A was also found to be 
insecticidal against the beet army worm, Spodoptera exigua, and the corn root worm, 
Diabrotica undecimpunctata. Larvae of both insects were fed on a diet treated with the alkaloid 
or solvent (control) and monitored for mortality over 4, 5, and 7 days. The 4-day and 7-day 
LC50S of agelastatin A against beet army worm were 26 pg/mL and 20.3 pg/mL respectively, 
while for corn root worm, the 5-day and 7-day LC50S were 37 pg/mL and 32 pg/mL. These 
values were comparable to a commercial preparation of the biopesticide Bacillus thuringiensis 
tested against beet army worms under the same conditions.
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This toxicity is certainly related to the fish feeding deterrent activity of brominated 
pyrrole alkaloids present in Caribbean reef sponges of the genus Agelas.6 More particularly, 
the sub-structure 4,5-dibromopyrrole-2-carboxylic acid was identified as a potently active 
compound against a common generalist fish, the bluehead wrasse Thalassoma bifasciatum, at 
the dose of 10 mg/ml. This confirms the ecological role of the pyrrole-imidazole alkaloids as 
defensive secondary metabolites of the marine sponges in which they are present.
1.3. Biosynthetic Possibilities for Various Members of the 
Oroidin Family of Alkaloids
The unusual Cn highly fused pyrrole-imidazole framework present in (-)-agelastatin A 
(and its congeners) has led to suggestions that this compound is a member of the oroidin 
family of alkaloids, since oroidin (5, Scheme 1), isolated from Agelas oroides,76 is historically 
the central member in a series of similar alkaloids. Pietra et al. suggested in their preliminary 
report that agelastatin A could be biogenetically derived from the oroidin analogue, hymenidin 
(6, Scheme 1).2
Me Me
I / — NH
5; R = Br (Oroidin)
6; R -  H (Hymenidin)
■NH
NH
1
(-)-Ageiastatin A
Scheme 1. A putative biosynthetic pathway for (-)-agelastatin from hymenidin
The first biosynthetic study of a marine sponge using a cell culture of Teichaxinella 
morchella (Axinellidae) was reported by Kerr et a l9 They demonstrated by feeding studies 
using labelled proline and histidine that these amino acids are precursors of odiline (9) (syn: 
stevensine) via 3-amino-1-(2-aminoimidazolyl)-prop-1-ene (7) and 4,5-dibromo-2-carboxylic 
acid (8) (Scheme 2). This hypothesis is further supported by the recent isolation of clathramide 
A (10, Figure 2) from the sponge Agelas clathrodes.10,11
Histidine
ProlineOdiline
Scheme 2. The biogenetic precursors of odiline from the sponge Teichaxinella morchella
3
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While the pyrrole part is generally accepted to originate from proline, alternative precursors for 
the aminoimidazole fragment have been proposed, such as homoarginine.12,13,14 The latter 
hypothesis is reinforced by the recent isolation of Mx-(4-bromopyrrolyl-2-carbonyl)- 
homoarginine (11, Figure 2) from the marine sponge Agelas wiedenmayeri.13
More recently, a universal chemical pathway to the oroidin-based pyrrole-imidazole 
alkaloids and their congeners was proposed by Al Mourabit and Potier.15 They suggested that 
the members of the pyrrole-imidazole alkaloid family can be traced back to simple precursors 
such as 7 and 8. These precursors can show ambivalent reactivity, which is responsible for the 
molecular diversity observed in this group of alkaloids. While on one hand, pyrrole-2-carboxylic 
acid and its 4- or 5-brominated derivatives such as 8 can exert their nucleophilicity at N(1) or 
C(3), on the other hand, tautomerism of the vinylogous aminoimidazole building block 7 can 
explain the ambident reactivity at several positions of this compound. Various tautomers form, 
and their behaviour is probably controlled by the enzymatic system responsible for the 
biosynthesis of these secondary metabolites, by virtue of it being able to exchange protons with 
its substrate.
The versatility of this system can then give rise to polycyclic metabolites through 
various combinations with pyrrolic building blocks and diverse modes of cyclisation. With 
regards to agelastatin A, Al Mourabit and Potier suggested that oxidation of the hymenidin 
tautomer 12 was the key step in the intramolecular cyclisation pattern (Scheme 3). After the 
first C(8)-C(5) cyclisation (biogenetic numbering) to give 13, an unusual N(1)-C(7) connection 
can possibly occur; further transformation can then furnish agelastatin A (1) and its derivatives.
Br Br\
N T /!
H O CO2H -N I I  \O CO2 H NH
10
Clathramide A
11
Na-{4-bromopyrrolyt-2-cart>onyl)>homoarginine
Figure 2. Putative intermediates for the biosynthesis of oroidin-like alkaloids
oxidation
hydration 
methylation Br 
hydrolysis '
Me
H9 . N _ o  
H
,N.
O
1
O o
(-)-Agelastatin A
Scheme 3. Al Mourabit and Potier’s biosynthetic pathway for (-)-agelastatin A
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1.4. Synthetic Efforts Towards Some Members of the Oroidin 
Family of Alkaloids
Over the last thirty years, numerous pyrrole-imidazole alkaloids with various structures 
and interesting biological activities have been identified from several species of Agelasidae, 
Hymeniacidonidae, and Axinellidae.16 The versatility of the systems implicated in the 
biosynthesis of the oroidin-like pyrrole-imidazole alkaloids has consequently inspired many 
synthetic efforts. By finely tuning the reactivity of simple pyrrolic and 2-aminoimidazolic 
buildings blocks, many groups have achieved the elaboration of complex, naturally-occurring, 
pyrrole-imidazole structures.
1.4.1. Dibromophakellin and Related Alkaloids
Amongst the first known members of the pyrrole-imidazole alkaloid family, (-)- 
monobromophakellin and (-)-dibromophakellin ((-)-14 and (-)-15, Figure 3) feature prominently. 
Each was isolated from the marine sponge Phakellia flabellata by Sharma and Burkholder.17 
Their structure was confirmed by X-ray analysis.18,19 Interestingly, the optical isomer of 15, (+)- 
dibromophakellin, was subsequently found in an extract of the sponge Pseudoxaxinyssa 
cantharella.20 The structural assignment was also confirmed by X-ray analysis. A structurally 
related compound, (+)-dibromocantharellin (16, Figure 3) was also isolated from this sponge.20
HN'
■NH2
(->-14; R » H (-)-Monobromophakellin (+>-16
(->-15; R *  Br (-)-Dibrofnophakeilin (+)-Dibromocanthare<lin
Figure 3. Structure of dibromophakellin and dibromocantharellin
The first workers to establish a link between linear and cyclised pyrrole-imidazole 
alkaloids were Foley and Buchi.2' They prepared racemic dibromophakellin by oxidative 
cyclisation of non-naturally occurring dihydrooroidin 17 (Scheme 4). They treated the 
hydrochloride salt of 16 with bromine in acetic acid to obtain the unstable hydrobromide salt 18 
which, when reacted with a base, afforded racemic dibromophakellin 15. Intriguingly, when 18 
was dissolved in DMF or DMSO but without base, it underwent electrophilic substitution on 
carbon to furnish the dibromoiminium salt 19 which hydrolysed to the pyrrolinone 20.
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f-BuOK (1.5 equiv ), 
2-butanol, 20 °C, 20 min.
O l V N H a
NH ^
0 = (  H
V -N H
Br
17
Dihydrooroidin
Br2, AcOH
^  NH
15
Dibromophakellin
BrDMSO or 
DMF
19 20
Scheme 4. The preparation of dibromophakellin by Buchi and Foley
The conditions for the oxidative cyclisation of 18 were later improved by Horne et al,22 
who used NBS in TFA and a Et3N/THF (1:1) quench to access racemic dibromophakellstatin in 
nearly quantitative yield.
1.4.2. The Pyrroloazepinones
An important subdivision of the pyrrole-imidazole family of alkaloids is represented by 
the tricyclic natural products hymenin (21), odiline (9), hymenialdisine (22), and 
debromohymenialdisine (23, Figure 4). Each feature a fused bicyclic pyrrolo[2,3-c]azepin-8-one 
ring system that bears a 2-aminoimidazole appendage.
HoN
NHNH NH
21
Hymenin Odiline (Stevensine)
22; R = Br (Hymenialdisine)
23; R -  H (Debromohymenialdisine)
24
Axinohydantoin
NH2
NH
25; R =■ H (Latonduine A)
26; R  ^C 0 2H (Latonduine B)
Figure 4. Structure of the pyrroloazepinone marine alkaloids and congeners
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Debromohymenialdisine (23) was isolated from the Great Barrier Reef sponge 
Phakellia flabellata in 1980.23 Subsequently, its brominated analogue, hymenialdisine (22) was 
extracted from the Mediterranean sponge Axinella verrucosa and from the Red Sea sponge 
Acanthella aurantiaca.24 Both compounds were also isolated from the Okinawan sponge 
Hymeniacidon a/cf/s. 12 Preliminary screening of hymenialdisine showed a moderate cytotoxicity 
against KB cancer cell lines in vitro.24 The cytostatic and antineoplastic properties of 
hymenialdisine and debromohymenialdisine were later confirmed in the U.S. National Cancer 
Institute’s murine P-388 lymphocytic leukemia test (ED50 = 2.0 pg/mL and 2.5 pg/mL, 
respectively) . 25 Both hymenialdisine and debromohymenialdisine were reported to inhibit the 
G2 DNA damage checkpoint (IC50 -  6  and 8  pM, respectively), and showed moderate 
cytotoxicity towards MCF-7 cells.26
Hymenialdisine was identified as a potent inhibitor of the mitogen-activated-protein- 
kinase-kinase-1 (MEK-1) with an IC50 of 6  pM .27 MEK-1 belongs to the Ras-MAPK signalling 
cascade, which is involved in transmitting cellular signals from the cytosol to the nucleus, for 
the modulation of cell proliferation and differentiation.28 More recently, hymenialdisine, was 
found to be a potent inhibitor of the pro-inflammatory cytokines, interleukin- 2  (IL-2 , IC50 = 2.5 
pM), and tumour necrosis factor-a (TNF-a, IC50 = 1.4 pM) . 29 These cytokines play an important 
role in the pathogenesis of rheumatoid arthritis and osteoarthritis. Their inhibition has been 
successful in clinical trials for the treatment of rheumatoid arthritis.30 Further investigations of 
the anti-inflammatory properties of hymenialdisine have shown that it inhibits cytokine 
production through inhibition of the transcription factor NF-kB in U937 cells, a cell of monocyte 
lineage, at a concentration of 1-2pM .31 Finally, hymenialdisine was identified as a potent inibitor 
of cyclin-dependant kinases such as CDK5 (IC50 = 28 nM), glycogen-synthase-kinase-3p (IC50 
= 10 nM) and casein kinase 1 (CK1, IC50 = 35 nM) . 32 Inhibition of these kinases have potential 
applications for treating neurodegenerative disorders such as Alzheimer disease.
Hymenin (21) was isolated from the Okinawan sponge Hymeniacidon sp.33 Preliminary 
studies have shown that this alkaloid is a competitive antagonist of the a-adrenoreceptors in 
vascular smooth muscle.34 Odiline (also named stevensine, 9) was simultaneously isolated 
from the sponge Pseudoxaxinyssa cantharella by de Nanteuil et a / ,20 and from an unidentified 
sponge by Faulkner et al.35 The related axinohydantoin (24) was isolated by Pettit from an 
Axinella sp. in 1990.25 More recently, Andersen et al. published the isolation of two 
aminopyrimidines congeners, latonduines A and B (25 and 26), from the Indonesian sponge 
Stylissa carteri.36 Their unprecedented heterocyclic skeleta contain a six-membered 
aminopyrimidine ring instead of the five-membered aminoimidazole ring common to the oroidin 
family, suggesting that ornithine could be their biogenetic precursor rather than the amino acids 
L-proline and L-histidine as proposed by Kerr et al.9
7
Chapter 1: The Agelastatins and Related Marine Alkaloids
Chemical synthesis studies on these molecules have been carried out by the group of 
Horne.57 They investigated the controlled regioselective intramolecular cyclisation of oroidin- 
like compounds (Scheme 5). Thus, when the pyrrolecarboxamidoacetal 27 was deprotected 
under standard conditions (p-TsOH, acetone/water), aldehyde 28 could not be isolated. It 
reacted immediately with N(1) position of the pyrrole to produce longamide (29), a metabolite 
isolated from the Caribbean sponge Agelas lo n g is s im a This compound could then be 
dehydrated to form 30. When the same acetal was treated with methanesulfonic acid, it 
underwent ring closure at the C(3) position of the pyrrole with concomitant dehydration to afford 
pyrrolopyridinone 32.
p-TsOH. 
acetone/HjO 
reflux. 1 2 h
(70%)
^ S - i s J Q
H ' o  
27
CH3SO3 H, 
45 °C, 4 days
(80%)
Br.
NH
i t
28
NH
28
CH3SO3 H, 
45“C, 4 days
(99%)
Br.
Br
W NH
Longamide (29) 30
Br,
Br
NH
H O 
32
Scheme 5. Preparation of cyclised analogues of odiline by regioselective cyclisation
When the higher homologue 33 was submitted to the deprotection conditions used on 
27, aldehyde 34 was formed (Scheme 6). Moreover, while cyclisation to form the six- 
membered pyrrolopyrazine 30 occurred readily, the corresponding seven-membered ring 
closure was not observed. Cyclodehydration could be accomplished with methanesulfonic acid, 
which afforded the C(3) pyrroloazepine 35 exclusively.
Br.
/ v
NH
p-TsOH, 
acetone/H2O 
reflux, 1 2  h
(90%)
Br. r =Br. CH3 SO3 H,
Br^ N / n (80%) Br^ N -
H q H 0
NH
Q 33
34 35
Scheme 6. Preparation of the pyrroloazepine 35
This compound could be further elaborated and coupled with an aminoimidazole 
moiety. In this capacity, Horne et al. reported the total synthesis of the two alkaloids hymenin 
(21, Figure 4) and hymenialdisine (22) in 1997.39 Their synthesis was based on the preferential 
heterodimerisation of the two different heterocyclic units under acidic conditions. Thus, upon
8
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exposure to methanesulfonic acid, pyrroloazepine 35 underwent protonation to give the 
putative azafulvene ion 36, which reacted with 2-aminoimidazole to afford hymenin (21, 
Scheme 7). Oxidation of 21 with bromine in TFA, followed by mild hydrolysis with aqueous 
acetic acid afforded the imidazolone synthon 38 as a mixture of diastereoisomers. 
Regioselective debromination of the latter could be achieved by treating 38 with a catalytic 
amount of HBr in methanesulfonic acid. Under these conditions, HBr was generated in situ 
from 38 in a highly controlled manner that served to effect a selective protonation at the Im­
position of the pyrrole ring. Hymenialdisine (22) was produced in 33% yield, along with its 
debrominated analogue, debromohymenialdisine (23) in 27% yield. Those results are 
consistent with the fact that for bromination of 2-acylpyrrole systems, the p-position is generally 
the more reactive.40 Furthermore, the favorable regioselective p debromination most likely 
accounts for the formation of the vast majority of monobromo series of marine alkaloids 
isolated to date.16
Br.
Br H
" O
35
CH3 SO3 H. RT 
7 days (65%)
36
NK
H2N~ V
H
h2n^
21
Hymenin
CH3 SO3 H. HBr (cat), H
90*C, sealed tube. 12 h g,
22; R -  Br (Hymenialdisine)
23; R *  H (Debromohymenialdisine)
H2NU .^,,n_ .o
AcOH/H2 0, 
reflux (72%)
Br2, TFA. 
RT (95%)
H2N^N\^Br
Scheme 7. Preparation of hymenin and hymenialdisine by Horne et al.
A successful total synthesis of debromohymenialdisine was achieved by Annoura et 
al.,41 with complete control of the exocyclic olefin geometry. As illustrated below (Scheme 8), 
they started from linear pyrroloamide 39. After hydrolysis of the ester, PPA-mediated 
cyclization of 39 afforded aldisin 40. Protection of the nitrogen atoms with SEM groups yielded 
41. The Wittig-Horner reaction of the latter with ethyl diethylphosphonate/NaH afforded 42 as 
mixture of a,p and p,y-unsaturated esters. Deprotonation of 42 with KHMDS at low temperature 
generated the ester anion, which was quenched with 2-benzenesulfonyl-3-phenyloxaziridine to 
give the a-hydroxy-p.y-unsaturated esters 43, as a single regioisomer. Mesylation of the 
alcohol function afforded 44 quantitatively.
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'COOMe
H O
39
MsO^CQ2Et
NSEM
guanidine
^NSEM
SEM
10% aq. NaOH-MeOH (2:1),
RT. 5h
then PPA-P2 0 5 , 100°C, 1 h f t  
(45%) N
NaH, SEMCI, 
DMF, RT, 2 h
NH (52%)
O
40
,N'  V - nsem
SEM
41
CC^Et
MsCI. Et3 N, CHgC^. RT 
( 100%)
AIM6 3 , toluene,
80 °C, 4 h then 
CHCI3 -MeOH-H2Q^ 
(52%)
NSEM
NSEM
(EtO)2 POCH2 COOEt, 
NaH, DME, 50 ”C 
(83%)
PhSC^N-CHPh
KHMDS. THF,
-78<C, 2 h  N ' >EM
(72%) SEM
C 02Et
HN,DMF, 50®C, 5 h 
(22%)
•NSEM
SEM
47
5% aq. HCI-MeOH 
80°C ,2 h
HN,
(75%)
•NH
23
Scheme 8. Preparation of debromohymenialdisine by Annoura et al.
Reaction of 44 with guanidine (1.5 equiv.) in the presence of AIMe3 in toluene at 80*0  
caused cyclisation to produce the hydantoin derivative 46, presumably derived from hydrolysis 
of the initial guanidine adduct 45 during the work-up procedure. Despite many attempts with 
different conditions for the work-up (non-aqueous/basic), only hydantoin 46 could ever be 
obtained from this reaction. When 44 was treated with guanidine (5 equiv.) in DMF at 50°C, the 
cyclisation occurred with a shift of the double bond within the azepine ring system, in a 
stereospecific manner, to afford the desired olefin 47. It seems that the isomerisation of the 
double bond into the conjugated system leads to stabilisation of the guanidine moiety by 
resonance effect, which can then be isolated without conversion to the corresponding 
hydantoin. Subsequent removal of the SEM protecting group cleanly afforded 
debromohymenialdisine 23.
1.4.3. Dibromophakellstatin
A very interesting member of the oroidin family of pyrrole-imidazole alkaloids is (-)- 
dibromophakellstatin (48, Scheme 10), isolated by Pettit et al. from the Indian Ocean sponge
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Phakellia mauritania42 This alkaloid exhibits potent cell growth inhibitory effects against 
melanoma SK-MEL-5 and colon KM20L2 cell lines (ED50 = 0.11 pg/mL for both cells) . 42 
Dibromophakellstatin possesses a unique array of functionality including a cyclic urea, a 
pyrrole carboxylic acid, a pyrrolidine, and a vicinal diaminal stereocentre packaged together in 
a highly compacted arrangement within a heteroatom-dense, tetracyclic structure.
Synthetic efforts towards preparation of the dipyrrolopyrazinone core of 
dibromophakellstatin have been reported by Lindel et al. (Scheme 9), starting from 
pyrroloalcohols 49 and 50.43 Oxidation of the primary alcohol functionality in 49 and 50 to the 
corresponding aldehydes was achieved using IBX in DMSO, to prevent racemisation of the a- 
amino-aldehyde. The resulting aldehydes immediately cyclised to the A/.O-hemiacetals 51 and 
52. While the dibrominated analogue gave the syn diastereoisomer, the non-brominated 
analogue 49 afforded only the anti diastereoisomer. Dehydration of 52 could be effected using 
phosphorus oxychloride to afford olefin 53. Oxidation of the latter with m-CPBA yielded diol 54 
whose relative stereochemistry could not be assigned. Treatment of 54 with excess methanol 
at reflux afforded exclusively 55. The trans configuration in 55 was confirmed by X-Ray 
analysis.
IBX (2 equiv.) 
DMSO. 1 2  h. RT
(77%)
^,NH
OH
49: R -  H
50: R -  Br
IBX (2 equiv.) 
DMSO. 1 2  h, RT
OH
51
(77%)
o=<
Dibromophakellstatin
Br' 6 hOCH3 
55
CHCiyMeOH ( 1 :1 ) 
reflux, 1 h (67%)
POCI3. Py, 
6 h. O 'C toR T
(62%)(79%)
HO
54
Scheme 9. Preparation of the dipyrrolopyrazinone core of dibromophkellstatin
Recently, Romo et al. reported a total synthesis of (+)-dibromophakellstatin, the non­
natural optical isomer (Scheme 10) . 44 Their strategy was based on the desymmetrisation of the 
(^-symmetric, proline-derived, diketopiperazine (+)-56,45 obtained from naturally occuring l - 
proline in three steps. Acylation of the enolate derived from 56 with benzylchloroformate 
afforded diketopiperazine 57 in a highly diastereoselective fashion. This set the functionalised 
tricyclic core of dibromophakellstatin. Having fulfilled its role in controlling stereochemistry 
during acylation, the remaining H-containing a-stereocenter was removed by a selenation- 
selenoxide-elimination sequence which provided an intermediate pyrroline, which then
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underwent further oxidation to the pyrrole, affording 58. Diastereoselective reduction of the 
carbonyl group with sodium borohydride at low temperature afforded alcohol 59. The 
regioselectivity observed in this reduction is noteworthy and is probably attributable to greater 
electrophilicity induced, in this amide carbonyl, by the electron-withdrawing a-carboxybenzyl 
group, and the occurrence of chelation during the reduction.
1 ) KHMDS. THF, -78°C
u 2 )C C 0 2B n.-78"C to25 ‘C  „  ^  ,
H —---------£--------------------------- BnOp1 H
O (70%) D
(♦)-56
(dr. = 1 2 :1 )
1) KHMDS. THF.-78-C 
then PhSeBr (73%)
2) DMDO, CH2 CI2 ,
-78“CtoO°C (93%)
► Bn02C.,J
3) Se0 2 , dioxane, reflux f
(65%)
1) H2, 10% Pd/C,
BzCNHCL
3) CBzNHOH, DMAP 
(77% over 3 steps)
NH3, MeOH, 0°C 
(90%)
DIAD. PPh3. 
THF, reflux
BzCNHCL
NaBH4. MeOH 
-40 «C (8 8 %)
1) f-BuOK. ^ u O H
2) Ac2 0 . Py. CH2 Cl2  Bn02 C.„j
(58%)
Ha.
1 ) NH3. MeOH, 0°C CBzHN,
2) TiCI3, AcOK. THF/HzO H2Nv  _
(53% over 3 steps) o
Phl(02CCF3)2, 
Py, CH3CN
1) H2, 10% Pd/C, 
MeOH (50% for 
2  steps)
2) NBS (2 . 0  equiv.
THF (69%)
W-48
(•fFDibromophaketlstatin
HN,.
0=C=N*
Scheme 10. Total synthesis of (+)-dibromophakellstatin
The newly-set carbinolamine stereocenter was then epimerised with potassium fe/t-butoxide, 
and protected as an acetate, affording 60. The benzyl group was removed, and the resulting 
acid was coupled with benzyl A/-hydroxycarbamate to furnish hydroxamate 61. Aminolysis of 
the acetate followed by Mitsunobu coupling of the alcohol with the /V-hydroxy ester afforded 
unstable tetracyclic intermediate 63. This compound was immediately subjected to aminolysis, 
and N -0 bond cleavage with TiCI3, to deliver 64. Hofmann rearrangement on the latter afforded 
the transient isocyanate 65 which was trapped in situ to give the tetracyclic urea 66. 
Deprotection of the CBz group by hydrogenolysis followed by dibromination with 2 equiv. NBS 
afforded (+)-dibromophakellstatin ((+)-48).
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A racemic synthesis of dibromophakellstatin was later reported by Austin and co­
workers (Scheme 11)46 Their strategy utilised a hypervalent-iodine mediated syn-diazidation to 
set the vicinal diamine appropriate for the installation of the urea ring system. This novel route 
started with construction of the 2,3-dihydrodipyrrolopyrazine core by coupling 2- 
pyrrolidinemethanol 67 with trichloroacetylpyrrole 68. The resulting alcohol 69 was then 
oxidised with Dess-Martin periodinane to the corresponding aldehyde, which cyclised to the 
hemiaminal 70.
Dess-Martin 
periodinane, 
CH2 C>2 . RTCHgC^, RT
1 .1 '-thiocartxxiyl- 
di imidazole, 
imidazole, MeCN 
50 °C
75 76 77 48
Scheme 11. Austin s route to (±)-dibromophakellstatin
Mesylation of the alcohol in 70, and elimination with DBU afforded dihydropyrrolopyrazinone 72 
in 67% yield from 69. Several methods were screened for the direct formation of a vicinal 
diazide functionality. It was found that in situ formation of the hypervalent iodine species ~I(N3)2 
provided syn-diazide 73 as the main diastereomer (41%). Diazide 73 was converted into the 
corresponding diamine 75 by catalytic hydrogenation, and the thiourea ring was formed by 
treating 75 with thiocarbonyl-diimidazole. Conversion of thiourea 76 into urea 77 was efficiently 
achieved by peroxidation. Dibromination of 77 with NBS provided (±)-dibromophakellstatin, 
although in modest yields (24%), due to the presence of NBS-related side-products.
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1.4.4. The Bisguanidines : Palau’amines and Congeners
Amongst the most intriguing members of the pyrrole-imidazole family of marine 
alkaloids are the palau’amines and styloguanidines (Figure 5). These hexacyclic bisguanidines 
possess a common, highly complex cyclopentane ring that is stereogenic at every carbon, 
including one quaternary spiro centre. Palau’amine (78) was isolated by Kinnel et al. in 1993, 
from the sponge Stylotella agminata, collected in the Western Caroline Islands 47 It exhibited 
substantial antibiotic activity against Gram-negative and Gram-positive bacteria (it being active 
against Bacillus subtilis and Staphylococcus aureus at 10 pg/disk), as well as powerful 
cytotoxicity against tumour cell lines such as P-388 (IC50 = 0.1 pg/mL), A549 (IC50 = 0 . 2  
pg/mL), HT-29 (IC50 = 2 pg/mL) and KB (IC50 = 10 pg/mL). Its most striking biological property 
is probably its immunomodulatory activity. In the mixed lymphocyte reaction, palau’amine 
showed an IC50 < 18 ng/mL, with a cytotoxicity against murine lymphocytes of only 1.5 pg/mL. 
Palau’amine is laevorotatory, but its absolute stereochemistry remains to be determined.
NH
HQ X
H2N‘
n h 2
78: R \  R2 *  H (Palau'amine) 81: R1, R2 = H (Styloguanidina)
79: R1 » H, R2 *  Br (Monobromopalau'amine) 82 R1 = H, R2 = Br (Monostyloguanidine)
80: R \  R2 » Br (Dibromopalau'amine) 83: R1, R2 » Br (Dibromostyloguanidine)
Figure 5. Structure of the palau’amines and styloguanidines
The isomeric alkaloids styloguanidines (81-83) were isolated two years later by Kato et 
al. from the sponge Stylotella a u ra n tin iu m collected in the Yap Sea, along with palau’amine 
78 and the dibrominated palau’amine analogues 79 and 80. The styloguanidines are powerful 
chitinase inhibitors.
A concise route to an abbreviated tetracyclic core structure of palau’amine has recently 
been described by Overman et al.49,50 In their retrosynthetic planning, a disconnection had 
been made at the linkage between C(6 ) and the 2 -acylpyrrole unit to obtain the pentacyclic 
intermediate 84 (Scheme 12). This compound would be prepared from the 
hexahydrotriquinacene 85, having the required stereochemistry at C(10) and C(20). The 
stereochemical relationship between the central c/s-3-azabicyclo[3.3.0]octane core and the two 
spiroguanidines units in 85 would be established by an intramolecular cycloaddition on the 
azomethine imine 86. In this pivotal step, the single stereocentre of 86 would direct the three 
additional stereocentres in 85. Azomethine imine 86 would in turn be prepared from the 
corresponding a-ketoester 87.
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1  NH h n  Vi,
78
Palau'amine
•NHR
...Cl
RHN NHR
84
RN,
ROsC
<:
o '  c o 2r
87
R02C*^ C ^COsR 
£ N-NH £
85
( j Yr  hn^cc^r
RN
RO2C N2 
86
Scheme 12. Overman's retrosynthetic plan to palau’amine
Their synthesis of the abbreviated palau’amine core (compound 100 in Scheme 14) 
started with a conjugate addition of the sodium salt of glycine to ethyl (2-allyl)acrylate 88; this 
was followed by esterification and A/-Cbz protection to afforded 89 (Scheme 13). Dieckmann 
cyclisation of 89 and subsequent reduction of the p-ketoester product provided pyrrolidine 90. 
O-Mesylation of 90 and direct ozonolysis of the mesylate afforded aldehyde 91, which was 
submitted to a Wittig-Horner reaction with 2-(te/?-butyldimethylsiloxy)-2- 
(dimethylphosphono)acetate to to give dihydropyrrole 92. Desilylation of 92 with CsF provided 
racemic a-keto ester 93. Reaction of 93 with thiosemicarbazide in acetic acid at 70°C delivered 
tetracycle 96 by a sequence of reactions that included an intramolecular cycloaddition to form 
95, followed by an acylation of the thiourea.
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1 ) H2 NCH2 C0 2 Na, EtOH, A 
CC^Et 2) H2 S 0 4, EtOH, A 
J }  CBzCI- E,3N
Et02C ^
NCbz
EtOaC
(71%)
1) f-BuOK, THF, -78 “C
2) NaBH4, EtOH
(90%)
88
EK^ C
EtOjC
I —NCbz
HO
(I 90
-NCbz
EK^ C
-NCbz
CsF, AcOH, MeCN 
( 100%)
UCI. DBU, MeCN 
(MeO)2 POCH(OTBS)C02Me
(55% over 3 steps)
MeC^C' M eO^C' "OTBS 
92
NH2NHCSNH2 
AcOH, 70-C, 24 h
Ms1
1) MsCI, Et3 N, DMAP 
CgHg. 0 “C
2 ) O3 , CH2 CI2. PhaP
EtOzC
V NCbz
• ?o
91
CCHMe
NCSNH2
CbzN
EtOjC€ QN-NH CO^e
94
S
95
(87-95%) QV ^ ^ ^ C 0 2Me
hI ^ - nh
s
96
Scheme 13. Overman’s route to an abbreviated analogue of palau’amine
In order to fashion the second spirothiohydantoin, ester 96 was hydrolysed with lithium 
hydroxide, and the resulting acid was treated with phosphoryl isothiocyanate. This reagent also 
unexpectedly accomplished the reductive cleavage of the N-N bond. Finally, the desired bis- 
(acylguanidine) units were formed by sequential treatment of 98 with Mel and benzylamine.
CbVT>
°V ^ T ^ > C 0 2Me
hI ^ - nh
UOH then HCI
96
Cbzv.Ar A  Cbz'  ^ r \
Ov V s /  PO(NCS)3, THF, A /  /?
h I n -NH  (72% over 2 steps) HN> .NHHNV .NH
\  I T
97 98
Cbzs
,N N. HN^ ^NH
BnHN NHBn
100
BnNH2, EtOH 
t  70 °C
(8 6 % for 2  steps)
Cbzv
Mel. NaOH, 
H2 0 , MeOH 
RT
. .N N. . HN^ VNH
SMeSMe
99
Scheme 14. Completion of the synthesis of an abbreviated core structure of palau'amine
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A route to the fully substituted cyclopentane core of the related axinellamine was 
reported by Carreira et a/.51 A biomimetic Diels-Alder approach to the palau’amine core, using 
4-vinylimidazoles, was published by Lovely et al.52 A transient N-O-linked Pauson-Khand 
strategy was proposed by Austin et al. for the synthesis of the deschloro carbocyclic core of the 
palau’amines and styloguandines.53
More recently, Romo et al. reported the preparation of the spirocyclic core of 
palau’amine,54 following a biosynthetic pathway suggested by Kinnel.55 In this proposal 
(Scheme 15), a Diels-Alder reaction would occur between dehydrophakellin 77, an unknown 
metabolite related to dibromophakellin (15, Scheme 4), and a known metabolite, 2-amino-1-(2- 
aminoimidazolyl)prop-1-ene (7), isolated from the sponges Teichaxinella morchella and 
Ptilocaulis walpersi.** A subsequent chlorination involving a chloroperoxidase, would then 
initiate a pinacol-like 1,2-shift/ring contraction to deliver the spirocycle found in 78 after capture 
of the resulting iminium ion by water.
►V'UjN. N x
h2o
HoN ^
-NHR
101 78 (Palau amine)
Scheme 15. Proposed biosynthetic pathway to palau’amine
Following this proposal, Romo et al. investigated the Diels-Alder reaction between 
imidazolone 102 and pyroglutamic derived lactam 103. Reaction of these two compounds in 
benzene for 4 days afforded the desired endo cycloadduct 104 (enantiomeric excess > 95%), 
along with the minor regioisomer 105 (Scheme 16). However, a migration of the double bond 
occurred during the course of the Diels-Alder reaction to regenerate the imidazolone ring.
Ts
102
CT gn 103
2 ,6 -lutidine, CgH$ 
QS'C. 4days
Tipsa^^X T°
Bn 104
(64%)
TIPSO
/T^ NBn
105
(15%)
Scheme 16. Diels-Alder reaction en route to the palau’amine core structure
After protection of the alcohol in 104 with a TBS group, they investigated the 1,2-shift/ring- 
contraction sequence. Careful treatment of imidazolone 106 with dimethyldioxirane (DMDO) 
afforded diastereoselectively alcohol 109 (Scheme 17). Presumably, the mechanism of this
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reaction involves initial epoxidation of the double bond to form 107, epoxide ring-opening to 
give the iminium ion 108, and deprotonation to produce 109. An intermolecular chlorination 
from the convex face of carbinol-urea 109 thereafter promoted the desired suprafacial 1,2-alkyl 
shift to afford the chlorinated hydantoin 111. However, this product was epimeric at the C(17) 
chlorine-bearing atom in palau’amine. Further investigations will be necessary to control the 
regioselectivity of the chlorination process. A substrate-directed chlorination by the pendant 
alcohol fonction in 109 is being investigated to access the cyclopentane stereochemistry of 
palau’amine.54
Ts
TIPS
DMDO, CH2Cl2. 
MgSO«, -45<C 
V—/ QTBS lhen Me^
BnN-( ) ‘“y
O^N
Bn
106
(99%)
TIPSO O
OTBS
TIPS
OTBS
107
111
TIPSO
OTBS
Bn +
110
TIP!
OTBS
Bn
108
TsNCS. C6 H10, 
CH2Cl2 
-45*0 to 25 °C. 8  h TIPSO OTBS
(75%)
109
Scheme 17. Formation of the spirocyclic core of palau’amine
1.4.5. Sceptrin and Analogues
Sceptrin (112, Figure 6) is a novel structure that was originally isolated from Agelas 
sceptrum,57 and subsequently from the Caribbean sponge Agelas conifera.58 Sceptrin was also 
discovered in the Indopacific sponge Agelas nakamurai,59 along with debromosceptrin (113), 
and a new structure, nakamuric acid (114). Sceptrin shows interesting antimicrobial and 
antifungal activity against Staphylococcus aureus, Bacillus subtilis, Pseudomonas aeruginosa, 
Candida albicans.56
n h 2  n h 2
112 113 114
Sceptrin Debromosceptrin Nakamuric acid
Figure 6. The sceptrin family of alkaloids
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Sceptrin can be considered as a dimer of debromooroidin (hymenidin, 6) by a formal 
[2+2] cycloaddition reaction. Although the photochemical reaction would be allowed, any 
attempts to prepare sceptrin by the photodimerisation of debromooroidin have so far been 
unsuccessful. The biosynthesis of sceptrin is unlikely to occur by photodimerisation since there 
is not enough light at the depth where the sponge was found (-20 m to -30  m), and sceptrin is 
chiral ([a]D -7 .4 ° in methanol), while debromooroidin is not. An alternative biogenetic pathway 
has been suggested by Rinehart and co-workers,58 which involves ionic dimerisation (Scheme 
18).58
NH
NH-
Hymenidin
Sceptrin
Scheme 18. A putative biogenetic pathway for sceptrin
Sceptrin remained a prominent unanswered synthetic challenge until Baran et al. 
reported the first total synthesis of (±)-sceptrin in 2004.60 Their route to 112 is based on the 
known acid-promoted rearrangement of 3-oxaquadricyclane 116,61 to form the cyclobutane 
core of sceptrin. Cyclane 116 was prepared by Diels-Alder reaction cycloaddition of 2,5- 
dimethyl furan and dimethyl acetylene dicarboxylate, followed by photoirradiation.62 The 
conversion of 115 to cyclobutane 119 probably occurs via formation of carbenium ion 117, 
which is stabilised by both an a  methyl and an a  oxygen (Scheme 19). Addition of water yields 
hemiacetal 118 which rearranges to form the trans,trans,trans-cyclobutane 119.
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H3C‘^ N Cf/^ CH3 [4+2) Me ° 2CH^ ^ | ^  [2+2)
M 0 O 2 C  — — "' C O 2 M 6
115
MeOj.C CH3  hv
H2S0- Me0H' 24 h (50%^
MeC^CT^Ms
116
H3C02C
o c h 3
117
MeCfeC
119
CC^Me
j§ r
f— C 02Me 
C 02Me
119
O-H
118
Scheme 19. Rearrangement of 3-oxaquadricyclane 116
Next, diester 119 was converted to the corresponding diol 120 (Scheme 20) by 
protection of the ketone as the dimethylketal, reduction of the diester to the corresponding diol, 
and acidic work-up. Conversion of 120 to diazide 121 was achieved by mesylation and 
nucleophilic displacement with azide ion. Reprotection of the diazide as the dimethylketal was 
necessary to avoid scission of the sensitive cyclobutane ring in the ensuing catalytic 
hydrogenation and acylation steps. Chemoselective halogenation of 123 to secure bis-a- 
chloroketone 125 was achieved using benzyltrimethylammonium dichloroiodate. The reaction 
is thought to proceed via oxonium ion 124 since the ketone analogous to 123 does not provide 
125 under the same conditions. Next, treatment of 125 with sodium diformylamide gave 126, 
which afforded the bis-aminoketone 127 after acidic work-up. Treatment of the latter with 
cyanamide formed the two aminoimidazole ring systems, completing the first total synthesis of 
(±)-sceptrin in 24% overall yield from methylacetylene dicarboxylate.
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Me02C
1 ) (MeO)3 CH, caf.p-TsOH,
MeOH, 50"C, 24 h 0 0
^  2) DIBAL, CH2CI2 . -78°C, 1 .5 h H O -V  1) MsCI- O”0  to RT, 1 h N . - y  JL ..
w  then AcOH, HzO  V"l° 2) NaN3, DMF, 50 "C, 24 3  > — 0  Me
Me (100%)
O T '  s Q
125
X y r " '
124
1) (MeO)3 CH, cat. TsOH 
50 ”0 , 24 h
2 ) H2, Lindlar catalyst. 
MeOH,12 h
3)122, CH3CN, 4h
(70% from 120)
Br.
r  NH
Ph N*Me3 'N  u
ICI2  H H
Br,
MeO ,OMe
THF, 60°C.
1 ,75 h (97%)
(CHO^Na' 
CH3CN, 
35’C, 40 h
HN'
HCl, MeOH, 
23 °C, 16 h
HN-
(72% from 125)
HN,NH
112
Sceptrin126 H O
NH2127
Scheme 20. Total synthesis of sceptrin
Another synthesis of racemic sceptrin was subsequently reported by Birman et al.63 In 
their route (Scheme 21), they took advantage of the known photocycloaddition of maleic 
anhydride to trans-1,4-dichloro-2-butene to produce adduct 129. The latter was converted to 
the dimethyl ester 130, which was treated with sodium azide to furnish 131. Hydrolysis of the 
diester to the corresponding diacid occurred with epimerisation to the more thermodynamically 
stable a\\-trans diacid 132. This compound was then converted into bis-bromomethylketone 
134. Treatment of 134 with fe/t-butoxycarbonylguanidine 135 set the 2-aminoimidazole 
moieties, affording 136 in modest yields (30%). Reduction of the azido groups, followed by 
acylation with 122 produced 137. Removal of the Boc groups with TFA afforded sceptrin as its 
bis-trifluoroacetate salt.
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131
130
KOH, MeOH, 
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H
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CIOG
CIOC
1) PPh3, THF, 
NH4 OH, reflux 
N3 (93%)
N3  2) DMF, RT (82%)
Br.\   122
N—
BocHN—^  j]
M —"V
BocHN—<*
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SOCI2, reflux 
2  h
HOzG,
h o 2 c'
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CH2Cl2, 
RT. 1 h
(100%)
H2N—v ’ |
137 112
CCIn
Scheme 21. Birman’s route to (±)-sceptrin
Novel alkaloids are continuously isolated from various marine sponges. Amongst the 
latest reported feature the mukanadins A-C,64 sventrin,65 the slagenins A-C.66
1.5. Previous Synthetic Efforts Towards Agelastatin A
1.5.1. Weinreb’s Racemic Total Synthesis of Agelastatin A
The first total synthesis of (i)-agelastatin A was reported by Weinreb et al. in 1999.67-68 
Their approach used cyclopentadiene as the source of the highly functionalised cyclopentane 
ring of the natural product (Scheme 22). They expected that the hydroxy urea center in 1 would 
be controlled by the fact that the c/'s-configuration of the C-D ring-junction would be more 
favourable than the alternate trans arrangement which would be prohibitively strained. In their 
plan, cyclopentadiene was to be converted into oxazolidinone 139. The C(5a) nitrogen would 
then be introduced regioselectively on the convex face of 139 to give 138. The pyrrole A-ring 
would be attached to this nitrogen by acylation. Given the sensitivity of the C(1) bromide in 
agelastatin A (it can be reductively removed by treatment with sodium hydride), a synthetic
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equivalent of this substituent was deemed esential. A palladium-promoted cyclisation would 
then be used to ensure the BC ring junction formation.
r -V  5 y °  8 ^ % ^ °
BV  V  / r W 0 ^
= = >  'p — > c h  = = >  o~  ^  p
o
1 138 139
Agelastatin A
Scheme 22. Weinreb s retrosynthetic plan for agelastatin A
Hetero Diels-Alder methodology was used to construct the bicyclic carbamate 145 
(Scheme 23). Thus, condensation of cyclopentadiene with AAsulfinyl methyl carbamate 140 as 
the dienophile in benzene at 0°C afforded cycloadduct 141. As this product was prone to the 
retro Diels-Alder process, it was immediately reacted with phenyl magnesium bromide to 
produce the stable allylic sulfoxide 142. This compound was then heated with HMPT in ethanol 
to promote a [2,3]-sigmatropic rearrangement via sulfenate ester 143 to afford a 1:1 mixture of 
the desired olefinic oxazolidinone 145 and the uncyclized hydroxy ethyl carbamate 144. The 
latter could be converted to 145 with potasium ferf-butoxide in high yield. The oxazolidinone 
nitrogen was then protected with a Boc group to produce 146.
COjAAe 
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r%  . * r  w y
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Scheme 23. Preparation of the cyclic carbamate
NHCOpEt
f-BuOK 
THF (83%)
The C(5a) nitrogen was then introduced into carbamate 146 by a Sharpless-Kresze 
allylic amination (Scheme 24), which proceeds via preliminary ene reaction between 146 and 
the SES-protected bis-sulfodiimide 147 and a [2,3]-sigmatropic rearrangement. The resulting 
product 149 was then reduced with sodium borohydride to obtain the allylic sulfonamide 150. 
The SES (p-trimethylsilylethanesulfonyl) protecting group in 147, originally developed by 
Weinreb,69,70 was used as an alternative to p-toluenesulfonyl and methyl carbamate groups, 
because they thought it would be more easily removed by fluoride ion later in the synthesis.
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The Boc group in 150 was removed with TFA, and the resulting sulfonamide 151 was 
made less polar by di-AFbenzylation, producing 152. The SES group was cleaved off with 
caesium fluoride in hot THF, and the free amine was acylated with pyrrole-2-carboxylic acid 
chloride, securing 154. Palladium-promoted cyclization of 154 led to the tricyclic alkene 156. It 
is likely that this reaction proceeds via a 7t-allylpalladium intermediate 155 formed with 
inversion of configuration from carbamate 154. Alkylation of the pyrrole nitrogen in 155 
occurred with the expected c/s selectivity, because the the trans-fused 6,5-ring system would 
be highly strained.
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Scheme 24. Introduction of the C(5a)-N bond and first attempts at forming the ABC ring system
Palladium-based chemistry was also used in a preliminary attempt to form the D ring of 
agelastatin A (Scheme 25). Thus, amine 156 was converted to A/-methyl urea 157, which was 
treated with a catalytic amount of palladium acetate and copper acetate as the stoichiometric 
reoxidant to produce the tetracyclic ene urea 159. This reaction was thought to occur via a syn 
addition of the palladium(ll) and the urea nitrogen to the olefinic double bond in 157. A 
subsequent reductive (3-hydride elimination from the less hindered convex face of the tricycle 
led to the olefinic urea 159. Since hydration of 126 would not afford the correct C/D ring 
functionality, this route was eventually abandoned.
L2 Pd, 
Pd(OAc)2  H
Cu(OAc) 2
d m s o /h 2o  f f  7
1 ) Triphosgene,
DIEA. CH2CI2  _  .
2) MeNH2. THF V
Scheme 25. Preliminary attempts at forming the D ring of agelastatin A
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An alternative strategy was then envisioned, in which the olefinic double bond in 
tricyclic 156 would be selectively functionalised (Scheme 26). After conversion of 156 to the 
Boc derivative 160, the latter was hydroborated with diborane, to give after treatment with 
hydrogen peroxide, a mixture of alcohols that were immediately oxidized with pyridinium 
dichromate. The desired ketone 162 was obtained in 37% yield, along with what was thought to 
be the undesired alcohol 161. Unfortunately, the regioselectivity of this reaction could not be 
improved. However, the Boc group in 162 could be readily cleaved with TFA to afford a-amino 
ketone 163 which apparently did not self-condense. It did however readily cyclise upon 
treatment with triphosgene followed by addition of methylamine. Whilst this produced the 
correctly functionalised tetracyclic core of agelastatin A 164, removal of the two N-benzyl 
protecting groups from 164 was problematical. Therefore, this strategy had to be modified.
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Scheme 26. Formation of the tetracyclic core of agelastatin A by hydroboration
At this stage, a synthetic equivalent of 5-bromopyrrole-2-carboxylic acid was 
developed. Due to the sensitivity of the bromine group in the natural product, it was thought 
that a 2-trimethylsilyl-derivative such as 170 should be used instead. This grouping should 
efficiently promote a regioselective ipso substitution with bromine at a later stage. It should not 
be forgotten that direct bromination of pyrrole bearing an a-carbonyl group (ester, acid, 
aldehyde) often provides a mixture of the 4- and 5-substituted bromopyrrole.40 Thus, pyrrole 
was protected with a Boc group following the procedure of Grehn and Ragnarsson to obtain 
165,71 which was then cleanly dibrominated with NBS to afford 166.72 This derivative was then 
monometallated with n-butyllithium, and then monosilylated with chlorotrimethylsilylane, 
following the procedures previously reported by Cava et al.,73 producing 167. This compound 
could be lithiated again, and then carboxylated with solid carbon dioxide to prepare 168. 
Decarboxylation was effected cleanly by heating this compound neat at 150°C. The acid 
chloride 170 was then prepared from 169 by treating it with oxalyl chloride in the presence of a 
catalytic amount of DMF in dichloromethane.
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Scheme 27. Preparation of the pyrrole acid chloride 170
A new strategy was now devised to access the tetracyclic ring system of agelastatin A 
which involved an intramolecular conjugate addition of the pyrrole nitrogen in 175 to the 
cyclopentenone (Scheme 28). Thus, previously obtained sulfonamide 150 could be acylated 
with acid chloride 170 in quantitative yield, securing 171. The SES group was removed from
171 with TBAF in THF, yielding pyrroloamide 172. Hydrolysis of the oxazolidinone moiety in
172 occurred chemoselectively to give an inseparable 4:1 mixture of 174 and 173. Oxidation of 
the mixture with PDC afforded the desired unsaturated ketone 175 as well as recovered 
oxazolidinone 173. The latter could effectively be recycled by acylation with Boc20 . Conjugate 
addition occurred after 175 was treated with caesium carbonate in methanol; the tricyclic 
ketone 176 was formed in 61% yield. It should be noted here that a similar reaction performed 
on the PMB-protected analogue 179 yielded the cyclized ketone 180 in 100% yield. It is 
reasonable to assume that the presence of substituent on N(5) promotes a population of the 
required amide rotamer.
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Scheme 28. Completion of Weinreb’s total synthesis of agelastatin A
Next, replacement of the silyl group in 176 with NBS cleanly produced bromopyrrole 
177. Removal of the Boc group from 177 with TFA produced a product which rapidly dimerised, 
even in dilute solution. Weinreb finally reported that the Boc group could be effectively cleaved 
from 177 with excess trimethylsilyl iodide at room temperature. Subsequent addition of methyl 
isocyanate and dilute aqueous NaOH led to (±)-agelastatin A in 61% yield. It is likely that this 
process involved formation of a silyl carbamate such as 178. This intermediate was then 
converted to the free amine, which was trapped by the methyl isocyanate to effect the 
annulation of the D ring. This first total synthesis of racemic agelastatin A proceeded in 14 
steps and 7% overall yield.
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1.5.2. Feldman’s Enantioselective Route to (-)-Agelastatin A
In 2002, Feldman and co-workers reported the first enantioselective total synthesis of 
(-)-agelastatin A.74,75 Their strategy stemmed out of some original work of Oichiai,76 who 
showed that alkynyliodonium salts were competent electrophiles when partnered with soft 
nucleophiles. Such conditions lead to highly reactive alkylidenecarbenes, which can insert into 
an unactivated C-H bonds five atoms removed from the carbenic centre to furnish 
functionalized cyclopentenes with retention of stereochemistry at the newly formed stereogenic 
center. Alkynyliodonium salts such as 182 (Scheme 29) can be prepared from an 
alkynylstannane precursor like 181 using Phl(CN)OTf, a phenyliodonium transfer reagent 
recently developed by Stang.77
R—= —SnBu3 
181
Phl(CN)OTf 
Stang reagent
-IPhOTf + Bu3SnCN
182
Scheme 29. Preparation of alkynyliodonium salts
Feldman’s first plan for obtaining (-)-agelastatin A (Scheme 30) envisioned using 
cyclopentene 188 as a key intermediate. The latter would be obtained from alkynyliodonium 
salt 186 via alkylidene carbene 187.78 Accordingly, the cyclisation precursor 185 was prepared 
from Garner’s aldehyde 183 by a Fujisawa chelation-controlled imine addition reaction of 
trimethylsilylacetylene zinc chloride.79
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Scheme 30. Feldman's first generation route to (-)-agelastatin A
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This methodology delivered the required syn diamine arrangement. Acylation of the amine 184 
with tosyl isocyanate was followed by a Buchwald Si/Sn exchange reaction,80 affording 
tributylstannane 185. The latter was converted to the corresponding iodonium salt 186 using 
the Stang reagent. It was hoped that the reactive carbene species 187, formed upon treatment 
of alkynyl iodonium salt 186 with LiHMDS, would deliver the bicyclic alkene-containing product 
188 by insertion of the carbene into the adjacent C-H bond. Unfortunately, dihydropyrrole 190 
was obtained instead. This result indicated that the putative alkylidenecarbene 187 added to 
the Boc carbamate’s lone pair rather than inserting into the 1,5 C-H bond, forming an ylide 189 
that rearranged to 190. In light of the difficulties encountered in the regioselectivity of the 
carbene insertion reaction, this route was eventually abandoned.
A new strategy was thereafter devised, that revolved around generating the alkylidene 
carbene 192 from alkynyliodonium salt 191 by treatment with sodium toluenesulfinate (Scheme 
31). It was hoped that the desired 1,5 C-H insertion would occur to give the cyclopentene 194, 
although it was recognised that this reaction might compete with the carbene insertion into the 
y-O lone pair to provide dihydrofuran 193. A priori, the outcome of the carbene insertion 
reaction was therefore not guaranteed. The toluenesulfonyl grouping in 194 would then be 
used to trigger the conjugate addition of a nucleophilic amine group to C(5a) (agelastatin A 
numbering) to form 195. The same sulfone unit would later be used as a leaving group to 
permit attachment of the pyrrole group at C(9a) to afford 196. Finally, a selective bromination of 
the pyrrole ring at C(1) would provide the natural product 1 from 196.
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Scheme 31. Feldman's new plan towards (-)-agelastatin A
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Preliminary studies were attempted on the racemic substrate 197 (Scheme 32). Thus, 
treatment of stannane 197 with Stang’s reagent led to the alkynyl iodonium salt, and addition of 
this salt to a solution of sodium toluenesufinate afforded a mixture of the desired cyclopentene 
199 along with the O-lone-pair insertion product 198. Further elaboration of 199 into agelastatin 
A would require the stereoselective A/-attachment of a pyrrole carboxamide unit at C(5a). This 
overall transformation was successfully accomplished by a preliminary conjugate addition of 
benzylamine to the convex face of the bicyclic olefin, and A/-acylation of the resultant 
secondary amine with pyrrole-2-carboxylic acid chloride, which secured 200. Unfortunately, 
attempted cleavage of the oxazolidinone unit in 200 failed, leading to the elimination product 
201.
1 ) BnNH2
t  j r ^ " "  r t *
11 TotC^S To(02S BnN—^  T0 IO2 S
inBua r NvH
(31%) (41%) (64%)
197 198 199 200 201
Scheme 32. Preliminary studies on the carbene insertion reaction outcome
In order to circumvent the difficulties associated with dihydrofuran formation, the 
alternative substrate 202 was investigated; it contained a Boc group instead of a Bn (Scheme 
33). It was envisioned that the Boc group would serve a dual role in that it would enhance the 
lability of the oxazolidinone ring-system towards hydrolysis, and it would reduce the yoxygen 
lone-pair insertion by enhancing electron-withdrawal by the carbonyl group in the oxazolidinone 
system. Thus, the same iodination/cyclisation sequence performed on 202 afforded the desired 
cyclopentene 204 in 41% yield, and no O-lone-pair insertion product was detected. Instead, a 
1,2-sulfone shift rearrangement product 203 was now co-produced in significant yield. Feldman 
explained this result by the fact that the hydrogen targeted for 1,5 CH-insertion was attached to 
a more electron deficient atom in 202 than in 197, due to the presence of the electron 
withdrawing A/-Boc group. This probably slows the rate of the carbene insertion, therefore 
increasing the occurrence of the sulfone rearrangement. Unfortunately however, this strategy 
ultimately had to be abandoned, after the attempted benzylamine conjugate addition to the 
carbon-carbon double-bond in 169 was complicated by concurrent attack of the amine to the 
carbonyl.
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Scheme 33. The carbene insertion reaction on a revised substrate
Given these difficulties, it was eventually decided to investigate the effect of placing a 
less activating /V-substituent on the oxazolidinone. A protected A/-urea, such as N- 
CON(CH3)CH2Ph,81 was considered, since it would lower the electrophilicity of the 
oxazolidinone carbonyl while setting the N-methyl urea encountered in the targeted natural 
product. As expected, the alkynyliodonium salt derived from 206 combined with sodium 
toluenesulfinate to yield the cyclopentene 208 along with the product of 1,2-sulfone shift 207. 
The amounts of the two products were similar to those obtained with the AABoc substrate 202. 
Nucleophilic attack of o-nitrobenzylamine did not interfere with the oxazolidinone ring. The 
resulting secondary amine was acylated to furnish the C(5a) pyrrole carboxamide unit in 209. 
Hydrolysis of the oxazolidinone ring proceeded quantitatively to give alcohol 210. Exposure of 
this alcohol to Swem oxidation conditions initiated a sequence of reactions that included 
oxidation of the alcohol to the corresponding cyclopentanone, elimination of sulfinate to form a 
putative cyclopentenone, and finally internal conjugate addition of the pyrrole nitrogen onto the 
C(9a) position to form tricycle 211. The o-nitrobenzyl group was efficiently removed by 
irradiation of 211, to afford 212. Remarkably, attempted hydrogenolysis of a A/(5)-benzyl 
analogue of 211 led only to cleavage of the A/(8)-benzyl group; hence, the ultimate choice of 
the o-nitrobenzyl group.
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Scheme 34. Final modification of the /V-protecting group
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The asymmetric synthesis of (-)-agelastatin A (Scheme 35) started with the known 
alkynyloxirane 213,“  which was obtained from (fl)-epichlorohydrin by a Jacobsen hydrolytic 
kinetic resolution.83 Azide ring-opening, followed by reductive cyclization afforded 
oxazolidinone 214. A/-Acylation of 214 with o-NB-protected A/-methyl carbamoyl chloride, 
followed by silicon-to-tin exchange at the alkyne terminus secured 215. Exposure to Stang’s 
reagent, and then to sodium toluene sulfinate procured the desired cyclopentene 217 in 34% 
yield, along with the rearrangement product 216, now obtained in a much higher 41% yield. 
Conjugate addition of o-nitrobenzylamine proceeded nicely, and the resulting amine was 
acylated with pyrrole 2-carboxylic acid chloride as before, yielding 218. Oxazolidinone 
hydrolysis, followed by Swern oxidation afforded 219. Photochemical cleavage of the two o-NB 
groups procured (-)-debromoagelastatin A 220. Selective bromination of the latter at C(1) could 
be efficiently achieved with less than 4% contamination by the dibromo analogue of 220, using 
exactly 1 equivalent NBS in a solvent mixture of THF and MeOH.
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Scheme 35. Feldman’s enantioselective total synthesis of (-)-agelastatin A
In conclusion, Feldman et al. completed an enantioselective total synthesis of (-)- 
agelastatin A starting from an enantiomerically enriched alkynyloxirane, obtained by Jacobsen 
hydrolytic kinetic resolution. The cyclopentane core of the natural product was fashioned by a 
carbene insertion reaction that employed an alkynyliodonium salt. A regioselective bromination 
of the debromo analogue of agelastatin A completed this total synthesis.
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1.5.3. O’Brien’s Approach to the Cyclopentane Core of Agelastatin 
A
During the course of their studies on cyclopentadiene aziridines, O’Brien and co­
workers reported a concise racemic synthesis of the cyclopentenone 227 (Scheme 36), 
containing the fra/is-diamino functionality shown and appropriate stereochemistry for a possible 
future conversion to (i)-agelastatin A.84 Thus, cyclopentadiene was directly converted to N- 
tosylaziridine 221 by reaction with Phl=NTs and 10 mol% of Cu(acac)2, following a procedure 
reported earlier by Knight and Muldowney.85 Regioselective ring-opening of A/-tosylaziridine 
221 with ammonia on the more activated allylic position, followed by protection of the resulting 
amine with a Boc group afforded cyclopentene 222 as the sole regioisomer of the reaction. 
Epoxidation of alkene 222 afforded epoxide 223 as a single diastereoisomer. In order to set the 
required distribution of hydroxyl (or keto) and diamino functionality present in agelastatin A, 
epoxide 223 was rearranged into the corresponding allylic alcohol by treatment with four 
equivalents of the racemic diamine-derived base 224 to give 225. For isolation purposes, the 
crude alcohol was acetylated, securing 226. Hydrolysis of the O-acetate and oxidation of the 
hydroxyl with PDC furnished cyclopentenone 227, which could potentially be converted to 
racemic agelastatin A, as it contains the correct arrangement of frans-diamino functionality and 
the unsaturated enone present in the natural product. It should also be possible to run the 
lithium amide-mediated rearrangement of epoxide 223 under kinetic resolution conditions, in 
order to generate allylic alcohol 225 in an enantiomerically enriched form, although this was not 
attempted in this particular study.
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Scheme 36. O'Brien’s approach to the cyclopentane core of (i)-agelastatin A
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2.1. Retrosynthetic Analysis of (-)-Agelastatin A
In their racemic route to agelastatin A, Weinreb and co-workers successfully converted 
enone 175 into the natural product by a four-step sequence that involved a Michael-type 
addition for construction of the ABC core.68 Given that our primary interest in synthesising (-)- 
agelastatin A was to obtain sufficient quantities of the natural product to do more 
comprehensive biological testing, and also put in place a route for obtaining analogues, it 
seemed logical to capitalize on Weinreb’s past successes in this area, in our planning of an 
enantiospecific pathway to agelastatin A. Accordingly, we decided to intersect with the known 
enone 175, except now, this would be prepared in optically pure form.
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Scheme 37. Initial retrosynthetic plan for agelastatin A
Enone (-)-175 appeared derivable from 228 by oxidation of the allylic alcohol function 
and acylation of the N-Boc protected amine. A ring-closing metathesis reaction would be 
employed for cyclopentene ring-assembly in 228. Diene 229 would itself be prepared from the 
corresponding aldehyde 195 by a Wittig-type olefination. The fact that this aldehyde would
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probably exist as an equilibrating mixture of hemiacetal anomers was not a major concern at 
this stage, since this sort of compound is known to undergo facile Wittig reaction, provided that 
the hemiacetal is deprotonated prior to olefination.86 We intended to use a Vasella reductive ring 
cleavage87 to prepare the aldehyde 230 from iodopyranoside 232, and the latter would be 
obtained from the corresponding benzylidene acetal 233. A regioselective trans-6\ax\a\ ring- 
opening with azide ion was envisaged for setting up the vicinal diamido functionality present in 
233. Such a sequence would involve the known Hough-Richardson aziridine 234, which is 
available in 5 steps from D-glucosamine hydrochloride 235.
2.2. Attempted Implementation of the First-Generation 
Synthetic Strategy for (-)-Agelastatin A
An early objective in our route to (-)-agelastatin A was the synthesis of aziridine 234 
from D-glucosamine hydrochloride. This could efficiently be performed following the reported 
procedure of Hough and Richardson (Scheme 3S).88 Their procedure commenced with the 
chemoselective A/-acylation of cheap and readily available D-glucosamine hydrochloride 235 
with benzoic anhydride in methanolic sodium methoxide to obtain 236;89 it continued with a 
Fischer glycosidation to form a-methylpyranoside 237. O-Benzylidenation of 237 was most 
conveniently achieved using benzaldehyde dimethylacetal in DMF using a catalytic amount of p- 
toluenesulfonic acid at 55 °C. Compound 238 was then O-mesylated at C(3) using 
methanesulfonyl chloride in pyridine. Upon treatment of 239 with sodium hydroxide in 2- 
methoxyethanol, it underwent ring closure to form the aziridine ring with concomitant loss of the 
labile A/-benzoyl unit, securing 234.90 It should be noted that all the compounds in this sequence 
are highly crystalline, and all the purifications can readily be effected on large scale by 
crystallisation. As a consequence, aziridine 234 could be prepared on 0.5 kg scale.
(PhC0 )2 0 . Na. 
MeOH. 5 h
(54%)
HCI cone.. MeOH. 
OH  “ i l_____
(68 %)
235
D-Glucosamine
hydrochloride
HO NHCOPh 
236
NHCOPh
Ph"
O—% NaOH, o —
/  V _ o  2 -methoxyethanolph..../
p...^ y»'QMe „ reflux- 4h o -
237
a-anomer
PhCH(OMe)2, 
catp-TsOH, 
DMF, 55°C. 5.5 h 
(100%)
N
H
234
Hough-Rlchardson
Aziridine
(76% for 2 steps)
MsCI, Py. 
.OMe 0<CtoRT,3h
MsO NHCOPh 
239
NHCOPh
238
Scheme 38. Preparation of aziridine 234 following the route of Hough and Richardson
35
Chapter 2: First Generation Strategy for (-)-Agelastatin A
During their work on epimino derivatives of glycosides, Guthrie and Murphy observed 
that the ring-opening of variously protected aziridines by nucleophilic species such as azide ion 
proceeded by a regioselective trans-diaxial pathway (Scheme 39). Thus, treatment of aziridines 
234 and 240 with 4 equivalents of sodium azide in boiling DMF in the presence of ammonium 
chloride, to quench the amide anion as it formed, afforded the altropyranoside 243 exclusively. 
In the case of AFacetylaziridine 240, the acetyl group was probably cleaved off by hydrolysis 
prior to ring-opening of the parent epimine, since only amine 208 was isolated from the reaction 
mixture. When a more stable p-toiuenesulfonyl protecting group was used as in 241, the 
corresponding altropyranoside 245 was obtained. Surprisingly, the same conditions applied to 
A/-benzoylaziridine 242 were claimed to give the glucopyranoside 246b exclusively in 70% yield. 
However, a subsequent reinvestigation by Chaby and coworkers in 1998 showed that the major 
component of this reaction mixture was indeed the trans-diaxial ring opening product 246a, 
which was formed in 70% yield alongside a 25% yield of the highly crystalline D- 
glucopyranoside 246b.91 In all cases, the protected aziridines reacted much faster than their 
parent aziridines.
Ph—■
O- •OMe
NR
234, R = H
240, R = Ac
241, R = p-Ts
242, R = Bz
NaN3, NH4 CI, DMF, reflux
OMe
243, R = H (82%)
244, R = H (65%)
245, R = p-TsOH (41%) 
246a, R = Bz (70%) 246b, R = Bz (25%)
Scheme 39. Ring-opening of differently-protected aziridine with sodium azide
Given its great stability to the various conditions that would be used in our planned 
synthesis of (-)-agelastatin A, a sulfonyl group seemed like a logical choice for attachment to the 
aziridine ring of 234. Nevertheless, removal of this group can often require harsh conditions, 
especially on primary amines. In light of this, the SES (P-trimethylsilylethanesulfonyl) protecting 
group seemed like an attractive choice. This group, designed by Weinreb for the protection of 
primary and secondary amines, combines the stability of sulfonamides with the lability of |3- 
silylethyl species.69 A/-SES protected sulfonamides are stable to Bronsted and Lewis acids 
(refluxing TFA, 6M HCI in refluxing THF, BF3 etherate, LiBF4 in refluxing MeCN); however, they 
are claimed to be easily cleaved, in excellent yield, with caesium fluoride (2-3 equiv.) in DMF
36
Chapter 2: First Generation Strategy for (-)-Ageiastatin A
after several hours exposure, or with TBAF.3H20  (3 equiv.) in refluxing MeCN. Note that A/-SES 
pyrrole can be cleaved with 1M TBAF in THF at room temperature.
NaHSOs, cat. PhC03<-Bu q  PPh3, SO jC Ij q
M e 0 H /H 2 0 .4 8 h  g * 0  CH2C l2 .4 h  M e_
(95%) M e -^ i '" ' 's /  'ONa (69%) VCI
Me Me
248 249
Scheme 40. Optimal preparation of SES chloride
The preparation of SES chloride (Scheme 40) proceeds by a radical addition of sodium 
bisulfite onto the carbon-carbon double bond of vinyltrimethylsilane 247, to afford 
toluenesulfonate salt 248. Conversion of this sulfonate to the corresponding sulfonyl chloride, 
using PCI5 in carbon tetrachloride afforded a 1.5:1 mixture of the sulfonyl chloride and the 
corresponding anhydride, respectively. The modified procedure reported by Weinreb et a/.,70 
which employs thionyl chloride and a catalytic amount of DMF, afforded exclusively the 
corresponding sulfonic acid on large scale. An alternative procedure by Huang and Widlanksi 
was used instead, and adapted for the large scale preparation of SES chloride.92 Thus, sodium 
sulfonate 248 was treated with triphenylphosphine and sulfuryl chloride in dichloromethane to 
give SES chloride 249 in 69% yield on large scale (typically 100 g). An improved method for 
preparing SESCI has recently been reported by Robins et al..93 Their method also utilises 
thionyl chloride as the chlorinating agent, but a stoichiometric amount of DMF is used, affording 
SESCI free from anhydride or acid.
Thus, protection of aziridine 234 was achieved with 1.2 equiv SES chloride and excess 
triethylamine in THF. The reaction proceeded nicely to give the N-SES protected aziridine 250 
in 67% yield (Scheme 41). Ring-opening of this compound with sodium azide, according to the 
protocol of Guthrie and Murphy, afforded altropyranoside 251 as the sole regioisomer in 60% 
yield. Infra-red analysis of this compound showed the expected N3 stretching band at 2105 cm'1. 
The trans-diaxial relationship between the C(2) and C(3) substituents in 251 was confirmed by 
the 500 MHz 1H-NMR spectrum of 251 in CDCI3, which showed a small coupling constant (J = 
2.7 Hz) between H(2) and H(3), indicating a frans-diequatorial relationship between these 
protons. Next, the benzylidene acetal was cleaved off by heating 251 in a 4:1 mixture of acetic 
acid/water. Catalytic reduction of the azido group in 252 was conveniently effected by 
hydrogenation over a 10% wet palladium on carbon catalyst in ethanol. Subsequent protection 
of the primary amine with Boc20  was regioselectively achieved using Carpino’s biphasic 
conditions,94 producing 254 in 62% yield. Success in this reaction was evidenced by infra-red 
analysis of the product, which showed disappearance of the N3 stretching band at 2105 cm 1,
I
Me
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and by 500 MHz 1H-NMR spectrum of 254 in CDCI3, which showed the presence of an amide- 
NH at 5.18 ppm and two hydroxy-protons at 3.06 and 2.52 ppm.
Ph"
•OMe'
Me
Me-^"
Me
S*°^  'Cl 
249
N
H
234
TEA, THF. RT. 24 h 
(67%)
Ph"
NHBocSESHN
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B0C2O, K2CO3 
THF/H2O, 13 h. RT
(62%)
O •OMe
N
SES
250
■OMe
SESHN NH2 
253
NaN3, NH«CI, 
DMF. 140°C .2h
(60%)
Ph-
OMe
SESHN
251
H2. cat. Pd/C 
EtOH, 3h
(95%)
AcOH, HzO 
reflux, 3 h 
( 100%)
SESHN
OMe
Scheme 41. Installation of the diamido functionality within the pyranoside ring system
In order to access the key iodide 232 needed for the Vasella reductive ring-cleavage, 
the selective iodination of primary alcohol 254 was next investigated. Regioselective 
halogenation of the C(6) position of monosaccharide glycosides is well documented in the 
literature. The combination of triphenylphosphine and /V-halosuccinimide95 or carbon 
tetrahalide96 are convenient methods for the direct substitution of primary alcohol by a halide 
(Cl, Br, I) in the presence of one or more secondary hydroxyl groups. Another convenient 
method using triphenylphosphine, iodine and imidazole has also been reported by 
Samuelsson.97 Unfortunately, none of these methods were effective for converting diol 254 into 
iodopyranoside 232, the starting material usually remaining untouched even after prolonged 
reaction times (24 hours). In light of these failures a two-step procedure was used instead 
(Scheme 42).
HO—»
H O -Y  y - 'O M e
SESHN NHBoc 
254
PPh3 . 12. toluene
or PPh3, Cl4, THF
HC •OMe
SESHN NHBoc 
232
TsCI, Et3 N, DMAP. 
CHjCfe. 14 h 
(85%)
•OMe
SESHN NHBoc 
255
Nal (10 equiv.), 
acetone, reflux, 24 h
(92%)
Scheme 42. Iodination of diol 254
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Thus, regioselective tosylation of the primary hydroxyl in 254 with p-toluenesulfonyl 
chloride and triethylamine in dichloromethane at 0°C afforded tosylate 255 in 85% yield. 
Evidence for the selective O-tosylation of the primary hydroxy group was provided by the 500 
MHz 1H-NMR spectrum of 255 in CDCI3, which showed a downfield shift of H(6) from 4.11 and 
3.90 ppm to 4.36 and 4.21 respectively. Subsequent nucleophilic displacement with 10 equiv. 
sodium iodide in refluxing acetone produced 232 in 92% yield. Evidence for incorporation of the 
iodo substituent into 232 was provided by its 125 MHz 13C-NMR spectrum in CDCI3, which 
showed C(6) at the very high field position of 6.6 ppm.
With iodopyranoside in hand, its reductive ring-cleavage was attempted with a view to 
securing 229 (Scheme 43). Ever since Bernet and Vasella first described the zinc-promoted 
ring-fragmentation of 6-halo derivatives of a-pyranosides, this methodology has been widely 
used as an entry to highly functionalised chiral 6,e-unsaturated aldehydes starting from 
carbohydrates. It proceeds by a preliminary oxidative addition of the Zn into the C-X bond, 
followed by a (5-elimination that produces methanol. Treatment of iodide 232 with zinc dust (size 
<10 pm) in a refluxing mixture of THF/water (4:1) afforded a single product, as evidenced by 
TLC. Infra-red analysis of this compound did not show the expected strong stretching band of 
aldehydes at 1720 cm'1. 500 MHz 1H-NMR analysis of this compound in CDCI3 revealed that it 
consisted of a 1:1 mixture of the two anomeric hemiacetals 231a and 231b.
••OMe 
V  HsO 
NHBoc
Zn powder, 
THF/HjO, reflux, 
5 h  _
(80%)
232
SESHN NHBoc
y ^ ^ .o H
SESHN NHBoc 
231a
V ^ °^ .O H
SESHN NHBoc 
231b
Scheme 43. The Vasella reductive ring-cleavage
The next step in our strategy was the olefination of hemiacetal 231 to form the 
corresponding diene 229. Standard Wittig olefination conditions using methyl 
triphenylphosphoranylidene, prepared in situ from methyl triphenylphosphonium bromide and n- 
BuLi in THF (entry 1, Table 2), or methyl triphenylphosphonium bromide and ferf-BuOK in THF 
(entry 2, Table 2), left the starting material untouched. Next, a Tebbe olefination reaction was 
attempted (entry 3).98 The Tebbe reagent was prepared in situ from a commercial solution of the 
precursor by addition of a catalytic amount of sodium hydroxide. A complex mixture of 
compounds was formed, from which none of the desired olefin could be isolated. The recently
39
Chapter 2: First Generation Strategy for (-)-Agelastatin A
reported Takai olefination" was next investigated (entry 4), since this method has proved useful 
in a number of related substrates. Unfortunately, all attempts at converting hemiacetal 231 into 
229 remained unsuccessful.
Table 2. Attempts at olefinating the hemiacetal
%
conditions HO"
SESHN NHBoc SESHN NHBoc
231 229
Entry Conditions Yield
n-BuLi (5 eq.), [Ph3PCH3]Br (5 eq.), THF, RT to reflux no reaction
f-BuOK (3.2 eq.), [Ph3PCH3]Br (2.2 eq.), THF, RT to
,, no reactionreflux
Cp2TiCH2AICI(CH3)2 (1eq.), THF/PhMe, 0°C to RT mixture
Zn (10 eq.), CH2I2 (3 equiv.), TMSCI (3 eq.), nQ reactjon
cat. PbCI2 (0.1 eq.), THF, RT
The new olefination method recently reported by Kociehski and co-workers100 was also 
investigated. The Kociehski method involves the use of a lithiated /V-phenyltetrazole sulfone of 
general structure 257 which adds to carbonyls in the manner shown below (Scheme 44). This 
sulfone gives significantly higher yields than the benzothiazolic counterparts previously reported 
by Julia,101 possibly because the phenyltetrazolyl anion is less prone to dimerisation. The 
Kociehski methodology was successfully applied to a synthesis of herboxidene by his group.102 
Nevertheless, no previous reports were found for the use of these reagents on hemiacetals.
N -N
256
= / R2 SO2 + /—1 +
R,
KHMOS
262
N -N  
£h
261
OLi
N -N
N'N^SO:
RjjCHO
Ph 
257
N -N
ph/ n rA
L'^AS Ri 
260 0
Ph
N—N-o-—  n
v C V *
R ° 1
258
R2
N—NLin
*s£r
Ph R
259
Scheme 44. Mechanism of Kocienski’s new olefination method
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For the olefination of hemiacetal 231, the new sulfone 265 was prepared by the route of 
Kociehski.102 Thus commercially available 1 H-phenyltetrazol-5-thiol 263 was alkylated with 
iodomethane after deprotonation with potassium hydroxide, and the resulting thioether 264 was 
oxidised with m-chloroperoxybenzoic acid to give sulfone 265.
N - n  1) KOH, EtOH, A. 2 h m-CPBA, NaHCOa. n_ nA Ksh 2 , ^ 2 -  .  a; X s M e   CH,Cb. „ h  .  N
k  l8,%) h  ,76%’ k
263 264 265
Scheme 45. Preparation of 5-methanesulfonyl-1 -phenyl-1 H-tetrazole
Unfortunately, the slow addition of LiHMDS to a mixture of hemiacetal 231 and sulfone 
265 in THF at -7 8  °C, followed by warming of the reaction to mixture to -30  °C left 196 intact 
after 12 hours (Scheme 46).
N -N
Vv
*9 a
N'N^ ‘S02Me
OH
\ j  Ph 265
SESHN NHBoc LiHMDS. PhCHa/THF, SESHN NHBoc
-78*0 to -30 "C.
231 Stif 1 2  h 229
Scheme 46. Atempted olefination of hemiacetal 231 with sulfone 265
Since all our attempts to olefinate 231 were unsuccessful, it seemed necessary to 
protect the secondary alcohol of 232 in order to prevent the formation of this hemiacetal. The 
TES protecting group was selected, given its acceptable stability to base and its ease of 
deprotection with fluoride ion or mild acids.103 Thus a step backward was taken in the route to 
(-)-agelastatin A, and alcohol 255 was treated with chlorotriethylsilane and DMAP in pyridine to 
afford the fully protected pyranoside 266 (Scheme 47). Nucleophilic displacement with iodide as 
before produced iodopyranoside 267. The Vasella reductive ring-cleavage afforded aldehyde
268 in 85% yield, as evidenced by the presence of a singlet at 5 9.60 ppm in the 500 MHz 
proton-NMR spectrum of the isolated product in CDCI3. However, repeated efforts to olefinate 
aldehyde 268 using the Wittig and Tebbe reaction failed, the starting aldehyde always being left 
intact. Fortunately, when aldehyde 268 was treated with sulfone 265 and potassium 
hexamethyldisilazide, diene 234 was obtained in 77% yield. Remarkably, when lithium 
hexamethyldisilazide was used as the base, no reaction occurred. Evidence for the formation of
269 was given by 500 MHz ^ -N M R  analysis in CDCI3, which contained resonances for 3 
olefinic protons at 8 5.77, 5.25, and 5.22 ppm.
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Scheme 47. Preparation of the diene
With diene 269 in hand, we next addressed the key ring-closing metathesis (RCM) 
reaction104 on 269 to form the corresponding cyclopentene. Amongst the most active ring- 
closing metathesis catalysts available, the Schrock molybdenum alkylidene 271 and the 
Grubbs-Hoveyda catalyst 276 are now commercially available. The Schrock catalyst is hardly 
affected by the electronic properties of the olefinic substrates and reacts with both electron-rich 
olefins (enol ethers) and electron-deficient olefins (acrylates). For a long time, it was the only 
catalyst to allow the formation of tri- and even tetrasubstituted olefins by RCM. Unfortunately 
however, this complex is extremely sensitive towards oxygen and moisture, and must be 
handled using Schlenk techniques. Moreover, the “hard” Movl center is often deactivated by 
“hard" nucleophiles such as nitrogen substituents on the olefin that form unreactive chelates. 
For these reasons, we ruled out use of the Schrock catalyst to mediate the conversion of 269 
into 270.
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(F3 C)2 (H3 C)OC
(F3C)2 (H3 C)OC'AxMeMe
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?Cy3
272
First-generation 
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C k YR u=\
r \
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Figure 7. RCM catalysts
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The ruthenium-based first-generation Grubbs catalyst 272105 was a much more 
attractive catalyst for the synthesis at hand given its high activity for all types of alkene 
metathesis reactions, its spectacular tolerance of a wide array of functional groups, and its 
reasonable stability towards oxygen, water and minor impurities in the solvents. Generally 
speaking, its ease of handling and commercial availability makes it an exceedingly practical 
catalyst for use in large scale syntheses. It is also commercially available. However, this catalyst 
often fails to react with electron-deficient olefins, such as rc-conjugated olefins (enones, enoic 
esters). Given that 269 contained non-conjugated and reasonably electron-rich alkenes, we 
anticipated success in the RCM reaction with 272. Unfortunately, catalyst 272 showed no 
reactivity towards 269 when it was heated at reflux in methylene chloride. Possibly, this lack of 
reactivity was due to deactivation of the catalyst by its coordination with the NH-substituents on 
the substrate.
Ring-closing metathesis reaction of diene 269
conditions (see table) TESQ1" ^ ^
SESHN NHBoc 
269 270
Entry Catalyst (mol%) Solvent Time Yield
1 272 (10%) c h 2c i2 8 h 0 %
2 272 (5%) PhMe 28 h 0%
3 274 (6%) PhMe 8 h 53%
4 276 (5%) PhMe 15.5 h 92%
Detailed mechanistic studies have shown that the dominant pathway for productive 
metathesis involves the dissociation of one of the two PCy3 ligands from 272. The replacement 
of one of the phosphine units by a more Lewis basic and sterically demanding ligand, such as 
the A/,A/’-disubstitued 2,3-dihydro-1 H-imidazol-2-ylidene unit led to the second-generation 
catalyst 273.106 The combination of a kinetically inert A/-heterocyclic carbene with a 
coordinatively labile phosphine somewhat limits the dissociative pathway. This probably 
explains the greater stability of catalyst 273 towards air/water, and its enhanced reactivity 
towards electron-deficient olefins. Further improvement was achieved by using the saturated 
analogue of 2,3-dihydro-1/-/-imidazol-2-ylidene, as in catalyst 274107 The lack of carbene 
stabilisation provided by the absence of a 7i-donating effect renders the carbene more basic 
than its unsaturated analogue. This leads to a catalyst with greater reactivity and better
Table 3.
SESHN NHBoc
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compatibilty towards functional groups (i.e. allylic alcohols). Reaction of diene 279 with 274 did 
afford some of the product 270 in refluxing toluene, but the reaction seemed to stop after ca. 
50% conversion. Nevertheless, this promising result raised our hopes and prompted us to 
examine the more active Grubbs-Hoveyda catalyst 276.
Detailed studies of 276 by Hoveyda have shown that the Lewis basic isopropoxy group 
stabilises the complex in its resting state, and that it readily opens a coordination site in the 
presence of the substrate. Moreover, increased steric hindrance around the Ru-centre protects 
the complex from side-reactions, such as carbene oxidation. Recently, the nitro-substituted 
Grubbs-Hoveyda catalyst 277 has been reported by Grela and co-workers.108 The presence of a 
nitro group on the benzylidene ring is thought to decrease the electron density at the oxygen 
atom. This leads to an increased initiation rate and therefore an increased catalytic activity. 
Fortunately, the Grubbs-Hoveyda catalyst 276109 became commercially during the course of the 
present study. To our great delight, treatment of diene 269 with 5 mol% of the Grubbs-Hoveyda 
catalyst in toluene at reflux afforded the cyclopentene 270 in an excellent 92% yield after 12 h. 
The reaction was performed using non-distilled solvent in a reaction vessel open to the air.
The successful preparation of cyclopentene 270 now potentially allowed us to channel 
into the final stages of the Weinreb route. We originally envisioned that the two silyl protecting 
groups of 270 would be easily removed with a fluoride source to afford 278, which would 
subsequently be converted into the amine 279 by formation of the oxazolidinone with phenyl 
chloroformate and deprotection of the Boc group with TFA. Acylation of 279 and protection of 
the oxazolidinone nitrogen atom with a Boc would then provide Weinreb’s advanced 
intermediate 172. Unfortunately, our attempts to remove the SES group from 270 with various 
fluoride sources (CsF, DMF, 95°C or TBAF, THF, 50°C)69 were unsuccessful. On one occasion, 
a single product was isolated from the reaction of 270 with 5 equiv. of TBAF in acetonitrile at 
SO'C; its structure was shown to be that of 282 based on mass spectrometry and 1H-NMR 
analysis. It is likely that the residual water present in the commercial 1M TBAF solution causes 
cleavage of the Boc group. Why the SES group should have remained intact is unclear.
A closer examination of the literature showed that the Ward group had experienced 
similar problems when attempting to remove the SES group from primary amines with TBAF in 
THF at reflux or with CsF in DMF at 95°C, during the course of their studies on actinobolin and 
bactobolin.110 Whether TBAF solutions (anhydrous or with 5% water) or CsF were used, all 
methods failed to produce the desired product. A recent report by Campbell and Hart indicated 
that the SES group could be removed from A/-acyl SES sulfonamides under mild conditions.111 
Therefore, we decided to prepare oxazolidinone 280 and attempt the removal of the SES group 
on this substrate, as this structure would get us closer to Weinreb’s intermediate 172 while 
enhancing the lability of the SES group. Thus, sulfonamide 271 was treated with sodium
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hydride, followed by phenyl chloroformate to form 280 in an unoptimised 31% yield. 
Unfortunately, treatment of this compound with TBAF in THF did not afford the desired 
unprotected oxazolidinone 281, but rather, some presently unidentified product.
TBAF (1.2 equiv.), 
MeCN, 30 min, RT
(100%)
1) NaH, THF. RT. 1h
2) PhOC(0)CI, 50 °C
SESHN NHBoc
228
" f t
T E S O -<  ^  TBAF. MeCN
SESHN NHBoc H2N NHBoc
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- f t
278
(31%)
1) O
PhO^ci 
aq. NaHC0 3 . 
CH2CI2
2) CF3 C 02H
c h 2 c i2
TBAF (3 equiv.)
- 10-  K
g ES NHBoc H NHBoc
e ft
280 281
Me3Si
-  U p  ■••••■■H NH2 NBoc
279 172
Weinreb's advanced 
intermediate
TBAF (5 equiv.).
MeCN. A, 15 h w
- f t
(76%) SESHN NH2 
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Scheme 48. Attempted preparation of Weinreb’s intermediate
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Chapter 3: Second Generation Strategy to 
(-)-Agelastatin A
3.1. Revised Retrosynthetic Plan
Given the problems that we had encountered in the deprotection of the SES group, we 
now decided to re-evaluate our strategy (Scheme 49). We resolved to comply with Weinreb’s 
arrangement of protecting groups, and attempted the preparation of oxazolidinone 171. 
Previously, this compound had been converted into the advanced intermediate 175 in two 
steps, by oxazolidinone hydrolysis and oxidation of the resulting alcohol. Pyrroloamide 175 itself 
was previously obtained by Weinreb from sulfonamide 150 by acylation with the pyrrole-2- 
carboxylic acid chloride derivative 170. Returning to our own retrosynthetic analysis, 150 
appeared derivable from the corresponding diene 283 by a Grubbs-Hoveyda ring-closing 
metathesis reaction. The Julia-Kocienski method would again be used to prepare 283 from 
aldehyde 284, which would already bear the oxazolidinone functionality present in intermediate 
171.
Me
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4 steps
 ^ }~r—  V y N H
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O
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Scheme 49. Revised retrosynthetic plan
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As before, a Vasella ring-cleavage would be used to access aldehyde 284 from iodide 
285; the latter would itself be obtained from the azido-alcohol 286 by reduction, acylation, and 
iodination of the alcohol functionality. The oxazolidinone ring would be assembled from diol 287 
by intramolecular cyclisation of the secondary alcohol onto the adjacent cis methyl carbamate 
function. Finally, carbamate 287 would be prepared by azide ring-opening of a conveniently 
activated derivative of the Hough-Richardson aziridine 234.
3.2. Attempted Implementation of the New Route
The new methoxycarbonyl protecting group on the aziridine ring would serve the dual 
role of activating the regioselective diaxial ring-opening as well as providing the carbonyl group 
of the oxazolidinone ring system. Thus, the Hough-Richardson aziridine was treated with methyl 
chloroformate to afford the carbamate 288 in 86% yield (Scheme 50). Although azide ring- 
opening of carbamate derivatives of 199 has not been reported, we were pleased to find that 
treatment of 252 with 4 equiv. sodium azide in DMF at reflux afforded exclusively the 
D-altropyranoside 289 in excellent yield. Removal of the benzylidene acetal from 289 was 
conveniently achieved by treating 289 with HCI in methanol. This was conveniently formed in 
situ by addition of acetyl chloride to anhydrous methanol at 0°C. Compound 287 was obtained 
in 94% yield.
P h . . . . /  V _ Q  Me0C(0)CI, Py ph.M1/
V..( >OM,CH=CI^ ' oRT' v •OMe NH4CI Ph" " (
234
Hough-Richardson
Aziridine
OMe
(86%)
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DMF. reflux. 4 h
Me02CHN N3
OMe
TsCI (1.5 equiv). 
DABCO (2 equiv.)
CHzCb.
O P  to RT. 1.5 h 
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I Hj. Pd(OH)2, 
I ethanol. 2  h
NaH, THF, 
Q RT, 0.5 h
0M e (100%)
AcCI, MeOH 
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•OMe
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Scheme 50. Implementation of the new route
When the resulting diol was exposed to 1.5 equiv. sodium hydride in THF, the 
oxazolidinone 286 was formed in quantitative yield. The reaction was conducted at low
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concentration (8 x 10'5 M) to favour the intramolecular process. Reasoning that reduction of the 
azido group at this stage would expose three nucleophilic functionalities that would be difficult to 
manage, we delayed this reduction step and attempted selective tosylation of the primary 
alcohol, in the presence of the very nucleophilic nitrogen of the oxazolidinone. We hoped that 
the less hindered alcohol in 286 would tosylate preferentially to this nitrogen. In this regard, the 
standard tosylation procedure (TsCI 1.1 equiv., triethylamine, DMAP, CH2CI2) afforded a 1:1 
mixture of the mono-O-tosylated and A/,0-ditosylated oxazolidinones. Given that pyridine is 
known to catalyse this transformation by formation of an activated pyridinium tosylate salt 
(Scheme 51), we hypothesised that the salt generated from DABCO might preferentially react 
with the primary OH.112 Indeed, treatment of 286 with 1.5 equiv. of p-TsCI and 2 equiv. of 
DABCO in CH2CI2 produced O-tosylated alcohol 290 in an excellent 87% yield, without any 
ditosylation product being detected by TLC. Confirmation that the sulfonylation occurred at the 
primary OH was given by 500 MHz 1H-NMR analysis of 290 in CDCI3, which showed the 
deshielded oxazolidinone NH at 6.12 ppm, and the downfield chemical shift of the two C(6)-H at 
4.25 and 4.17 ppm.
DABCO
Scheme 51. Formation of activated tosylation agents with DABCO and pyridine
With O-tosylate 290 in hand, reductive hydrogenation of the azido grouping was 
attempted by stirring 290 under a saturated hydrogen atmosphere with 20% palladium 
hydroxide on carbon in ethanol. Although complete disappearance of the starting material was 
observed by TLC after 2 hours, no product could be isolated from the reaction mixture. Careful 
observation of the three-dimensional structure of 290 showed that the presence of the fused 
oxazolidinone ring greatly facilitates attainment of a boat conformation in the pyranoside ring. 
As a consequence, the transient nucleophilic amino group of 291 would be in a favourable 
position to effect an internal nucleophilic displacement of the tosylate, to afford 292, which 
would probably stick to the metal catalyst. Alternatively, polymerisation may also have occurred. 
Given our inability to isolate any product from this reduction, it is not possible at the present 
moment to positively say what actually happened.
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Scheme 52. Putative intramolecular cyclisation of amine 291
Reasoning that the presence of a Boc group on the oxazolidinone would probably 
destabilise the boat-like conformation of 290, and help prevent the undesired intramolecular 
cyclisation, we set about preparing 293 from the oxazolidinone 290. When 293 was submitted to 
the catalytic hydrogenation protocol, again, no product could be isolated from the reaction 
mixture, and the starting material was found to completely disappear after 2 h according to TLC 
analysis.
OMe
Boc20 , DMAP, T s '  
Et3 N, CHoCU,
RT, 0.5h
(82%)
290
OMe
H2, Pd(OH)2, 
ethanol
Scheme 53. Preparation of Boc-protected oxazolidinone 293 and attempted hydrogenation
In conclusion, incorporation of the oxazolidinone ring at an early stage of the route 
seemed to create problems since it changed the three-dimensional structure of the glycoside 
skeleton, and it appeared to modify the reactivity of the functionalities attached to it. Not only 
was the reduction of the azide problematical when a leaving group was attached at C(6), but we 
now foresaw that the Vasella ring-cleavage would be potentially troublesome since the 
favourable trans-diaxial relationship between the C(1)-OMe and the C(6)-CH2X bonds would no 
longer be present. Therefore, we considered it necessary to slightly change the planned route 
and delay the formation of the oxazolidinone until later in the route.
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4.1. Modified Retrosynthetic Plan
Conceptually, our new route to (-)-agelastatin A would be similar to the last strategy. 
Now, however, formation of the oxazolidinone in 150 would be delayed until after the RCM step, 
and we would use a TES group to protect the backbone O-atom in 295. Thus, we would still 
attempt the preparation of sulfonamide 150, which would be converted into (-)-agelastatin A 
using Weinreb’s 7-step procedure. A Julia-Kociehski olefination would again be used to create 
the key RCM diene 295 from aldehyde 296, and this, in turn, would be synthesised from the 6- 
iodopyranoside 297 by a Vasella reductive ring-cleavage. Iodide 297 would originate from diol 
298; the latter would be prepared by removal of the benzylidene group from sulfonamide 299. It 
would be derived from reduction of the azido group in 289 and sulfonylation of the resulting 
amine with SES chloride. Azide 289 had already been prepared in the previous route from the 
Hough-Richardson aziridine.
Me
HQ
TMSTMS ■NBoc■NHBoc■NH
NH SESSES4 steps 2  steps 1 step
175 171
  _ 0
7  NBoc
NHSES 
150
(-)-Agelastatin A
Vasella Reductive 
Ring-Cteavage
Julia-Kocienski
Olefination
Grubbs-Hoveyda 
Ring-Closing 
Metathesis \
TESO""^ ; -O M e  
MeOjjCHN' NHSES 
297
>  ^ L►••••< CHO =  OHC ) - (TESO*,,M^  = x ^ -Q T E S < ^
MeC^CHN' NHSES SESHN NHCOjMe
V  Vl^OTES
^ ^ ^ —NHCOaMe
296
lodination,
Protection
\
Benzylidene
Removal
HO*"( > -O M e
M eO^HN*' NHSES 
298
3  (>•■< > -O M e
MeO
NH NHSES
299
296
P h - (  ) - o
0- " (  V -O M e
Q J—(
V -N H  N3, 
MeO
289
NHSES
295
p*-<
0 " (  V -O M e
Reduction,
Sulfonylation
N
H
234
Hough-Richardson
Aziridine
Scheme 54. Third retrosynthetic strategy
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4.2. Implementation of the New Route: An Enantiospecific 
Formal Total Synthesis of (-)-Agelastatin A
Azide 289, previously prepared by us in two steps from the Hough-Richardson aziridine, 
was reductively hydrogenated in methanol in the presence of Pearlman’s catalyst (20% Pd(OH)2 
on C) to obtain amine 300. According to 1H-NMR analysis, 300 was obtained in almost pure 
condition and, as a consequence, was used for the next step without further purification. We 
next attempted protection the amino group with a SES group.
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C6 H8. 75°C, 2 2  h V , . , /  \ . . . (
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MeO
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O
y —NH NHSES 
MeO
298
TES0>"( )"'O M e 
O ^
V -N H  NHSES 
MeO
297
Scheme 55. Preparation of iodide 261
The traditional protocol for introducing a SES group, which uses SESCI and Et3N in 
DMF, proved disappointing. It provided the desired sulfonamide 299 in a rather modest 23% 
yield after 11 days, along with other unidentified products (entry 1, Table 1). The sulfonylation 
protocol employing DABCO (that was previously employed so successfully in the sulfonylation 
of 286) afforded 299 in only 14% yield (entry 2). Carpino’s biphasic conditions (SESCI, 
NaHC03, CH2CI2/H2O) did not produce any trace of 299 (entry 3). Fortunately, it was found that 
treatment of 300 with SES chloride in pyridine afforded 299 in 61% yield on a one-gram scale 
(entry 4). Eventually, an optimised procedure was identified that lowered the amount of valuable 
SES chloride used, which ran the reaction at a concentration of 0.2 M. Under these conditions, 
299 was obtained in 80% yield on a ten-gram scale. However, this protocol was found to be less 
satisfactory on larger scale, with yields typically being lower, ranging from 50 to 54%. A novel 
procedure using silver cyanide was therefore investigated. Originally developed for carrying out 
amidations on base-sensitive peptidic substrates,113 this process proved successful in a number 
of situations where electron-deficient or hindered amines were coupled to hindered aminoacid
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chlorides.114,115 This is the first time, however, that this protocol has been applied to the 
sulfonylation of a primary amine. In our experience, the AgCN method is much more reliable 
than the base-mediated methods on large scale, since 299 is typically produced in 69% yield 
when 300, AgCN, and SESCI (1.5 equiv.) are heated in freshly distilled benzene at reflux under 
nitrogen.
Table 4. Sulfonylation of amine 300 with SES chloride
Entry Conditions Yield
1 SESCI (1.5 equiv.), Et3N (5.5 equiv.), DMF (C 0.15 M), RT, 11 d 23 %
2 SESCI (1.5 equiv.), DABCO (3 equiv.), CH2CI2 (C 0.06 M), RT, 18 h 14%
3 SESCI (2 equiv.), K2C 0 3 (12 equiv.), CH2CI2/H20  3:1 (C 0.09 M), RT, 26 h 0 %
4 SESCI (3 equiv.), DMAP (0.1 equiv.), Py (C 0.08 M), RT, 1 h 61 %
5 SESCI (1.5 equiv.), DMAP (0.1 equiv.), Py (C 0.2 M), RT, 20 h 80 %
6 SESCI (1.5 equiv.), AgCN (1.5 equiv.), CeH6 (C 0.3 M), reflux, 23 h 69%
Removal of the benzylidene acetal from 299 was accomplished with anhydrous HCI in 
methanol; this process proceeded smoothly, affording diol 298 in 85% yield. Regioselective O- 
tosylation of 298 was thereafter achieved in 79% yield by a portionwise addition of TsCI (1.05 
equiv.) over several hours to a mixture of 298, DMAP and Et3N at 0°C. The TES protecting 
group was attached to the resulting alcohol 301 without difficulty, by treatment with 
chlorotriethylsilane in pyridine; 302 was produced in 89% yield. Finally, tosylate 302 was 
converted into iodide 297 by nucleophilic displacement with sodium iodide in acetone at reflux. 
This reaction produced 297 in a nearly quantitative yield.
Preparation of the bicyclic oxazolidinone 150 was next attempted (Scheme 56). The 
Vasella reductive ring-opening of 297 with zinc dust in aqueous THF procured aldehyde 296 in 
excellent yield (97%). Olefination of 296 with sulfone 265 using Kocienski’s protocol effectively 
produced diene 295. It was not possible to remove all of the hydroxytetrazole by-product from 
diene 295 on a preparative scale. However, this impurity did not adversely affect the 
subsequent Grubbs-Hoveyda ring-closing metathesis reaction, which cleanly converted 295 into 
the cyclopentene 303. Yet again, it still proved difficult to remove all of the tetrazole by-product 
from 303 by S i02 flash-chromatography. Therefore, an approximate 47% combined yield over 2 
steps is quoted.
Whilst the O-desilylation of 303 with TBAF was problematical, the TES group could be 
cleaved from 303 with TFA in aqueous THF; 304 was obtained in 56% yield. The latter was 
converted to the oxazolidinone 151 by potassium carbonate treatment in hot methanol.
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However, it was generally more advantageous to obtain the oxazolidinone 151 directly from 303 
by heating the latter with K2C 0 3 in MeOH at reflux for 3 hours. An accurate yield of 36% can 
now be quoted for the pure 151 so obtained from aldehyde 296.
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Scheme 56. Preparation of bicyclic oxazolidione 151
Now we were then faced with the challenging issue of having to chemoselectively N- 
acylate the oxazolidinone nitrogen in 151 in the presence of the sulfonamide functionality to 
obtain (-)-150. Fortunately, this could be achieved reasonably cleanly and efficiently (in ca. 63% 
yield), by slow addition of a solution of Boc20  in CH2CI2 to a solution of 151, DMAP and Et3N in 
CH2CI2 (Scheme 57).
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Scheme 57. Completion of the formal total synthesis of (-)-agelastatin A
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Racemic 150 had previously featured as an advanced intermediate in Weinreb’s total 
synthesis of (+)-agelastatin A, and the 1H and 13C NMR spectra of our optically pure (-)-150 
matched those recorded by these workers for (+)-150 in the same solvent. Our enantiopure 150 
also had a large negative [a ]0 (-88 0 at c 0.22 in CH2CI2), and its relative and absolute 
stereostructure were further confirmed by X-ray crystallography. We had thus completed a 
formal enantiospecific total synthesis of (-)-agelastatin A.
54
Chapter 5: A Reinvestigation of Weinreb’s Endgame for Agelastatin A
Chapter 5: A Reinvestigation of Weinreb’s 
Endgame for Agelastatin A
A re-examination of Weinreb’s synthetic endgame for racemic agelastatin A has led to 
us making a number of important process improvements and modifications for the synthesis of 
the penultimate precursor of the enantiomerically pure natural product (Scheme 58). Although 
the /V-acylation of (-)-150 with acid chloride 170 could be reproduced in a perfectly satisfactory 
80% yield (Weinreb quoted a 100% yield in the (±)-system), difficulties were encountered in 
reproducing the 66% yield they reported for cleavage of the SES group from (-)-171 with n- 
Bu4NF in THF. In our hands, the yield of (-)-172 was typically 30%. A more satisfactory protocol 
for cleaving the SES group from (->-171 exposed it to CsF in DMF at RT for 19 h, prior to 
heating it at 50 °C for 5 h. The latter procedure furnished the desired product (-)-172 in an 
improved 46% yield on a gram-scale.
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Scheme 58. Formation of the tricyclic core of (-)-agelastatin A
Weinreb’s recommended method for accessing 174 regioselectively hydrolyses the 
oxazolidinone ring in 172 with 8 equiv. LiOH in THF/water (9 :1). Although Weinreb reported 
that a 4:1 ratio of 174:173 was formed, we have observed that a 7:3 mixture of (-)-174:(-)-173 is
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typically produced under these conditions; similar results were obtained with 1 equiv. Cs2C 03 in 
MeOH,116 but the process was now much slower (20 h). Because of the difficulties involved in 
separating (-)-174 from (-)-173 by S i02 flash chromatography, we took the chromatographed 
(but unseparated) mixture forward for the subsequent oxidation step with TPAP and NMO and 
obtained a mixture of (->-175 and (-)-173. The TPAP oxidation method generally proved superior 
to the CrtVPy protocol originally reported by Weinreb, it being far easier to work-up, and it 
using only catalytic quantities of the transition metal oxidant, which is preferable for large-scale 
work. The separation of (-)-175 from (-)-173 by S i02 column chromatography again remained 
very difficult at this stage. The cyclisation of (-)-175 to (-)-176 was therefore attempted by 
exposing the mixture of (-)-175 and (-)-173 to Cs2C 03 in MeOH, under conditions similar to 
those originally reported by Weinreb, but involving substantially less Cs2C 0 3. When the reaction 
was complete, TLC analysis of the crude reaction mixture invariably indicated the presence of 
three main reaction components: 305, (-)-173, and (-)-176, which were now readily separated 
by Si02 flash chromatography; the desired product (-)-176 was generally isolated in 18% overall 
yield for the three steps from (-)-172.
Surprisingly, Weinreb and coworkers did not report the formation of 305 in their 
cyclisation reaction, yet it was found that this undesired by-product was always produced in 
around 7% overall yield from (-)-172. Evidence for the proposed structure was provided by the 
500 MHz 1H-NMR spectrum of 305 in CDCI3 which showed 2 multiplets for two C-H protons at 6 
3.33 and 2.47 ppm, and the absence of two olefinic CH protons between 5 and 6 ppm. One 
possible mechanism (Scheme 59) that accounts for the formation of 305 invokes y- 
deprotonation occurring in (-)-175 to generate a cyclopentadienol or a caesium 
cyclopentadienolate. The latter then undergoes further deprotonation to produce an aromatic 6- 
7t anionic species that reprotonates to give 305. The cyclopentenone isomerisation seen here is 
analogous to the well-known base-mediated prostaglandin A2 to B2 rearrangement reported by 
Roberts and Newton.117 The extensive n-7i conjugation in 305, and intramolecular H-bonding of 
the 2 N-H protons is reflected by the low-field position of the two amido N-H protons in the 500 
MHz ^-N M R  spectrum of this compound in CDCI3 (Scheme 59). Presumably, the greater 
degree of conjugation experienced by 305, and the extra thermodynamic stability of the 
tetrasubstituted double bond help explain the ease with which this product is formed.
MeO-H
NHBocNHBoc NHBoc
(->-175 6*>anion
aromatic
305
Scheme 59. A possible mechanism for the formation of 305
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The fact that 305 was co-produced in this cyclisation immediately raised concerns about 
whether compound 176 might be generated as a racemate. The fact that 176 was formed in 
optically enriched form was indicated by its large negative specific optical rotation in CHCI3 ([oc]D 
-134° (c 0.5 CHCI3)). Clearly, the pyrrole-N  of (-)-175 had to be competitively and irreversibly 
adding to the enone at a rate faster than the y-deprotonation and a-enolisation/protonation 
processes were proceeding according to Scheme 59, otherwise racemic 176 (and a more 
complex mixture) would almost certainly have been the end-result.
The bromination of (->-176 provided optically pure (->-177 when carried out according to 
the Weinreb protocol (Scheme 60); the latter was obtained in 74% yield with an [a]D of -112° in 
MeOH. Weinreb et al. had previously converted (±)-177 into (+)-agelastatin A by a two-step, 
one-pot, operation. They used TMSI to remove the Boc group and form a transient 
trimethylsilylurethane species, that was then cleaved and trapped in situ with methyl isocyanate 
and aqueous sodium hydroxide. This protocol was designed to preclude the formation of a 
dimeric pyridazine, which could potentially occur by condensation of two a-amino-ketone 
functionalities.118,119 In spite of several attempts, no trace of the natural product was ever 
detected when we used this method. In our hands, addition of new commercial TMSI (obtained 
from a sealed ampule) under nitrogen to a solution of 177 did lead to the disappearance of 
starting material and a mixture of slower-moving products was formed according to TLC 
analysis. However, formation of the urea/hemiaminal ring-system did not occur subsequently 
when MeNCO and NaOH were added. Although we attempted to isolate the primary amine after 
deprotection with TMSI or TFA, none of these efforts were successful.
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0-CtoRT, 1 hTM!
NHNH (74%)
(->-178
Me O
1)TMSI,CH2CI2, V - f
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2) MeN«C=0, C6H6,
aq. NaOH, 2 h, RT_____________ \__ /
NH
(-)-Agelastatin A
Scheme 60. Our attempts at preparing (-)-agelastatin A from ketone (-)-176
In conclusion, a number of process improvements have been made to Weinreb’s 
endgame for securing agelastatin A. However, we were unsuccessful in repeating his final one- 
pot process for converting (-)-177 into (-)-agelastatin A. In light of the collective problems we 
experienced in this endgame, we eventually decided to investigate an alternative method for 
securing (-)-agelastatin A from (-)-150.
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6.1. A New Retrosynthetic Strategy for (-)-Agelastatin A that 
Would Intersect with Oxazolidinone (-)-150
Since we were unable to reproduce Weinreb’s last step for preparing (-)-agelastatin A 
from 177, we now sought to develop an alternative engame that would avoid the safety issues 
associated with use of the highly toxic methyl isocyanate for forming the B-ring of the natural 
product (Scheme 61). Feldman et al. had successfully deployed an N-benzyl carbamoyl group 
as a protected precursor of the urea; this cyclised intramolecularly onto the adjacent ketone 
after hydrogenolysis. It seemed therefore logical to capitalise on their success, and use a similar 
stratagem in our modified endgame.
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Scheme 61. New endgame for (-)-agelastatin A
The new route that we envisaged would transform oxazolidinone (-)-150 into the 
pyrrolo-amide 308 by two regioselective acylations. The first one would be effected on the 
oxazolidinone nitrogen with carbamoyl chloride 309; the second one would take place at the 
sulfonamide functionality. Subsequent removal of the SES group would secure 308. A base- 
promoted hydrolysis of the oxazolidinone ring, and an oxidation of the resulting alcohol would 
furnish 307. Upon treatment with a suitable base, the latter would undergo an intramolecular 
Michael-type addition of the pyrrole nitrogen onto the double bond of the unsaturated ketone 
and produce (-)-306. Hydrogenolysis of the A/-benzyl group and monobromination of the pyrrole 
ring would then hopefully complete the total synthesis of (-)-1.
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6.2. Implementation of the New Endgame Strategy
The new endgame started with the regioselective A/-carbamoylation of oxazolidinone 
(-)-150 with carbamoyl chloride 309.81 This was conveniently achieved by using a combination 
of n-BuLi and DABCO as the bases. Thus, (-)-150 was treated with n-BuLi at low temperature, 
and carbamoyl chloride 309 was added. The mixture was heated at reflux for 4 h, and DABCO 
(3 equiv.) was then added and the heating continued for 18 h. The regioselectivity of this 
reaction can certainly be explained by the formation of a /V-lithiated species which is stabilised 
by coordination of the oxygen lone pairs of the adjacent sulfonamide group. The structure of the 
carbamoyl oxazolidinone 310 was subsequently confirmed by X-Ray analysis. A second N- 
acylation with pyrrole acid chloride 170, triethylamine and DMAP produced the desired 
pyrrolocarboxamide 311 in 89% yield. As before, syringe pump addition of a solution of the acid 
chloride in CH2CI2 to a solution of sulfonamide 310 was required to perform this acylation 
(Weinreb’s procedure).
Although fluoride-induced cleavage of the SES group in 311, using 1 equiv. TBAF in 
THF at 0*0, afforded 308 in a poor yield (34%), we found that this deprotection could be 
effected much more efficiently by using Bu3SnH and AIBN in PhMe at reflux. The free 
pyrroloamide was typically obtained in 60% yield. This procedure was originally developed by 
Smith et al. for the desulfonylation of multifunctional p-keto-phenylsulfones under neutral 
conditions.120 This method was subsequently applied to the deprotection of arylsulfonylated
p
(-)-150 NHSES
N -B n n-BuLi, DABCO, THF, -78°C to reflux, 21 h 
(88%)Me'
309
N -B n
TMS^n C0CI
H 170
r \
N -B n
4, AIBN 
reflux.
N—Bn
•  $  V
' A ‘
310
NHSES Et3 N, DMAP, RT, 4 h (89 %)
Bu3SnH,
PhMe, , 
8  h
(60% )
TM
( LiOH, THF/H20
N -B n  RT, 95 h
 ^ PDC, DMF, 
N -B n  r t ,  1 .5  h
O O O 312; R = H
Scheme 62. Preparation of cyclopentenone (-)-307
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amides by Parsons.121 To our knowledge, this is the first time that a SES group has been 
reductively removed from an amide nitrogen by Bu3SnH under free radical conditions. A small 
amount of the C-desilylated product 312 (up to 7%) was also sometimes encountered in this 
Bu3SnH reduction depending on its overall duration.
Our next objective was to hydrolyse the oxazolidinone ring of 308 whilst leaving the 
urethane unit intact. Although this reaction could be accomplished cleanly with aq. LiOH in THF 
at room temperature, it did required long reaction times (128 h) to deliver workable yields of 
product. In this regard, the desired allylic alcohol 313 could usually be isolated in 40% yield 
along with 48% of 308 which was then recycled. Based on the quantity of 308 that was typically 
recovered, the yield of 313 was calculated to be 77%. Evidences for the success of this reaction 
was given by the appearance of an OH streching band at 3312 cm'1 on the infra-red spectrum of 
313. Moreover, 125 MHz 13C-NMR analysis of 313 in CDCI3 showed disappearance of the 
oxazolidinone carbonyl as well as the downfield shift of the urethane carbonyl to 159 ppm. 
Subsequent oxidation of alcohol 313 with the TPAP/NMO system in acetonitrile produced enone 
(-)-307 in 66% yield. However, it was found that pyridinium dichromate was slightly more 
effective in this capacity, affording (-)-307 in a highly reproducible 73% yield.
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Scheme 63. Attempts at cyclising enone (-)-307
60
Chapter 6: Total Synthesis of (-)-Agelastatin A
We next investigated the the base-mediated ring-closure of enone (-)-307 to secure 
ketone (-)-306. Et3N in MeOH, or 10 mol% Bu3P in THF,122 were completely ineffective at 
mediating this cyclisation, enone 307 being recovered untouched in either case. When enone 
307 was treated with 2 equiv. DBU in THF at room temperature, the rearranged enone 314 was 
produced in 70% yield. Presumably, a rearrangement similar to the one previously observed 
during the reinvestigation of Weinreb’s endgame took place. Sodium hydride was also 
investigated for effecting the desired ring-closure of 307, but this base failed to deliver the 
cyclised ketone 306, and a complex mixture of compounds was produced, including the 
rearranged cyclopentenone 314. Potassium hexamethyldisilazide in THF likewise gave rise to 
complicated reaction mixtures, as did K2C 0 3 in MeOH. Surprisingly, Cs2C 03 in MeOH produced 
315 as the only readily isolable reaction product in 64% yield, along with other decomposition 
products.
In light of these failures, several Bransted and Lewis acids were surveyed for their 
ability to instigate the desired cyclisation. PPTS (5 equiv.) in THF and MeOH was initially 
screened in this capacity. Unfortunately, this led to the pyrrole TMS of 307 being replaced by 
hydrogen. The latter product was also formed when TMSOTf (1.1 equiv.) was used to activate 
enone 307 in methanol; it was co-produced with 314. Given all these disappointments, a step 
backwards was taken, and the Swern oxidation and in situ cyclisation of 307 was attempted 
under conditions analogous to those reported by Feldman and co-workers on their related 
system.75 With our substrate, this led to a 16% isolated yield of 306, 20% yield of enone 314, 
and a 62% recovery of 307.
3. Completion of the (-)-Agelastatin A Total Synthesis: A 
Lesson From Nature
At about this time, we happened to again read the Potier/AI Mourabit paper on the 
possible biosynthesis of (-)-agelastatin A,15 and a key feature of their proposal was the internal 
Michael-type addition of a bromopyrrole in intermediate 13 (Scheme 3) for ABC ring-assembly. 
It occurred to us that if Nature could accomplish the same type of reaction under near neutral 
conditions, that perhaps the increased acidity of the bromopyrrole-NH could hold the key to 
ultimate success in our own synthetic venture. We reasoned that because Et3N in MeOH had 
left enone 307 intact, after several hours of exposure, that we might be able to bring about 
cyclisation under similar conditions, if we could lower the pKa of the pyrrole nitrogen in 307 
through chemoselective bromination. Accordingly, 307 was reacted with 2 equiv. of N- 
bromosuccinimide in THF for 3 h, in the expectation that a single 2,3-dibromopyrrole would 
form, whose pKa would be significantly lower. To our surprise, a complex mixture of mono-, di-, 
and tri-bromo pyrroles arose on TLC, and none of the starting enone remained. Therefore, 
rather than attempting to purify the individual products, Hunig’s base (5 equiv.) was added 
directly to the reaction mixture to promote the required intramolecular Michael-type addition.
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The only component of this mixture that was obtained in reasonably pure condition was the 
tribromopyrrole 317. Use of 3 equiv. of NBS for the bromination did not increase the amount of 
317 that was formed, but instead, caused over-bromination and significant product 
decomposition.
N-Bn
t m ; Me
(-J-307
1) NBS (2 equiv.), THF, 
0°C, 2 h, then RT, 1 h
2) f-Pr2NEt (5 equiv.),
RT, 18 h
Br,
H2  (1 atm.). Pd/C, MeOH, RT, 3 h
(13% over 4 steps)
L
Me O 
HO*,
,.NH
316; R = H 
317; R = Br
6 -  
C t i,>NH
318
5b,8a-diepr- 
debromoagelastatin A
H2  (1 atm.), NaOAc (3 equiv.) 
Pd/C, MeOH, RT, 2 h
(35% over 3 steps)
O II C 
-- Me
N—Bn
C - i Ho
(-)-212
Scheme 64. Conjugate intramolecular addition of enone (-)-270 and subsequent debromination
The crude mixture from the 2 equiv. of NBS reaction/Hunig’s base cyclisation was then 
extractively worked-up and directly submitted to debromination using a catalytic amount of 10% 
Pd/C in MeOH in the presence of AcONa (3 equiv.). The success of this conversion was 
apparent from the presence of three aromatic protons at 5 6.78, 6.25 and 6.86 ppm in the 500 
MHz 1H-NMR spectrum of 212 in CDCI3. The desired ketone (-)-212 was readily isolated by 
chromatography in 35% yield over 3 steps. Initially, the reaction was performed without the 
inclusion of AcONa. It was expected that the HBr liberated during the debromination reaction 
would actually promote the A/-debenzylation of 212 to form debromoagelastatin A directly in one 
operation. In fact, 5b,8a-diep^debromoagelastatin A (318) was formed instead; it was isolated in 
13% yield over 3 steps. The structure of this epimer was confirmed by a 500 MHz 2D NMR- 
NOESY experiment in CD3OD, which showed a strong nuclear Overhauser effect (NOE) effect 
between H(5a) and H(5b) (Figure 8). Moreover, the 500 MHz 1H-NMR spectrum of 318 in 
CD3OD showed a 3J coupling constant between H(5a) and H(5b) of 7.3 Hz, which is consistent 
with a cis relationship between these two protons (this coupling is absent in the spectrum of 
debromoagelastatin A where these protons are in a trans relationship). It is likely that the 
epimerisation of 316 at C(5b) (agelastatin numbering) which led to 318 is promoted by the acid 
liberated during the debromination.
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NOE
NH
k9a /5a
'NOE
NOE
NOE
318
epf-debromoagelastatin A 
Figure 8. NOE effects in 5b,8a-diepidebromoagelastatin A
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Figure 9. 500 MHz 1H NOESY spectrum of 318 in CD3OD
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Initially, the A/-debenzylation of (-)-212 by catalytic hydrogenation was attempted using 
Pearlman’s catalyst (20% Pd(OH)2/C) in methanol (Scheme 65). Unfortunately, this led to the 
formation of methyl acetal 319 in a 36% yield. Conducting this reaction in THF, however, 
completely avoided this undesired reaction, and afforded debromoagelastatin A (-)-220 in 66% 
yield. Regioselective mono-bromination of 220 with NBS in a 1:2 mixture of MeOH/THF 
according to the protocol described by Feldman et al. provided (-)-agelastatin A (-)-1 in 84% 
yield.
Me 0 Me O
Pd(OH)2. THF, 
H2 (1 atm.), 24 h
NBS (0.9 equiv.) 
MeOH/THF (1:2) Bf
(84%)(66%)
N -Bn
O
(-)-220 ( - ) - l
O
Me O
(-F212
Pd(OH)2, MeOH, 
H2  (1 atm.), 24 h
(36%)
O
319
Scheme 65. Removal of the AAbenzyl group and subsequent bromination
Via the above route, about 220 mg of (-)-Agelastatin A has been prepared, and this is 
currently being evalated in more detail as an antitumour agent. More details of the biology are 
presented in Chapter 7.
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Chapter 7. Evaluation of the Biological 
Properties of (-)-Agelastatin A
7.1. Growth Inhibition Assays
The in vitro potency of (-)-agelastatin A as an antitumour agent was compared with 
cisplatin through growth inhibition assays conducted against a panel of 15 human tumour cell 
lines. These results were obtained by Quintiles Ltd. (Edinburgh, U.K.), the pharmaceutical 
services company.
Table 5. Comparative in vitro antitumour profile of (-)-agelastatin A
Human Tumour Cell Line (-)-Agelastatin A Mean ICso (pM)
Cisplatin 
Mean ICso (pM)
NCI-H460 (Lung) 0.195 0.832
LoVo (Colon) 0.975 3.315
DLD-1 (Colon) 0.398 2.362
HCT116 (Colon) 0.344 2.249
HT-29 (Colon) 0.670 4.736
ACHN (Renal) 2.133 1.057
MDAM B435s (Breast) 0.497 5.627
MES-SA (Uterine) 0.162 0.285
MES-SA/Dx5 (Uterine) 8.420 5.826
HepG2 (Hepatic) 0.846 3.300
DU145 (Prostate) 0.701 1.051
BxPC-3 (Pancreatic) 0.414 2.409
AsPC-1 (Pancreatic) 0.642 6.151
RT112/84 (Bladder) 0.234 3.793
SK-MEL-5 (Melanoma) 0.485 6.393
Experimentally, the cells were plated into 96-well plates at an appropriate cell density 
relating to the doubling time of each cell line, and the exposure time required in the study. The 
cells were incubated overnight in order to allow the cells to adhere. The cells were then treated 
with test substance at a range of concentrations. After incubating for 72 hours, the cells were 
stained, and the plates were read at the appropriate wavelength on a plate reader, the
65
Chapter 7. Evaluation of the Biological Properties of (-)-Agelastatin A
absorbance for each well relating to the number of cells present. From there, the Quintiles 
group determined and compared the potency of the test substances, by calculating an IC50 
value (the concentration of test substance that inhibits 50% of cell growth compared with control 
cells) from a computer-generated concentration-response curve. The data they obtained are 
shown above (Table 5). The results show that (-)-agelastatin A is between 1.5 and 16 times 
more potent than cisplatin at inhibiting cancer cell growth in all but two cancer cell lines.
From these results, a particular cell line, HCT116, was selected for in vivo human 
mouse xenograft studies. The primary purpose of this study was to evaluate toxicity rather than 
demonstrate efficacy, although some reduction in tumour growth was noted. When (-)- 
agelastatin A was administered intraperitoneally at 2.5 mg/kg/day for 4 successive days to a 10 
mouse cohort that had been intraperitoneally inoculated with HCT-116 solid human carcinoma, 
it produced a 31% mean inhibition of growth by day 4 without toxicity. Although a 30% inhibition 
of tumour growth was maintained at day 7, by day 15, a 15% inhibition of tumour growth was 
apparent, which declined to 10% inhibition by day 20. The results suggest that (-)-agelastatin A 
is cytostatic rather than cytotoxic, and that it is well tolerated at this dosage. Further antitumour 
testing will be performed to assess the antitumour effects of continuous dosing of (-)-agelastatin 
A to mice.
7 .2 . Inhibition of GSK-3J3
During their screening of the inhibitory effects of (-)-agelastatin A on certain kinases of 
neurological therapeutic significance, Meijer found that it inhibited GSK-3P (glycogen synthase 
kinase-3p) with an IC50 of 12 pM, although it did not inhibit the related kinases, CK1 (casein 
kinase 1), CDK1/cyclin B, (cyclin dependent kinase 5/cyclin B) or CDK5/p25.123 GSK-3P is a 
ubiquitously expressed multifunctional serine/threonine kinase found in all eukaryotes. It was 
first isolated as an enzyme capable of phosphorylating and inhibiting the enzyme glycogen 
synthase. 124 Beyond its role in glycogen metabolism, GSK-3p acts as a downstream regulatory 
switch that regulates the output of numerous signalling pathways initiated by diverse stimuli. 125 
These pathways are involved in a wide range of cellular processes ranging from glycogen 
metabolism to cell cycle regulation and proliferation. Given its potential involvement in many 
pathophysiological processes when deregulated, GSK-3p has emerged as a very promising 
therapeutic target, particularly when its upregulation may be linked to pathology. 126 Amongst 
these diseases, non-insulin-dependent diabetes mellitus and neurodegenerative disorders such 
as Alzheimer disease are the most prominent.
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A sample of (-)-agelastatin A that we had prepared by total synthesis was tested against 
GSK3P to confirm the original report that it is an inhibitor of GSK-3p. This assay was very kindly 
performed by Prof Adrian Harwood and Dr Jonathan Ryves at the Biology Department, UCL. 
They obtained an IC5o of 6.5 pM for our material, which is consistent with the reported IC50 of 12 
pM obtained by Meijer. Their results are depicted below (Figure 10).
Ag^laaiatfn A: ICM * 6.S
<*
<
i
o I---
0.1 to 1001 1000
( J Agrtastalin A (pM)
Figure 10. Inhibition of GSK3p by (-)-Agelastatin A
As a consequence of this preliminary biological evaluation, we have confirmed the great 
potential of (-)-agelastatin A as a human antitumour drug, and we have also confirmed that it is 
a potentially important new lead for the design of novel GSK-3p inhibitors.
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Materials and methods
Dichloromethane, toluene, benzene, acetonitrile and triethylamine were freshly distilled 
from CaH2 under nitrogen, diethyl ether and THF were freshly distilled from sodium metal under 
nitrogen. Thin-layer chromatography was performed on pre-coated glass-backed plates (Merck 
Kieselgel 60 F254), and visualised by staining with anisaldehyde/H2S0 4 /Ac0 H in EtOH and 
heating. Flash column chromatography was carried out on Sorbisil C60 40/60A (230-400 Mesh) 
silica gel. All ’H-NMR spectra were recorded on a Bruker AMX 400 (400 MHz) or a Bruker AMX 
500 (500 MHz) spectrometer. Chemical shifts are reported in parts per million from 
tetramethylsilane with the solvent resonance as the internal standard (CDCI3 : 8 7.24 ppm, 
DMSO-d6 : 5 2.49 ppm, CD3OD : 8 3.30 ppm, C6D6 : 8 6.15 ppm, Tol-d8 : 8 7.24 ppm). Data are 
reported as follows : chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, 
m = multiplet, br = broad), coupling constant and assignment. The coupling constants were not 
averaged. All 13C-NMR spectra were recorded on a Bruker AMX 400 (100 MHz) or a Bruker 
AMX 500 (125 MHz) spectrometer. Chemical shifts are reported in parts per million from 
tetramethylsilane with the solvent resonance as the internal standard (CDCI3 : 8 77 ppm, 
DMSO-d6 : 8 39.5 ppm, CD3OD : 8 49.0 ppm, C6D6 : 8 128.0 ppm, Tol-d8 : 8 20.4 ppm). Infrared 
spectra (IR) were recorded on a Perkin Elmer 1600 Series FTIR spectrometer, with v ^  in 
inverse centimeters. Bands are characterised as broad (br), strong (s), medium (m) or weak (w). 
High resolution mass-spectra (HMRS) were measured by the UCL Chemistry Department Mass 
Spectrometry Service on a VG Analytical 70S instrument. Optical rotations were measured on a 
Polaar 2000 Automatic polarimeter.
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N-benzoyl-D-glucosamine (236)89
(PhC0 )2 0 . Na, MeOH
HO NHCOPh
D-Glucosamine
hydrochloride
To a solution of sodium (38.4 g, 1.67 mol) in methanol (3.6 L) was added d - 
glucosamine hydrochloride (300 g, 1.39 mol) under gentle stirring at room temperature. Sodium 
chloride separated, and after 15 minutes, the suspension was filtered. To the clear filtrate under 
mechanical stirring was added benzoic anhydride (441 g, 1.95 mol) in small portions over 15 
min. After the end of the addition, the mixture was stirred at room temperature for 5 hours, and 
stored at 5°C for 3 days to allow the product to crystallise. The crystals were filtered off, washed 
with methanol, Et20  and dried under high vacuum, affording 236 (204 g, 54%) as a white solid. 
M.p. 208-209°C (Lit.89 m.p. 204-206 <€).
Methyl 2-benzamido-2-deoxy-a-D-gluco-pyranoside (237)88
HCI conc., MeOH
HO NHCOPh HO NHCOPh
A/-Benzoyl-D-glucosamine 236 (204 g, 720 mmol) was suspended in methanol (1.2 L), 
and conc. HCI (27 mL) was added. The mixture was reluxed for 28 h. After cooling to room 
temperature, the product was crystallised from the reaction mixture by addition of Et20  (2 L) and 
Petrol (1L). The crystals were filtered off, and washed with Et20 , yielding 237 (145 g, 68%) as a 
white solid. M.p. 225-227*€ (Lit.88 m.p. 224-227<C); 1H-NMR (500 MHz, 298 K, DMSO-d6) 5 
8.14 (d, J=  7.7 Hz, 1 H, arom.), 7.84 (d, J=  7.3 Hz, 2 H, arom.), 7.51 (t, 7.4 Hz, 1 H, arom.),
7.45 (t, J = 7.7 Hz, 2 H, arom.), 5.03 (d, J = 5.4 Hz, 1 H, C(4)-OH), 4.77 (d, J = 5.7 Hz, 1 H, 
C(3)-OH), 4.69 (d, J = 3.5 Hz, 1 H, H1), 4.55 (t, 6.0 Hz, 1 H, C(6)-OH), 3.87 (ddd, J =  10.9,
7.8, 3.6 Hz, 1 H, H2), 3.70 (m, 1 H, H3), 3.67 (ddd, J=  9.3, 5.7, 1.9 Hz, 1 H, H6), 3.50 (ddd, J =
11.9, 6.0, 5.8 Hz, 1 H, H6), 3.37 (ddd, J =  9.8, 5.6, 1.9 Hz, 1 H, H5), 3.24 (s, 3 H, OMe), 3.19 
(m, 1 H, H4); 13C-NMR (125 MHz, 298 K, DMSO-d6) 5 166.5 (C=0), 134.3 (arom.), 131.2 
(arom.), 128.1 (arom.), 127.4 (arom.), 97.8 (C1), 72.8 (C5), 70.8 (C4), 70.3 (C3), 60.9 (C6), 54.8 
(C2), 54.4 (OMe); HRMS Calcd for CuH^NOe (M+H)+: m/z 298.12906. Found: m/z 298.12772.
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Methyl 2-benzamido-4,6-0-benzylidene-2-deoxy-a-D-gluco-pyranoside (238)m
PhCH(OMe)2, 
cat p-TsOH,
•••OMe DMF, 55“C
( 100%)
HO NHCOPh 
238
HO NHCOPh 
237
Methyl 2-benzamido-2-deoxy-a-D-gluco-pyranoside 237 (145 g, 488 mmol) was 
dissolved in DMF (2.2 L). Benzaldehyde dimethylacetal (110 mL, 732 mmol) was added, 
followed by p-toluenesulfonic acid (19 g, 97.5 mmol). The mixture was distilled on a rotary 
evaporator under vacuum (29 mm Hg) at 55*0. After 5.5 h, the slurry was cooled to room 
temperature, and washed with absolute ethanol. The crystals were further washed with Et20 , 
and dried under high vacuum overnight, yielding the title compound 238 (190 g, 100%) as a 
white solid. M.p. 237-238°C (Lit.88 m.p. 239-245°C); 1H-NMR (500 MHz, 298 K, CDCI3) 5 7.79 
(d, J =  7.2 Hz, 2 H, arom.), 7.53-7.33 (m, 8  H, arom), 6.52 (d, J=  8 . 6  Hz, 1 H, NH), 5.57 (s, 1 H, 
PhCH), 4.82 (d, J =  3.8 Hz, 1 H, H 1 ), 4.43 (ddd, J=  9.9, 9.0, 3.9 Hz, 1 H, H2), 4.29 (dd, J=  9.3,
3.9 Hz, 1 H, H6 ), 4.01 (dd, J =  9.6, 9.6 Hz, 1 H, H3), 3.81 (m, 1 H, H5), 3.78 (dd, 10.2, 9.4 
Hz, 1 H, H6 ), 3.64 (t, J = 9.1 Hz, 1H, H4), 3.42 (s, 3H, OCH3); 13C-NMR (125 MHz, 298 K, 
CDCI3) 8  168.5 (C=0), 137.1 (arom.), 133.6 (arom.), 132.0 (arom.), 129.2 (arom.), 128.6 
(arom.), 128.3 (arom.), 127.2 (arom.), 126.3 (arom.), 102.0 (PhCH-), 98.9 (C1), 82.1 (C4), 70.8 
(C3), 6 8 . 8  (C6 ), 62.4 (C5), 55.4 (-OCH3), 54.4 (C2); HRMS Calcd for C21H24NO6 (M+H)+: m/z 
386.16035. Found: m/z 386.16076.
Methyl 4,6-0-benzylidene-2,3-dideoxy-2,3-epimino-a-D-allo-pyranoside (234)90
MsCI (120 mL, 1.55 mol) was added dropwise to a stirred solution of alcohol 238 (200 g, 
0.516 mol) in pyridine (2 L) at 0°C. After the end of the addition, the mixture was stirred at 0°C 
for 1 h, and at room temperature for 2 hours. The mixture was then carefuly poured into 
ice/water (3L) to precipitate the mesylate. The crystals were filtered off, and thoroughly washed 
with water. The crystals were dried by azeotroping any remaining water with toluene. A small 
sample was purified by recrystallisation from hot ethanol to give 239 as white needles. M.p. 
197-198°C (Lit.90 m.p. 207.5-208.5^); 1H-NMR (500 MHz, 298 K, CDCI3) 8  7.84 (d, J=  7.2 Hz,
—OMe
MsCI, Py, RT Ph""^
-O M e
NaOH,
2 -methoxyethanol
reflux
(76% for 2 steps)
HO NHCOPh 
238
MsO NHCOPh
239
N
H
234
Hough-Richardson
Aziridine
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2 H, arom.), 7.50-7.35 (m, 8  H, arom.), 6.62 (d, J =  8 .8 , 1H, NH), 5.58 (s, 1 H, PhCH-), 4.96 (d, 
J = 3.6 Hz, 1 H, H1), 4.93 (dd, J =  10.1, 9.9 Hz, 1 H, H3), 4.59 (ddd, J =  9.5, 3.6, 1.5 Hz, 1 H, 
H2), 4.33 (dd, J = 10.3, 4.5 Hz, 1 H, H6 ), 3.94-3.78 (m, 3 H, H4, H5 and H6 ), 3.38 (s, 3H, - 
OCH3), 2.93 (s, 3H, SO2CH3); 13C-NMR (100 MHz, CDCI3) 5 167.5 (C=0), 136.6 (arom.), 133.7 
(arom.), 131.8 (arom.), 129.3 (arom.), 128.6 (arom.), 128.4 (arom.), 127.3 (arom.), 125.9 
(arom.), 101.8 (PhCH-), 99.1 (C1), 79.0 (C4), 78.1 (C3), 6 8 . 8  (C6 ), 63.0 (C5), 55.6 (-OCH3),
52.7 (C2), 38.5 (SO2CH3); HRMS Calcd for C22H26N08S (M+H)+: m/z 464.13791. Found: m/z 
464.13743.
The crude mesylate 239 was dissolved in a mixture of 2-methoxyethanol (1.9 L) and 
water (100 mL). Sodium hydroxide (124 g, 3.10 mol) was then added, and the mixture was 
refluxed. After 4 h, the solution was cooled down to room temperature, and diluted with water (3 
L). The product was extracted with chloroform ( 6  x 400 mL). The combined organic layer was 
washed with water (1 L), brine (500 mL), dried (MgS04), and treated with decolourising 
charcoal. After filtration, the solution was concentrated in vacuo, and the brown solid obtained 
was purified by recrystallisation in a hot mixture of AcOEt/Petrol, yielding aziridine 234 (104 g, 
76% combined yield for 2 steps) as a white solid. [a]D +148.2 0 (c 1, CH3CI3), Lit.90 [a]D +147 0 
(c 1, CH3CI3); IR (KBr) 3301 (s), 3225 (w), 3008 (m), 2924 (m), 28996 (m), 2838 (w), 1635 (w), 
1539 (w), 1457 (w), 1393 (m), 1316 (w), 1290 (w), 1245 (w), 1218 (w), 1106 (s), 1070 (s), 1015 
(s), 961 (m), 936 (m), 891 (m), 753 (m), 695 (m), 620 (w); 1H-NMR (500 MHz, CDCI3, 298 K) 5 
7.50-7.45 (m, 2 H, arom.), 7.37-7.29 (m, 3H, arom.), 5.56 (s, 1 H, PhCH-), 4.88 (d, J=  3.8, 1 H, 
H1), 4.20 (dd, 10.1 Hz, 5.0 Hz, 1 H, H6 ), 3.98 (br s, 1 H, H5), 3.89 (br d, J =  8.5 Hz, 1 H, 
H4), 3.64 (dd, J = 10.4, 10.4 Hz, 1 H, H6 ), 3.42 (s, 3 H, -OCH3), 2.71 (m, 2 H, H2 and H3); 13C- 
NMR (125 MHz, CDCI3, 298 K) 5 137.4 (arom.), 129.1 (arom.), 128.3 (arom.), 102.6 (PhCH-),
95.8 (C1), 77.9 (C4), 69.1 (C6 ), 59.4(C5), 55.5 (-OCH3), 33.0 (C3), 30.1 (C2); HRMS Calcd for 
C14Hi8N 0 4 (M+H)+: m/z 264.12358. Found: m/z 264.12312.
P-Trimethylsilylethanesulfonyl chloride (249)69,92
NaHS0 3 , cat. PhC03 f-Bu o  PPh3 .S 0 2 CI2
_______ MeOH/HzO Me CH2 CI2
Me 1 ^  (95%) M e -^ i ONa (6 9 o/o)
Me Me
247 248 249
Me-Si
Sodium 2-trimethylsilylethanesulfonate (248)69 A solution of sodium bisulfite (143 g, 
1 .37 mol) in water (250 mL) was slowly added to a solution of vinyltrimethylsilane (68.4 g, 0.683 
mol) in methanol (250 mL). ferf-Butyl peroxybenzoate (2.6 mL, 0.0137 mol) was then added, 
and the mixture was heated at 60 'C (temperature of the bath) for 48 hours. After cooling to
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room temperature, the mixture was filtered and concentrated under vacuum. The remaining 
water was removed by azeotroping the mixture with methanol (3 x 250 mL). The resulting solid 
was extracted with 1 L of methanol, which was concentrated to dryness to afford a white solid. 
This solid was dried under high vacuum for 1 day to give 113.6 (81 %) of the title compound. 1H- 
NMR (500 MHz, CDCI3, 298 K) 6 2.73-2.70 (m, 2 H), 1.04-1.01 (m, 2 H), 0.03 (s, 9 H); 13C-NMR 
(125 MHz, CDCI3 , 298 K) 6 48.1, 12.7, -2.0.
2-Trimethylsilylethanesulfonyl chloride (249)”  Sulfuryl chloride (140 mL, 1.74 mol) 
was added dropwise to a stirred solution of triphenylphosphine (414,4 g, 1.58 mol) in 
dichloromethane (2 L) at 0°C. After 2 hours, The crude sodium 2-trimethylsilylethanesulfonate 
(110.2 g, 0.790 mol) was added in portions. After the addition was complete, the cold bath was 
removed and the solution was stirred at room temperature for 2 hours. The mixture was then 
concentrated under vacuum, and the residue was triturated with diethyl ether (1 L) to crystallise 
the triphenylphosphine oxide formed. The suspension was filtered, and the filtrate was 
concentrated under vacuum. The same procedure was repeated twice using diethyl ether (2 x 
500 mL), then petroleum spirit (500 mL). After the final crystallisation, the crude yellow oil was 
purified by filtration on a silica pad, eluting with 1:9 AcOEt:Petrol, to give 92.6 g (58 %) of a light 
yellow oil. IR (neat) 1370 (s), 1253 (m), 1176 (s), 860 (s), 840 (s), 692 (m), 535 (m); 1H-NMR 
(500 MHz, CDCI3 , 298 K) 8 3.60-3.56 (m, 2 H, Chh), 1.30-1.26 (m, 2 H, Chh), 0.08 (s, 9 H, 
TMS); 13C-NMR (125 MHz, CDCI3, 298 K) 5 63.4 (CH2), 11.9 (CH2), -2.1 (TMS).
Methyl 4,6-0-benzylidene-2,3-dideoxy-2,3-[N-(2-trimethylsilylethylsulfonamido)]epimino- 
a-D-allo-pyranoside (250)
SESCI (5.00 g, 24.9 mmol) was added dropwise to a solution of the Hough-Richardson 
aziridine 234 (5.50 g, 20.8 mmol) and triethylamine (26.8 ml, 191 mmol) in freshly distilled THF 
(80 ml). After 24 hours stirring at room temperature under nitrogen, water was added (50 ml), 
and the product was extracted with diethyl ether (3 x 30 ml). The combined organic layer was 
washed with water (50 ml), brine (20 mL) and dried over MgS04. After evaporation of the 
solvent under reduced pressure, the product was recrystallised in hot isopropanol to give 250 
(5.5 g) as a white solid. A further crop (0.5 g, overall yield 67%) was obtained after 
concentration of the mother liquor, and purification of the residue by Si02 flash chromatography
(67%)
234 250
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(Et20/Petrol 1:1). [a]D +77.3 0 (c 0.4, CH3CI3); IR (KBr) 2955 (s), 2920 (m), 1677 (w), 1455 (m), 
1395 (s), 1325 (s), 1287 (m), 1255 (s), 1224 (s), 1144 (s), 1108 (s), 1067 (s), 981 (s), 913 (s), 
836 (s), 756 (s), 699 (s) 672 (m), 630 (w), 597 (m), 563 (w), 540 (w), 515 (w); 1H-NMR (500 
MHz, CDCI3, 298 K) 8 7.45-7.43 (m, 2 H, arom.), 7.33-7.32 (m, 3H, arom.), 5.57 (s, 1 H, 
PhCH-), 4.94 (d, J = 4.1 Hz, 1 H, H1), 4.21 (dd, J =  10.3, 5.0 Hz, 1 H, H6), 4.03 (ddd, J =  10.0, 
9.5, 5.0 Hz, 1 H, H5), 3.89 (dd, 9.1, 2.6 Hz, 1 H, H4), 3.66 (dd, 10.3, 10.3 Hz, 1 H, H6), 
3.44 (s, 3 H, -OChb), 3.36 (dd, J = 7.2, 4.1 Hz, 1 H, H2), 3.24 (dd, J = 7.2, 2.5 Hz, 1 H, H3), 
3.19 (ddd, J =  14.1, 14.1, 4.3 Hz, 1 H, SES), 3.11 (ddd, 14.1, 14.1, 4.2 Hz, 1 H, SES), 1.22 
(ddd, J=  13.9, 13.8, 4.4 Hz, 1 H, SES), 1.11 (ddd, 13.9, 13.8,4.3 Hz, 1 H, SES),-0.07 (s, 9 
H, TMS) ; 13C-NMR (125 MHz, CDCI3, 298 K) 5 137.1 (arom.), 129.2 (arom.), 128.3 (arom.), 
126.2 (arom.), 102.5 (PhCH-), 94.0 (C1), 75.2 (C4), 68.9 (C6), 60.5 (C5), 56.0 (-OCH3), 49.2 
(SES), 38.9 (C3), 38.6 (C2), 9.6 (SES), -2.3 (TMS); HRMS Calcd for C19H30NO6SSi (M+H)+: m/z 
428.15630. Found: m/z 428.15586.
Methyl 2-azido-4,6-0-benzylidene-2,3-dideoxy-3-(2-trimethylsilyl-ethylsiilfonamido)-a-D- 
altro-pyranoside (251)
o- •OMe
NaN3, NH4CI, 
DMF, 140°C, 2 h
(60%)
N
SES
SESHN
OMe
250 251
Sodium azide (3.10 g , 47.4 mmol) and ammonium chloride (1.00 g, 19.0 mmol) were 
suspended in solution of the AFprotected aziridine 250 (5.07 g, 11.9 mmol) in DMF (65 ml), and 
the mixture was refluxed for 2 hours. After cooling to room temperature, water (100 ml) was 
added and the product was extracted with diethyl ether (3x 20 ml). The combined organic layer 
was washed with water (10 mL), brine (5 mL), and dried (MgS04). After evaporation of the 
solvent in vacuo, the residue was purified by recrystallisation in hot isopropanol to give 251 (
3.08 g, 55%) as a white solid. The mother liquor was concentrated, and after S i02 flash 
chromatography (Et20/Petrol 1:1), another crop of the product (0.280 g, overall yield 60 %) was 
obtained. [a]D +60.2 0 (c 0.21, CH3CI3); IR (KBr) 3359 (m), 2950 (m) 2878 (m), 2187 (w), 2105 
(s), 1436 (m), 1332 (s), 1259 (s), 1142 (s), 1112 (s), 1078 (m), 1046 (s), 989 (m), 945 (m), 844 
(m), 768 (m), 701 (m), 540 (w), 508 (w); 1H-NMR (500 MHz, CDCI3, 298 K) 5 7.43-7.40 (m, 2 H, 
arom.), 7.33-7.30 (m, 3 H, arom.), 5.60 (s, 1 H, PhCH-), 5.38 (d, J=  9.3 Hz, 1 H, -NHSES), 4.70 
(s, 1 H, H1), 4.31 (m, 1 H, H6), 4.03 (ddd, J =  9.3, 2.8, 2.7 Hz, 1 H, H3), 3.98 (dd, J = 2.8, 1.1 
Hz, 1 H, H2), 3.93-3.81 (m, 2 H, H4 + H5), 3.79-3.76 (m, 1 H, H6), 3.44 (s, 3 H, -OCH3), 2.88- 
2.83 (m, 2 H, SES), 0.94-0.89 (m, 2 H, SES), -0.25 (s, 9 H, TMS) ; 13C-NMR (125 MHz, CDCI3, 
298 K) 5 137.0 (arom.), 129.2 (arom.), 128.4 (arom.), 126.0 (arom.), 102.4 (PhCH-), 99.4 (C1),
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73.8 (C4), 69.0 (C6 ), 62.3 (C2 ), 59.4(C5), 56.0 (-OCH3), 51.8 (C3), 50.4 (SES), 10.0 (SES), -2.3 
(TMS); HRMS Calcd for C19H3iN40 6SSi (M+H)+: m/z 471.17335. Found: m/z 471.17315.
Methyl 2-azido-2,3-dideoxy-3-trimethylsilylethylsulfonamido-a-D-altropyranoside (252)
SESHN N3
AcOH, H20  
reflux. 3 h 
( 100%)
SESHN
Benzylidene acetal 251 (1.33 g, 2.83 mmol) was refluxed for 3 hours in a mixture of 
water ( 6  ml), acetic acid (25 ml) and methanol ( 6  ml). After cooling to room temperature, the 
solvents were removed by distillation in vacuo. The residue was purified by Si02 flash 
chromatography (AcOEt/Petrol 6:4) to give 252 (1.05 g, 100%) as a thick oil. [a]D +32.8 0 (c 
0.45, CH3CI3); IR (neat) 3340 (s), 2953 (s), 2 1 1 1  (s), 1445 (m), 1323 (s), 1257 (s), 1141 (s), 983 
(m), 953 (m), 858 (s), 785 (m), 760 (m), 699 (s), 539 (m), 503 (m); 1H-NMR (500 MHz, CDCI3, 
298 K) 6  5.64 (d, J = 9.5 Hz, 1H, -NHSes), 4.69 (s, 1 H, H1), 3.97 (m., 1H, H4), 3.85 (m, 2 H, 
H6 ), 3.77 (m, 2  H, H2  and H3), 3.69 (m, 1 H, H5), 3.05 (m, 2 H, SES), 2.85 (br s, 1 H, -CH2OH), 
2.39 (s, 1 H, -CHOH), 1.06 (m, 2H, SES), 0.05 (s, 9H, TMS); 13C-NMR (125 MHz, CDCI3 298 K) 
5 99.6 (C1), 70.3 (C5), 63.9 (C4), 62.2 (C6 ), 61.5 (C2), 55.8 (-OCH3), 54.3 (C3), 50.0 (SES),
10.4 (SES), -2.05 (TMS); HRMS Calcd for C12H27N40 6SSi (M+H)+: m/z 383.14205. Found: m/z 
383.14392.
Methyl 2-butoxycarbonylamino-2,3-dideoxy-3-trimethylsilylethylsulfonamido-a-D-
altropyranoside (254)
“> sH O - (  V  "OMe 
SESHN* N3
H2, ca t Pd/C 
EtOH, 3 h •OMe
B0C2O, KjCOs 
THF/H20 , 13 h. RT
(62%)
252
SESHN NH2 
253
HO"K< O -O M e
SESHN NHBoc 
254
Azide 252 (1.22 g, 3.19 mmol) was vigorously stirred in the presence of 10% wet Pd/C 
(1.2 g, 0.319 mmol) in absolute ethanol (40 ml) under a hydrogen atmosphere (1 atm.). After 2 
hours stirring, the suspension was filtered on a pad of celite, and the solvent was evaporated in 
vacuo. The white crude solid thus obtained was dissolved in 3:1 THF/water (40 ml). Di-ferf-butyl 
dicarbonate (1.00 g, 4.79 mmol) was added, followed by K2CQ3 (0.8 g, 6.28 mmol). The mixture
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was vigorously stirred at room temperature for 13 h. The mixture was diluted with AcOEt (100 
mL), and the layers were separated. The organic layer was washed with brine (20 mL), and 
dried (MgS04). After removal of the solvent under vacuum, the residue was purified by S i02 
flash chromatography (AcOEt/Petrol 6:4) to yield carbamate 254 (0.910 g, 62%) as a white 
solid. [a]D -18.6 0 (c 0.5 CH3CI3); IR (KBr) 3360 (m), 2958 (m), 1708 (s), 1522 (m), 1370 (m), 
1324 (s), 1253 (s), 1144 (s), 1094 (m), 1049 (s), 978 (w), 860 (m), 741 (s), 699 (w), 500 (w); 1H- 
NMR (500 MHz, CDCI3, 298 K) 5 5.75 (d, J =  8.8 Hz, 1 H, -NHSes), 5.18 (d, J =  7.8 Hz, 1 H, - 
NHBoc), 4.95 (s, 1 H, H1), 4.11 (m, 3 H, H2, H4 and H6), 3.90 (br s, 2 H, H3 and H6), 3.62 (m, 
1 H, H5), 3.41 (s, 3 H, -OCH3), 3.21 (m, 2 H, -ChUSOs), 3.06 (d, J =  7.1 Hz, 1 H, -CH2OH), 2.52 
(br s, 1 H, -CHOH), 1.43 (s, 9 H, Boc), 1.15 (td, J =  13.5, 3.4 Hz, 1 H, SES); 1.05 (td, J =  13.5, 
4.6 Hz, 2 H, SES), 0.09 (s, 9 H, TMS); 13C-NMR (125 MHz, CDCI3, 298 K) 5 154.5 (C=0), 100.0 
(C1), 80.5 (Boc), 68.8 (C5), 62.5 (C4), 62.0 (C6), 55.5 (-OCH3), 54.1 (C3), 52.6 (C2), 48.6 
(SES), 28.2 (Boc), 10.5 (SES), -2.1 (TMS); HRMS Calcd for C17H37N20 8SSi (M+H)+: m/z 
457.20398. Found: m/z 457.20456.
Methyl 2-butoxycarbonylamino-2,3-dideoxy-6-p-toluenesulfonyl-3-trimethylsilyl-
ethylsulfonamido-a-D-altropyranoside (255)
SESHN NHBoc
TsCI, Et3 N, DMAP, 
CH2 CI2 , 14 h, (85%) H O -(<  i)-O M e
SESHN NHBoc 
255
To the solution of diol 254 (416 mg, 0.911 mmol) in freshly distilled CH2CI2 (16 ml) 
under nitrogen was added anhydrous Et3N (1.90 ml, 13.7 mmol), and the solution was cooled to 
0°C. Recrystallised p-TsCI (209 mg, 1.09 mmol) and DMAP (11.0 mg, 0.0911 mmol) where 
added to the mixture under stirring. The cold bath was removed and the solution was stirred for 
14 hours at room temperature. The solution was washed with sat. aq. NH4CI (5 mL), water (5 
mL), brine and dried (MgS04). After evaporation of the solvent, the residue was purified by S i02 
flash chromatography (AcOEt/Petrol 4:6) to give the title compound (455 mg, 85 %) as a white 
solid. [a]D +22.6 0 (c 0.5, CH3CI3); IR (KBr) 3372 (s), 2958 (m), 1710 (s), 1512 (m), 1367 (s), 
1253 (m), 1177 (s), 1143 (s), 1098 (m), 1054 (m), 965 (m), 841 (m), 667 (w), 554 (w); 1H-NMR 
(500 MHz, CDCI3, 298 K) 8 7.79 (d, J = 8.2 Hz, 2 H, arom.), 7.33 (d, J = 8.0 Hz, 2 H, arom.), 
5.63 (d, 9.1 Hz, 1 H, -NHSES), 4.84 (d, J =  7.8 Hz, 1 H, -NHBoc), 4.55 (s, 1 H, H1), 4.36 (d,
J =  10.6 Hz, 1 H, H6), 4.21 (dd, 10.8, 5.5 Hz, 1 H, H6), 3.85 (d, J =  7.5 Hz, 1 H, H2), 3.75-
3.72 (m, 1 H, H3), 3.68 (m, 1 H, H5), 3.63 (dd, J=  10.0, 3.9 Hz, 1 H, H4), 3.36 (s, 3 H, -OCH3), 
3.16 (m, 2 H, SES), 2.43 (s, 3 H, PhCHa), 1-41 (s, 9 H, Boc), 1.12 (td, J =  13.6, 3.6 Hz, 1 H, 
SES), 1.00 (td, J=  13.8, 4.4 Hz, 1 H, SES), 0.06 (s, 9 H, SES) ; 13C-NMR (125 MHz, CDCI3, 298
75
Chapter 8: Experimental
K) 5 154.4 (C=0), 145.0 (arom.), 132.8 (arom.), 129.9 (arom.), 128.0 (arom.), 99.8 (C1), 80.8 
(Boc), 69.2 (C6), 67.2 (C5), 61.9 (C4), 55.7 (-OCH3), 53.9 (C3), 52.5 (C2), 48.6 (SES), 28.2 
(Boc), 21.7 (PhCH3), 10.5 (SES), -2.1 (TMS); HRMS Calcd for C24H43N2O10S2Si (M+H)+: m/z 
611.21283. Found: m/z 611.21169.
Methyl 2-butoxycarbonylamino-2,3-dideoxy-6-iodo-3-trimethylsilylethylsulfonamido-a-D- 
altropyranoside (232)
Nal (1.10 g, 7.37 mmol) was dissolved into a solution of tosylate 255 (450 mg, 0.737 
mmol) in acetone (20 mL), and the mixture was refluxed for 24 hours. The solvent was 
evaporated under reduced pressure, and the residue was taken up in ethyl acetate (50 mL). 
The solution was washed with a sat. aq. Na2S20 3 (5 mL) water (5 mL) , brine (2 mL), and dried 
(MgS04). After concentration of the solution, the residual solid was purified by Si02 flash 
chromatography (AcOEt/Petrol 2:8) to give 232 (383 mg, 92%) as a yellow solid, unstable to 
light exposure. [a]0 -2 .2  0 (c 0.5, CH3CI3); IR (KBr) 3425 (s), 1708 (s), 1324 (m), 1143 (s); ’H- 
NMR (500 MHz, CDCI3, 298 K) 5 5.69 (d, J = 9.2 Hz, 1 H NHSES), 4.80 (d, J = 7.8 Hz, 1 H,
NHBoc), 4.63 (s, 1 H, H1), 3.89 (d, J =  7.8 Hz, 1 H, H2), 3.75 (m, 1 H, H3), 3.65 (dd, J =  10.6,
1.9 Hz, 1 H, H6), 3.53 (dd, J =  9.8, 4.1 Hz, 1 H, H4), 3.48 (m, 1 H, H5) superimposed upon 3.46
(s, 3 H, -OCHa), 3.28 (dd, J =  10.7, 7.6 Hz, 1 H, H6), 3.24-3.11 (m, 2 H, SES), 1.41 (s, 9 H,
Boc), 1.11 (m, 1 H, SES), 1.00 (m, 1 H, SES), 0.05 (s, 9 H), TMS) ; 13C-NMR (125 MHz, CDCI3, 
298 K) 5 154.4 (C=0), 100.1 (C1), 80.8 (Boc), 68.8 (C5), 66.5 (C4), 55.9 (-OCH3), 54.1 (C3),
52.8 (C2), 42.0 (SES), 28.2 (Boc), 10.6 (SES), 6.6 (C6), -2.0 (TMS); HRMS Calcd for 
C^HaelNzOySSi (M+H)+: m/z 567.10572. Found: m/z 567.10483.
Nal (10 equiv.), acetone, 
reflux. 24 h, (92%)
SESHN NHBoc SESHN NHBoc
255 232
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Hemiacetal 231
SESHN NHBoc
••■OMe  i —
(80%)
Zn powder, 
THF/H2 0 , reflux OH
SESHN NHBoc
232 231
Zinc powder (Aldrich 20,998-8, 3.70 g, 56.5 mmol) was suspended in a solution of 
iodide 232 (3.67 g, 5.39 mmol) in a 9:1 mixture of THF/water (30 ml), and the mixture was 
refluxed. After 2 h, the mixture was cooled down to room temperature and filtered on a Celite 
pad. After concentration under vacuum, the residue was taken in AcOEt (100 mL) and water (20 
mL). The layers were separated, and the organic layer was washed with water (20 mL), brine 
(10 mL) and dried (MgS04). The solvent was removed in vacuo and the residue was purified by 
Si02 flash chromatography (AcOEt/Petrol 4:6) to give 231 (180 mg, 80%) as a white foam. [a]D 
+2.8 0 (c 1, CH3CI3); IR (neat) 3349 (br s), 2956 (s), 1694 (s), 1517 (s), 1455 (w), 1428 (w), 
1391 (w), 1368 (m), 1322 (s), 1251 (s), 1170 (s), 1139 (s), 1009 (m), 936 (w), 895 (w), 862 (s), 
759 (s), 700 (m) ; 1H-NMR (500 MHz, toluene-d8, 373 K) 8 5.89 (ddd, J =  17.1, 10.4, 6.8 Hz, 1 
H, H6P), 5.80 (ddd, J =  16.3, 10.6, 5.7 Hz, 1 H, H6a), 5.27 (ddd, J = 17.2, 1.5, 1.5 Hz, 1 H, 
H7a), 5.21 (ddd, J =  17.1, 1.6, 1.2 Hz, 1 H, H7p), 5.07 (br d, J =  7.8 Hz, 1 H, NHBoc j3), 5.00 
(ddd, J=  10.4, 1.6, 1.1 Hz, 1 H, H7P), 4.96 (ddd, J =  10.4, 1.5, 1.5 Hz, 1 H, H7a), 4.95 (m, 2 H, 
H2), 4.86 (br d, 7.3 Hz, 1 H, NHSES P), 4.52 (br d, J =  6.7 Hz, 1 H, NHBoc a), 4.38 (dddd, J 
= 5.7, 5.7, 1.4, 1.4 Hz, 1 H, H5a), 3.94 (dddd, J =  6.9, 6.9, 1.0, 1.0 Hz, 1 H, H5p), 3.91 (ddd, J =
9.9, 7.9, 4.7 Hz, 1 H, H3p), 3.84 (ddd, J = 7.4, 4.4, 2.0 Hz, 1 H, H3a), 3.67 (ddd, J = 9.8, 8.0,
8.0 Hz, 1 H, H4p), 3.03 (br s, 1 H, OH a), 2.88 (m, 2 H, SES a), 2.77 (m, 2 H, SES P), 2.58 (br 
s, 1 H, OH P), 1.36 (s, 9H , Boc p), 1.32 (s, 9 H, Boc a), 0.97 (m, 2 H, SES a + P), -0.12 (s, 9 H, 
SES a), -0.14 (s, 9 H, SES P) ; 13C-NMR (125 MHz, toluene-d8, 373 K) 8 156.8 (C=0), 156.0 
(C=0), 138.6 C6p), 137.0 (C6a), 117.4 (C6p), 116.7 (C7a), 101.7 (C2a), 95.2 (C2p), 84.6 
(C5a), 83.1 (C5P), 80.5 (Boc), 64.8 -C3a), 64.1 (C4a), 62.4 (C4p), 59.8 (C3p), 51.3 (SES P),
50.9 (SES a), 28.7 (Boc), 11.3 (SES), -1.9 (TMS); HRMS Calcd for C16H33N20 6SSi (M+H)+: m/z 
409.18285. Found: m/z 409.18359.
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Sulfone 265
N -N 1) KOH, EtOH, A
2) Mel. A m-CPBA, NaHC03, CH2 CI2
(81%)
N^'S02Me
1
Ph
263 264 265
5-Methy1sulfanyl-1 -phenyl-1 H-tetrazole (264). To a solution of potassium hydroxide 
(17.3 g, 0.309 mol) in absolute ethanol (560 mL) was added 1-phenyl-1H-tetrazole-5-thiol 263 
(50 g, 0.281 mol) and the mixture was refluxed. After 2 hour, the reaction mixture was cooled 
down to room temperature and iodomethane (19.2 mL, 0.309 mol) was slowly added. The 
mixture was refluxed for another 2 hours. After cooling to room temperature, water (1 L) was 
added, and the solution was extracted with diethyl ether (3 x 500 mL). The combined organic 
layer was washed with saturated aq. NaHC03 (200 mL), brine (200 mL), and dried (MgS04). 
The solvent was removed under vacuum to yield 43.6 g (81 %) of a white solid. M.p. 76°C; IR 
(KBr) 1593 (m), 1501 (s), 1465 (m), 1418 (s), 1385 (s), 1313 (s), 1278 (s), 1248 (s), 1166 (w), 
1095 (s), 1078 (m), 1042 (w), 1012 (m), 979 (s), 788 (s), 693 (s), 554 (m); 1H-NMR (400 MHz, 
CDCI3, 298 K) 5 7.56-7.52 (m, 5 H, Ph), 2.81 (s, 3 H, Me); 13C-NMR (100 MHz, CDCI3 298 K) 5
154.9, 133.6, 130.1, 129.8, 123.7, 15.4; HRMS Calcd for C8H9N4S (M+H)+: m/z 193.05478. 
Found: m/z 193.05519.
5-Methanesulfonyl-1 -phenyl-1 H-tetrazole (265). 3-Chloroperoxybenzoic acid (77 % in 
water, 122.5 g, 0.546 mol) was added portionwise to a suspension of the above thioether (42 g, 
0.219 mol) and NaHC03 (92 g, 1.1 mol) in dichloromethane under mechanical stirring. The 
mixture was vigorously stirred for 10 hours. Saturated solutions of aq. NaHC03 (1 L) and aq. 
Na2S20 3 (500 mL) were added, and the stirring was continued for another 1 hour until the 
solution became clear. The layers were separated. The aqueous layer was further extracted 
with dichloromethane (2 x 200 mL). The combined organic layer was washed with water (300 
mL), brine (150 mL), and dried (MgS04). The solvent was removed under vacuum to yield an oil 
which crystallised upon addition of diethyl ether. The pale yellow solid thus obtained was 
recrystallised in hot ether to afford 37.1 g (76 %) of a bright white solid. M.p. 86°C; IR (KBr) 
1593 (m), 1497 (m), 1458 (w), 1405 (w), 1336 (s), 1157 (s), 1107 (w), 1073 (w), 1054 (w), 1018 
(w), 960 (m), 768 (s), 689 (s), 570 (m), 533 (s), 500 (s); 1H-NMR (400 MHz, CDCI3, 298 K) 5 
7.69-7.67 (m, 2 H, Ph), 7.61-7.58 (m, 3 H, Ph), 3.61 (s, 3 H, Me); 13C-NMR (100 MHz, CDCI3 
298 K) 5 154.0, 132.9, 130.1, 131.5, 124.9, 43.8; HRMS Calcd for C8H9N40 2S (M+H)+: m/z 
225.04461. Found: m/z 225.04403.
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Methyl 2,3-dideoxy-2-methoxycarbonylamino-6-p-toluenesulfonyl-4-triethylsilyl-3-
trimethylsilyl-ethylsulfonamido-a-D-altropyranoside (266)
SESHN NHBoc 
255
TESCI, DMAP
(93%)
SESHN NHBoc 
266
To a solution of alcohol 255 (500 mg, 0.819 mmol) in dry pyridine (3 mL) under nitrogen 
was added chlorotriethylsilane (200 pL, 1.23 mmol), followed by DMAP (15 mg, 0.123 mmol). 
After 3 h stirring at room temperature, the solvent was evaportated by distillation under reduced 
pressure. The residue was taken up in AcOEt (50 mL), and the solution was extensively washed 
with 0.5N aq. HCI ( 5x10  mL), sat. aq. NaHC03 (10 mL), brine (5 mL) and dried (MgS04). The 
solvent was removed in vacuo and the residue was purified by Si02 flash chromatography 
(AcOEt/Petrol 3:7) to give 266 (555 mg, 93%) as a white solid. M.p. 101 °C; [a]D +20.30 (c 0.37, 
CH3CI3); IR (neat) 2957 (s), 1709 (s), 1599 (w), 1517 (w), 1458 (w), 1368 (s), 1250 (m), 1178 
(s), 1145 (s), 1095 (m), 1053 (m), 1021 (w), 968 (w), 942 (w), 862 (m), 739 (m), 698 (w), 665 
(m), 554 (s) ; 1H-NMR (500 MHz, CDCI3, 298 K) 6  7.79 (d, J = 8.3 Hz, 2 H, arom.), 7.39 (d, J =
8.0 Hz, 2 H, arom.), 5.36 (d, J =  8.3 Hz, 1 H, NHSES), 4.68 (d, J=  7.4 Hz, 1 H, NHBoc), 4.48 (s, 
1 H, H1), 4.29 (d, J=  10.7 Hz, 1 H, H4), 4.12 (m, 1 H, H5), 3.82 (d, J =  6.9 Hz, 1 H, H2), 3.76-
3.72 (m, 3 H, H2 + H6 ), 3.32 (s, 3 H, -OCH3 ), 3.14 (t, J =  13.4 Hz, 1 H, SES), 3.05 (t, J =  13.1 
Hz, 1 H, SES), 2.44 (s, 3 H, PhCHa), 1.42 (s, 9 H, Boc), 1.23 (m, 2 H, SES), 0.91 (m, 9 H, TES), 
0.58 (m, 6  H, TES), 0.03 (s, 9 H, T M S ); 13C-NMR (125 MHz, CDCI3, 298 K) 5 154.3 (C=0),
144.9 (arom.), 133.0 (arom.), 129.8 (arom.), 128.0 (arom.), 100.0 (C1), 80.5 (Boc), 69.2 (C4),
67.0 (C5), 63.7 (C6 ), 55.6 (-OCH3), 54.5 (C3), 52.7 (C2), 49.8 (SES), 28.2 (Boc), 21.6 (PhCH3),
10.4 (SES), 6 . 8  (TES), 4.5 (TES), -2.0 (TMS); HRMS Calcd for C3oH56N20 10S2Si2Na (M+Na)+: 
m/z 747.28125. Found: m/z 747.28164.
79
Chapter 8: Experimental
Methyl 2,3-dldeoxy-6-iodo-2-methoxycarbonylamino-4-triethylsilyl-3-trimethylsilyl-
ethylsulfonamido-a-D-altropyranoside (267)
'  Nal, acetone
reflux, 23 h
T E S O "( > -O M e ---------------------
> - - (  (74%)
SESHN NHBoc SESHN
266
TESO"'v4  i> -O M e
NHBoc
Sodium iodide (11.1 g, 74.3 g) was added to a solution of tosylate 266 (5.39 g, 7.43 
mmol) in acetone (300 mL), and the mixture was refluxed overnight. After 23 h, the mixture was 
cooled down to room temperature, and filtered. The clear yellow filtrate was concentrated in 
vacuo. The residue was taken up in AcOEt (200 mL), and the resulting solution was washed 
with water (30 mL), brine (20 mL), and dried (MgS04). The solvent was removed in vacuo and 
the residue was purified by S i02 flash chromatography (AcOEt/Petrol 15:85) to give 267 (3.75 g, 
74%) as a colourless oil. [a]D +15.4 0 (c 0.5, CH3CI3); IR (KBr) 2954 (s), 1685 (s), 1474 (m), 
1370 (m), 1341 (w), 1319 (s), 1250 (m), 1176 (m), 1148 (s), 1106 (m), 1088 (m), 1050 (m), 1027 
(m), 966 (m), 895 (w), 859 (m), 831 (m), 803 (w), 777 (w), 739 (w), 739 (m), 694 (w) ; 1H-NMR 
(500 MHz, CDCI3, 298 K) 5 5.42 (d, J=  9.1 Hz, 1 H, NHSES), 4.73 (d, 7.4 Hz, 1 H, NHBoc),
4.59 (s, 1 H, H1), 3.87 (d, J =  6.3 Hz, 1 H, H2), 3.76 (m, 1 H, H3), 3.65 (m, 1 H, H4), 3.64-3.49 
(m, 2 H, H6 + H5), 3.44 (s, 3 H, -OChh), 3.20 (m, 1 H, H6), 3.16 (m, 1 H, SES), 3.07 (m, 1 H, 
SES), 1.41 (s, 9 H, Boc), 1.07 (m, 2 H, SES), 0.96 (t, J =  8.0 Hz, 9 H, TES), 0.72-0.66 (m, 5 H, 
TES), 0.04 (s, 9 H, TMS) ; 13C-NMR (125 MHz, CDCI3, 298 K) 5 154.3 (C=0), 100.4 (C1), 80.5 
(Boc), 68.3 (C5), 68.1 (C4), 55.9 (-OCH3), 54.7 (C3), 52.9 (C2), 49.9 (SES), 28.2 (Boc), 10.5 
(SES), 7.5 (C6), 6.9 (TES), 4.9 (TES), -2.0 (TMS); HRMS Calcd for C23H49lN20 7SSi2Na 
(M+Na)+: m/z 703.17413. Found: m/z 703.17290.
Aldehyde 268
TESC •OMe
Zn, THF/H20 , 
5 h (85%)
SESHN NHBoc 
267
TESO* " \ 4  CHO \3
SESHN NHBoc 
268
Zinc powder (Aldrich 20,998-8, 7.05 g, 108 mmol) was suspended in a solution of iodide 
267 (3.67 g, 5.39 mmol) in a 4:1 THF/water (110 ml), and the mixture was refluxed. After 5 h, 
the mixture was cooled down to room temperature and filtered on a Celite pad. The solution 
was diluted with AcOEt (500 mL), and the layer were separated. The aqueous layer was further
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extracted with AcOEt (2 x 20 mL). The combined organic layer was washed with brine (50 mL) 
and dried (MgS04). The solvent was removed in vacuo and the residue was purified by Si02 
flash chromatography (AcOEt/Petrol 15:85) to give aldehyde 268 (2.2 g, 85%) as a colourless 
oil. IR (neat) 3357 (m), 2956 (m), 1385 (m), 1094 (s), 767 (s); 1H-NMR (500 MHz, CDCI3) 298 K) 
5 9.60 (s, 1 H, H1), 5.83 (ddd, J -  17.1, 10.4, 6.5 Hz, 1 H, H5), 5.76 (d, J=  6.2 Hz, 1 H, NHBoc), 
5.37 (d, J=  17.2 Hz, 1 H, H6), 5.30 (d, 10.5 Hz, 1 H, H6), 4.73 (d, 7.8 Hz, 1 H, NHSES),
4.42 (dd, J=  4.9, 6.1 Hz, 1 H, H4), 4.26 (br s, 1 H, H2), 3.87 (ddd, J=  7.8, 4.5, 3.4 Hz, 1 H, H3), 
2.97-2.93 (m, 2 H, SES), 1.46 (s, 9 H, Boc), 0.96 (t, J = 7.9 Hz, 6 H, TES), 0.93 (t, J = 7.9 Hz, 3 
H, TES), 0.65 (q, J -  7.8 Hz, 4 H, TES), 0.52 (q, J =  7.8 Hz, 2 H, TES), 0.07 (s, 9 H, TMS) ; 13C- 
NMR (125 MHz, CDCI3, 298 K) 5 200.2 (C1), 156.0 (C=0), 136.3 (C5), 118.6 (C6), 80.5 (Boc), 
75.9 (C4), 59.8 (C2), 57.5 (C3), 49.0 (SES), 28.2 (Boc), 10.2 (SES), 6.8 (TES), 6.7 (TES), -2.0 
(TMS).
Diene 269
SESHN NHBoc
N -N
■ s X SC^Me 
Ph 265
KN(SiMe3)2. THF, SESHN NHBoc
PhMe, -78 °C, 4h ___
(77%) 2 6 9
To a solution of sulfone 265 (1.14 g, 5.10 mmol) and aldehyde 268 (2.22 g, 4.25 mmol) 
in freshly distilled THF (110 mL) at - 7 8 °C under N2 was added KHMDS (0.5 M soln. in toluene, 
10.2 mL, 15.7 mmol) in a dropwise manner. After the end of the addition, the mixture was stirred 
at - 7 8 for 4 h. Water (40 mL) was added to quench the reaction, and the mixture was allowed 
to warm to room temperature under vigorous stirring. The product was extracted with AcOEt (3 
x 100 mL). The combined organic layer was washed with brine (50 mL), and dried (MgS04) 
After concentration under vacuum, the residue was purified by S i02 flash chromatography 
(AcOEt/Petrol 1:9) to afford diene 269 (1.70 g, 77%) as an oil. [a]D +22.6 0 (c 1, CH3CI3); IR 
(neat) 3356 (brs), 2956 (s), 1691 (s), 1457 (m), 1320 (m), 1250 (m), 1169 (s), 911 (m), 899 (w), 
734 (s); ’H-NMR (500 MHz, CDCI3, 298 K) 8 5.84 (ddd, J =  17.0, 10.4, 6.4 Hz, 1 H, H 6), 5.77 
(ddd, J =  17.2, 10.3, 7.0 Hz, 1 H, H2), 5.29 (d, J =  17.3 Hz, 1 H, H7), 5.28 (d, J =  10.3 Hz, 1 H, 
H7), 5.25 (d, 17.6 Hz, 1 H, H1), 5.22 (d, J =  10.3 Hz, 1 H, H1) superimposed upon 5.20 (m,
1 H, NHBoc), 4.60 (d, J =  8.9 Hz, 1 H, NHSES), 4.27 (m, 1 H, H5), 4.14 (m, J = 7.3 Hz, 1 H, 
H3), 3.46 (dd, J=  7.3, 3.9 Hz, 1 H, H4), 2.95 (m, 2 H, SES), 1.41 (s, 9 H), Boc), 1.04-1.00 (m, 2 
H, SES), 0.92 (t, 9 H, TES), 0.57 (q, 6 H, TES), 0.02 (s, 9 H, TMS) ; 13C-NMR (125 MHz, CDCI3, 
298 K) 8 156.0 (C=0), 136.1 (C6), 118.5 (C7), 117.9 (C1), 79.9 (BOC), 74.1 (C5), 62.3 (C4), 
54.4 (C3), 50.5 (SES), 28.3 (BOC), 10.4 (SES), 6.8 (TES), 4.8 (TES), -1.9 (TMS); HRMS Calcd 
for C23H49N20 5SSi2 (M+H)+: m/z 521.29005. Found: m/z 521.29048.
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Preparation of Cyclopentene 270
TESO"
SESHN NHBoc
276 (5 mol%), PhMe, 
reflux, 15.5 h (92%)
SESHN NHBoc
269 270
To a degassed solution of diene 269 (1.50 g, 2.88 mmol) in freshly distilled toluene (150 
mL) under nitrogen was added the Grubbs-Hoveyda catalyst 276 (90 mg, 0.144 mmol), and the 
mixture was refluxed. After 15.5 h, the solvent was removed in vacuo, and the residue was 
purified by S i02 flash chromatography (AcOEt/Petrol 1:9) to afford the title cyclopentene 270 
(1.31 g, 92%) as an oil. [a]D -149.4 0 (c 0.5, CH3CI3); IR (neat) 3358 (m), 2956 (s), 1710 (s), 
1517 (m), 1418 (w), 1366 (m), 1331 (s), 1250 (s), 1171 (s), 1141 (s), 1072 (s), 1014 (m), 942 
(w), 861 (w), 838 (w), 734 (m); 1H-NMR (500 MHz, CDCI3) 298 K) 5 5.95 (dd, J =  6.2, 1.5 Hz, 1 
H, H3), 5.87 (ddd, J=  6.2, 2.4, 2.3 Hz, 1H, H2), 5.03 (d, J=  8.8 Hz, 1 H, -NHSES), 4.77 (br s, 1 
H, NHBoc), 4.58 (ddd, J =  5.9, 2.4, 1.0 Hz, 1 H, H1), 4.52 (dd, J = 6.4, 6.2 Hz, 1 H, H4), 3.61 
(ddd, J = 8.7, 6.4, 5.9 Hz, 1 H, H5), 2.97 (m, 2 H, SES), 1.41 (s, 9 H, Boc), 1.04 (m, 2 H, SES), 
0.93 (t, J =  10.4 Hz, 9 H, TES), 0.59 (q, 10.6 Hz, 6 H, TES), 0.03 (s, 9 H, -TMS); 13C-NMR
(125 MHz, CDCI3, 298 K) 8 155.7 (C=0), 137.1 (C3), 132.6 (C2), 79.8 (Boc), 73.5 (C1), 61.3 
(C5), 60.7 (C4), 50.3 (SES), 28.3 (Boc), 10.6 (SES), 6.7 (TES), 5.0 (TES), -2.0 (TMS). HRMS 
Calcd for C2iH44N20 5SSi2Na (M+Na)+: m/z 515.24070. Found: rrtfz515.24105.
Amino-alcohol 282
TBAF (1M soln. in THF, 1 mL, 1 mmol) was added under nitrogen to a solution of 
cyclopentene 270 (100 mg, 0.203 mmol) in freshly distilled acetonitrile (3 mL). After 10 minutes, 
the mixture was heated at 80°C for 15 h. After cooling to room temperature, the solvent was 
removed by distillation under reduced pressure, and the residue was submitted to S i02 flash 
chromatography (CH2CI2/MeOH 95:5) to give 282 (43 mg, 76%) as a colourless oil. IR (neat) 
3363 (br s), 2956 (m), 1635 (m), 1384 (m), 1319 (m), 1251 (m), 1140 (s), 862 (m), 756 (m); 
Positive-CI MS m/e 279 (MH+).
TBAF (5 equiv.), 
MeCN, A, 15h
SESHN NHBoc SESHN
270 282
82
Cyclopentenol 228
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TE sa,
f t
TBAF (1.2 equiv.), HO<, 
MeCN, 30 min, RT
SESHN
270
NHBoc (100%) SESHN NHBoc 
228
TBAF (1 M soln. in THF, 1.5 mL, 1.5 mmol) was added under nitrogen to a solution of 
270 (600 mg, 1.21 mmol) in freshly distilled acetonitrile (18 mL), and the mixture was stirred at 
room temperature. After 0.5 h, the solvent was removed by distillation under reduced pressure, 
and the residue was purified by S i02 flash chromatography (AcOEt/Petrol 4:6) to afford the title 
compound (473 mg, 100%) as a white solid. M.p. 131 °C; [a]D -80.0 0 (c 0.065, CH3CI3); IR 
(neat) 2961 (m), 1696 (s), 1513 (m), 1453 (w), 1392 (m), 1366 (m), 1328 (m), 1312 (m), 1251 
(m), 1170 (s), 1141 (s), 1089 (w), 1061 (m), 1004 (m), 976 (w), 941 (w), 8 8 8  (m), 842 (w), 802 
(w), 780 (w), 757 (w), 740 (w), 698 (w), 632 (w), 594 (w), 544 (w), 517 (w) ; 1H-NMR (500 MHz, 
CDCI3, 298 K) 5 6.03 (dt, J =  6.0, 2.4 Hz, 1 H, H2), 5.94 (dd, J =  6.1, 1.6 Hz, 1 H, H3), 5.54 (br 
s, 1 H, -NHSES), 4.79 (br s, 1 H, -NHBoc), 4.65 (ddd, 5.5, 2.6, 1.3 Hz, 1 H, H1), 4.62 (br s, 1 
H, H4), 3.49 (ddd, J =  5.5 Hz, 1 H, H5), 3.01 (m, 2 H, SES), 1.81 (br s, 1 H, -OH), 1.43 (s, 9 H, 
Boc), 1.05 (m, 2 H, SES), 0.04 (s, 9 H, SES); 13C-NMR (125 MHz, CDCI3, 298 K) 5 156.1 (0=0),
136.5 (C3), 133.2 (C2), 80.2 (Boc), 73.2 (C1), 62.3 (C5), 60.2 (C4), 49.4 (SES), 28.3 (Boc), 10.4 
(SES), -2.0 (TMS); HRMS Calcd for C15H31N20 5SSi (M+H)+: m/z 379.17228. Found: m/z 
379.17164.
Cyclopentene-oxazolidinone 280
A solution of alcohol 228 (100 mg, 0.264 mmol) in freshly distilled THF (2 mL) was 
added under nitrogen to a suspension of NaH (60% dispersion in mineral oil, 13 mg, 0.317 
mmol) in freshly distilled THF. After the gas evolution ceased, the mixture was stirred at room 
temperature. After 1 hour, phenyl chloroformate (50 pL, 0.396 mmol) was added dropwise, and 
the stirring was continued for 16.5 h. More NaH (6.4 mg, 0.132 mmol) was added. After 30 min., 
more phenyl chloroformate (20 pL, 0.158 mmol) was added to the mixture. After 30 min. stirring, 
the mixture was heated at 50°C for 2.5 h. After cooling to room temperature, the solution was
s
228
1) NaH, THF. RT, 1h
2) PhOC(0)CI, 50 °C
NHBoc
280
Chapter 8: Experimental
diluted with Et20  (20 mL), and quenched with water (5 mL). The layer were separated. The 
organic layer was washed with sat. aq. NaHC03, brine, and dried (MgS04). After concentration 
in vacuo, the residue was purified by S i0 2 flash chromatography (AcOEt/Petrol 2:8) to afford the 
title compound (33 mg, 31%) as an oil. IR (KBr) 3391 (m), 2956 (m), 1779 (s), 1710 (s), 1517 
(m), 1364 (s), 1251 (s), 1172 (s), 1048 (m), 862 (m), 520 (m); 1H-NMR (500 MHz, CDCI3, 298 K) 
S 6.04-6.02 (m, 2 H, H5 and H6 ), 5.70 (d, J =  7.5 Hz, 1 H, H6 a), 5.04 (br s, 1 H, NHBoc), 4.66 
(d, 7.3 Hz, 1 H, H3a), 4.61 (br s, 1 H, H4), 3.50-3.43 (m, 2 H, SES), 1.39 (s, 9 H, Boc), 1.04-
0.99 (m, 2 H, SES), 0.05 (s, 9 H, TMS); 13C-NMR (125 MHz, CDCI3, 298 K) 5 154.8, 152.2,
137.0, 129.9, 83.7, 80.3, 64.2, 63.7, 49.9, 44.9, 28.2, 9.5, -2.0.
Methyl 4,6-0-benzylidene-2,3-dideoxy-2,3-(N-methoxycarbonyl)epimino-a’D-allo-
pyranoside (288)
Ph.... MeOC(0)CI.Py Ph“ " 
'"OM e  CH2Cl2 , 0*C to RT
(86%)
OMe
234 288
To a stirred solution of the 2,3-epimine 234 (10 g, 38 mmol) in dry CH2CI2 (100 mL) and 
dry pyridine (9.2 mL, 114 mmol) at 0 °C was added methyl chloroformate (3.6 mL, 45.6 mmol) 
dropwise over 10 min. When the addition was complete, the cooling bath was removed, and the 
reaction mixture was allowed to warm to room temperature. After stirring for 4.5 h, water (100 
mL) was added to the reaction mixture, and the resulting biphasic solution partioned in a 
separatory funnel. The organic layer was removed, and the aqueous fraction further extracted 
with CH2CI2 (3 x 150 mL). The combined organic layers were washed with 0.5 M aq. HCI (2 x 
100 mL), brine (100 mL), dried over MgS04, filtered and concentrated in vacuo. The title 
compound 288 crystallised in pure condition when the crude residue was triturated with EtOAc 
and petrol; the product 288 was obtained in two crops (8.2 g and 2.3 g, 8 6 % overall). M.p. 
157°C; [a]o +64.3° (c 0.12, CH2CI2); IR (KBr) 1724 (s), 1443 (s), 1416 (w), 1392 (m), 1366 (m), 
1307 (s), 1220 (s), 1189 (w), 1137 (m), 1110 (s), 1065 (s), 1021 (s), 986 (s), 956 (m), 859 (w), 
750 (m), 695 (m); 1H-NMR (500 MHz, CDCI3, 298 K) 5 7.49 (m, 2 H, arom.), 7.38-7.32 (m, 3 H, 
arom.), 5.56 (s, 1 H, Ph-CH-), 4.90 (d, J=  3.1 Hz, 1 H, H1), 4.20 (dd, 10.2, 5.1 Hz, 1 H, H6 ),
4.01 (m, 1 H, H5), 3.84 (dd, J=  9.1, 1.6 Hz, 1 H, H4), 3.73 (s, 3 H, -C 0 2CH3), 3.65 (dd, 10.3,
10.3 Hz, 1 H, H6 ), 3.46 (s, 3 H, -OCHa), 3.11 (narrow m, 2 H, H2 + H3); 13C-NMR (125 MHz, 
CDCI3, 298 K) 5 162.5 (C=0), 137.2 (arom.), 128.3 (arom.), 126.4 (arom), 102.6 (PhCH-), 94.5 
(C1), 76.3 (C4), 68.9 (C6 ), 60.1 (C5), 55.9 (-OCH3), 54.1 (-COzCHa), 39.3 (C3/C2), 36.9 
(C3/C2). HRMS Calcd for C16HzoN06 (M+H)+: m/z 322.12905. Found: m/z 322.12876. Anal, for 
C,6H19N 06. Calcd. C: 59.81; H: 5.96; N: 4.36. Found. C: 59.83; H: 5.94; N: 4.30.
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Methyl 2-azido-4,6-0-benzylidene-2,3-dideoxy-3-methoxycarbonylamino-a-D-altro-
pyranoside (289)
Ph1NaN3, NH4CI 
DMF, reflux, 4 h
(88%) MeQ2CHN N;
289
Ph....
O'1 —OMe
OMe
288
A mixture of 288 (8.2g, 25.5 mmol), NaN3 (6.63 g, 102 mmol), and NH4CI (2.1 g, 40.8 
mmol) in dry DMF (150 mL) were heated at reflux for 4 h, whereafter TLC analysis (4:1 
EtOAc:Petrol) revealed that all of 288 had been consumed and that a single slower-moving 
product 289 had formed. The reaction mixture was cooled to RT, H20  (200 mL) was added, and 
the aqueous solution was extracted with EtOAc (3 x 200 mL). The combined organic layers 
were washed with H20  (2 x 200 mL) and brine (100 ml), and dried over MgS04. After removal of 
the drying agent by filtration, the solvent was removed in vacuo. The resulting white solid was 
suspended in Et20  (50 mL) and the pure product 289 (5.9 g, 65%) was isolated by suction 
filtration. The mother liquor was concentrated in vacuo, and the resulting white solid was 
recrystallised from Et20/Petrol. A further crop of pure 289 (2.27 g) was isolated thereafter. The 
combined overall yield of 289 = 8.17 g (8 8 %). M.p. 130<€ ; [a]D +34.1 0 (c 0.5, CH2CI2); IR (KBr) 
3423 (s), 2106 (s), 1736 (s), 1514 (s), 1458 (m), 1404 (m), 1374 (m), 1350 (m), 1315 (m), 1267 
(s), 1221 (s), 1129 (s), 1091 (s), 1063 (s), 1048 (s), 1024 (s), 988 (s), 956 (s), 933 (m), 894 (m), 
825 (m), 763 (m), 700 (m); 1H-NMR (500 MHz, CDCI3, 298 K) 5 7.43-7.38 (m, 2 H, arom.), 7.37- 
7.30 (m, 3 H, arom.), 5.64 (d, J= 9.0 Hz, 1 H, -NHC02Me), 5.61 (s, 1 H, Ph-CH-), 4.66 (s, 1 H, 
H1), 4.41 (m, 1 H, H3), 4.27 (66, J = 10.1, 4.5 Hz, 1 H, H6 ), 3.98 (dd, J = 9.8, 4.0 Hz, 1 H, H4), 
3.92 (m, 1 H, H5), 3.88 (s, 1 H, H2), 3.81 (dd, J = 10.2, 10.0 Hz, 1 H, H6 ), 3.67 (s, 3 H, - 
COzCHs), 3.42 (s, 3 H, -OCHj); 13C-NMR (125 MHz, CDCI3, 298 K) 8  156.6 (C=0), 137.0 
(arom.), 128.9 (arom.), 128.2 (arom.), 126.0- (arom.), 101.6 (Ph-CH-), 99.2 (C1), 74.0 (C4), 68.9 
(C6 ), 61.2 (C2), 59.2 (C5), 55.7 (-OCH3), 52.3 (-COzCHa), 49.3 (C3). HRMS Calcd for 
C16H21N406 (M+H)+: m/z 365.14610. Found: m/z 365.14552. Anal, for C16H20N4O6. Calcd. C: 
52.74; H: 5.53; N: 15.38. Found. C: 52.90; H: 5.25; N: 15.10.
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Methyl 2-azido-2,3-dideoxy-3-methoxycarbonylamino-a-D-altropyranoside (287)
Me02CHN N3
AcCI, MeOH 
0.5 h (94%)
MeC
289 287
To a solution of the benzylidene acetal 289 (640 mg, 1.76 mmol) in anhydrous methanol 
(20 mL) was added acetyl chloride (380 pL, 5.27 mmol) dropwise. After the end of the addition, 
the mixture was stirred at room temperature for 30 minutes. The reaction was quenched with 
sat. aq. NaHC03 (5 mL), and the solution was extracted with AcOEt (3 x 20 mL). The combined 
organic layer was washed with brine (10 mL) and dried (MgS04). After concentration under 
vacuum, the residue was purified by S i02 flash chromatography (AcOEt/Petrol 85:15) to give 
diol 287 (457 mg, 94%) as a colourless oil which solidifies upon standing. [a]D +26.0 0 (c 0.5, 
CH3CI3); IR (neat) 3419 (br s), 2 1 1 2  (s), 1636 (m), 1448 (w), 1320 (m), 1253 (m), 1142 (m), 
1110 (m), 1079 (m), 1052 (m), 981 (w), 954 (w), 893 (w), 860 (m), 758 (m), 701 (w) ; 1H-NMR 
(400 MHz, CDCI3, 298 K) 5 5.93 (d, 8.2 Hz, 1 H, NH), 4.67 (s, 1 H, H1), 4.25 (t, J=  4.0 Hz, 1
H, H3), 4.02 (dd, J =  13.9, 4.2 Hz, 1 H, H4), 3.88 (dd, J = 11.9, 3.7 Hz, 1 H, H6 ), 3.83 (dd, J =
11.9, 4.7 Hz, 1 H, H6 ), 3.73 (m, 1 H, H2), 3.71 (s, 3 H, -OMe), 3.69 (m, 1 H, H5), 3.44 (s, 3 H, - 
OMe), 2.63 (br s, 2 H, -OH); 13C-NMR (125 MHz, CDCI3> 298 K) 5 158.1 (C=0), 98.4 (C1), 68.7 
(C=0), 64.5 (C4), 62.5 (C6 ), 60.7 (C2), 55.6 (-OMe), 52.7 (-OMe), 51.6 (C3). HRMS Calcd for 
C9H17N406 (M+H)+: m/z 277.11480 Found: m/z 277.11491.
Oxazolidinone 286
To a solution of diol 287 (207 mg, 0.499 mmol) in freshly distilled THF (10 mL) under N2 
was added sodium hydride (60% in mineral oil, 100 mg, 2.50 mmol) in one portion. After 30 
minutes stirring at room temperature, water (5 mL) was added to quench the reaction. The 
mixture was extracted with AcOEt ( 3 x 1 0  mL). The combined organic layer was washed with 
brine (2 mL) and dried (MgS04). After concentration under vacuum, the residue was purified by 
Si02 flash chromatography (AcOEt/Petrol 8:2 to 10:0) to give oxazolidinone 286 (192 mg, 
100%) as a colourless oil. [a]D +42.40 (c 0 .2 1 , CH3CI3); IR (neat) 3420 (r s), 2118 (s), 1752 (s), 
1637 (w), 1399 (w), 1336 (m), 1101 (m), 1048 (s), 987 (w), 956 (w), 760 (m); 1H-NMR (400
MeC
287 286
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MHz, DMSO-de, 298 K) 5 8.42 (s, 1 H, -NH-), 4.99 (br s, 1 H, -OH), 4.55 (d, J = 6.9 Hz, 1 H, H1), 
4.52 (t, J=  9.0 Hz, 1 H, H4), 3.89 (dd, J =  10.1, 7.0 Hz, 1 H, H2), 3.81 (ddd, J=  8.3, 5.5, 2.2 Hz, 
1 H, H5), 3.61 (dd, J = 9.5, 9.4 Hz, 1 H, H3), 3.56 (m, 1 H, H6 ), 3.46 (m, 1 H, H6 ); 13C-NMR 
(125 MHz, DMSO-dg, 298 K) 5 158.6 (0=0), 101.5 (C1 ), 72.2 (C4), 70.3 (C3), 64.4 (C5 ), 62.6 
(C6 ), 56.2 (-OMe), 52.6 (C2); HRMS Calcd for C8H13N40 5  (M+H)+: m/z 245.08859. Found: m/z 
245.08826.
Azido-oxazolidinone 290
OMe
TsCI (1.5 equiv), 
DABCO (2 equiv.)
CH2 CI2,
0°C toRT. 1.5 h
(87%)
..<4 0 " ' 0 M e
286 290
To a solution of alcohol 286 (1.97 g, 8.06 mmol) and DABCO (1.81 g, 16.1 mmol) in 
CH2CI2 (80 mL) at 0 °C was added p-toluenesulfonyl chloride (2.31 g, 12.1mmol) in several 
portions over 30 minutes under stirring. After the addition was complete, the cold bath was 
removed and the stirring was continued for 2 hours. Water (20 mL) was then added. The layers 
were separated, and the aqueous layer was further extracted with CH2CI2 (2 x 20 mL). The 
combined organic layer was washed with sat. aq. NH4CI (40 mL), brine (20 mL), and dried 
(MgS04). After concentration in vacuo, the residue was purified by Si02 flash chromatography 
(AcOEt/Petrol 6:4) to afford the title compound (2.78 g, 87%) as a white solid. M.p. 94°C; [a]D 
+50.8 0 (c 1 , CH3CI3); IR (neat) 3351 (br m), 3020 w), 2938 (m), 2841 (w), 2118 (s), 1767 (s), 
1597 (m), 1495 (w), 1449 (w), 1364 (s), 1312 (w), 1288 (w), 1258 (w), 1229 (m), 1176 (s), 1144 
(m), 1096 (m), 1052 (s), 991 (s), 913 (m), 876 (w), 818 (m), 760 (s), 6 6 8  (m), 588 (w), 555 (s), 
517 (w^H-NMR (500 MHz, CDCI3, 298 K) 6  7.81 (d, J = 8.3 Hz, 2 H, arom.), 7.37 (d, J = 8.1 
Hz, 2 H, arom.), 6.12 (s, 1 H, -NH-), 4.62-4.57 (m, 2 H, H1 + H4), 4.25 (dd, J =  11.1, 2.5 Hz, 1 
H, H6 ), 4.17 (dd, J =  11.1, 5.4 Hz, 1 H, H6 ), 4.07-4.04 (m, 1 H, H5), 3.60-3.58 (m, 2 H, H2 + 
H3), 3.44 (s, 3 H, -OMe), 2.46 (s, 3 H, Tos.); 13C-NMR (125 MHz, CDCI3, 298 K) 6  157.7 (C=0),
145.3 (arom.), 132.3 (arom.), 130.0 (arom.), 128.0 (arom.), 100.7 (C1), 71.6 (C4), 68.3 (C6 ),
67.5 (C5), 63.8 (C3), 55.7 (-OMe), 52.0 (C2), 21.6 (Tos.); HRMS Calcd for C15H19N40 7S 
(M+H)+: m/z 399.09744. Found: m/z 399.09768.
87
Chapter 8: Experimental
N-Boc oxazolidinone 293
Boc20, DMAP, Ts< 
Et3 N, CH2 CI2,
RT. 0.5h•••OMe
(82%)
Boc
OMe
290 293
To a solution of azide 290 (2.50 g, 6.27 mmol), triethylamine (4.4 mL, 31.4 mmol), and 
DMAP (77.0 mg, 0.627 mol) in CH2CI2 (100 mL) was added di-ferf-butyl dicarbonate (2.05 g, 
9.41 mmol) in one portion. After 30 minutes stirring at room temperature, water (30 mL) was 
added. The layers were separated, and the aqeuous layer was further extracted with CH2CI2 (2 
x 20 mL). The combined organic layer were washed with sat. aq. NH4CI (30 mL), brine (20 mL), 
and dried (MgS04). After concentration in vacuo, the residue was purified by S i02 flash 
chromatography (AcOEt/Petrol 3:7) to afford the title compound (2.57 g, 82%) as a white solid. 
M.p. 137°C; [<x]D +8 8 . 6  0 (c 1 , CH3CI3); IR (KBr) 2994 (s), 2940 (s), 2847 (w), 2265 (m), 2119 
(s), 1846 (s), 1712 (s), 1597 (s), 1473 (w), 1456 (s), 1332 (s), 1306 (s), 1257 (s), 1195 (s), 1116 
(s), 1060 (s), 999 (s), 956 (s), 914 (s), 894 (m), 859 (m), 828 (s), 788 (s), 766 (s), 742 (s), 665 
(s), 636 (w), 597 (m), 552 (s); 1H-NMR (500 MHz, CDCI3, 298 K) 6  7.77 (d, J = 8.3 Hz, 2 H, 
arom.), 7.34 (d, J = 8.0 Hz, 2 H, arom.), 4.60 (d, J = 5 .0  Hz, 1 H, H1), 4.51 (dd, J = 8 .2 , 8.2 Hz, 
1 H, H4), 4.27 (dd, J =  8.0, 8.0 Hz, 1 H, H3), 4.22 (dd, J =  11.1, 3.0 Hz, 1 H, H6 ), 4.15 (dd, J = 
11.1, 5.1 Hz, 1 H, H6 ), 3.99 (m, 1 H, H5), 3.76 (dd, J = 8.1, 5.0 Hz, 1 H, H2), 3.37 (s, 3 H, - 
OMe), 2.44 (s, 3 H, Tos), 1.53 (s, 9 H, Boc); 13C-NMR (125 MHz, CDCI3, 298 K) 5 150.8 (C=0),
148.8 (C=0), 145.4 (arom.), 132.4 (arom.), 130.0 (arom.), 128.0 (arom.), 100.0 (C1), 85.1 (Boc),
6 8 . 6  (C4), 68.0 (C6 ), 67.0 (C5), 60.5 (C2), 55.9 (-OMe), 54.5 (C3), 27.8 (Boc), 21.7 (Tos.); 
HRMS Calcd for CzoH^OgS (M)+: m/z 499.14986. Found: m/z 499.15022.
Methyl 4,6>Obenzylidene-2,3-dideoxy-3-methoxycarbonylamino-2-trimethylsilyl-
ethylsulfonamido-a-D-altropyranoside (299)
OMe
H2, cat. Pd(OH)2, 
MeOH. 7 h
(ca. 95%)
SESCI, AgCN, ph 
C6 H6, 75 °C, 22 h •OMe
J — NH NHSES 
MeO
299
A suspension of 20% Pd(OH) 2 on C (Aldrich, wet type) (2.7 g, 2.6 mmol) and azide 289 
(9.4 g, 26 mmol) were suspended in MeOH (280 mL) and the reaction vessel was sequentially 
evacuated and purged with H2 gas five times before being allowed to stir vigorously under a
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hydrogen atmosphere (1 atm) at room temperature for 3 h. The suspension was then filtered 
through a pad of Celite® and the solvent concentrated in vacuo. The resulting oil 300 (8.3 g) was 
sufficiently pure for use in the next step and was not purified any further.
To a mixture of amine 300 (10.4 g, 30.7 mmol) and AgCN (6.2 g, 46.1 mmol) in freshly 
distilled C8H6 was added SESCI (9.3 g, 46.1 mmol) in one portion. The reaction mixture was 
heated at 75 °C for 22 h and then cooled to room temperature before being filtered through 
Celite®. The filtrate was concentrated in vacuo and the crude residue purified by Si02 flash 
chromatography with 3:1 Petrol:EtOAc as eluent. Compound 299 (9.4 g, 61%) was obtained as 
a pale yellow oil. [a]D +18.2 0 (c 0.5, CH2CI2); IR (Neat) 3427 (w), 3267 (br w), 3016 (w), 2954 
(m), 1721 (s), 1517 (s), 1455 (m), 1413 (w), 1376 (w), 1354 (w), 1324 (s), 1252 (s), 1147 (s), 
1108 (s), 1070 (m), 1045 (s), 963 (w), 921 (m), 890 (m), 860 (s), 841 (s), 757 (s), 700 (m), 664 
(w), 541 (w), 510 (w); 1H-NMR (400 MHz, toluene-d8, 363.8 K) 5 7.41-7.38 (m, 2 H, arom.), 
7.09-6.97 (m, 3 H, arom.), 5.38 (s, 1 H, Ph-CH-), 5.34 (br d, J =  8 .6  Hz, 1 H, -NHC02Me), 4.76 
(d, J =  9.4 Hz, 1 H, -NHSes), 4.62 (s, 1 H, H1), 4.30 (m, 1 H, H3), 4.00 (dd, J =  10.2, 5.0 Hz, 1 
H, H6 ); 3.90 (d, 8.4, 1.3 Hz, 1 H, H2), 3.72 (ddd, J =  10.0, 9.9, 5.0, 4.9 Hz, 1 H, H5), 3.58
(dd, J =  10.0, 4.7 Hz, 1 H, H4), 3.52 (dd, J =  10.1, 10.1 Hz, 1H, H6 ), 3.33 (s, 3 H, -C 02CH3), 
2.99 (dd, J = 9.2, 8.3 Hz, 2 H, Ses), 2.92 (s, 3 H, -OCH3), 1.06 (m, 2 H, Ses), -0.10 (s, 9 H, - 
TMS); 13C-NMR partial spectrum(125 MHz, toluene-d8, 298 K) 6  156.9 (C=0), 138.1 (arom.), 
126.7 (arom.), 102.4 (C1), 1 0 2 .1  (Ph-CH-), 74.1 (C4), 69.2 (C6 ), 59.2 (C5), 55.3 (C3), 55.2 (- 
OCH3), 51.8 (-COzCHa), 51.7 (C2), 50.2 (Ses), 11.0 (Ses), -2.1 (-TMS). HRMS Calcd for 
C21H34N20 8SSiNa (M+Na)+: m/z 525.17027. Found: m/z 525.16969.
Methyl 2,3-dideoxy-3-methoxycarbonylamino-2-trimethylsilylethylsulfonamido-a-D-
altropyranoside (298)
•OMe
MeO
^ - N H  NHSES
299
AcCI, MeOH. 
0 °C. 1 h then 
RT for 0.5 h
(85 %)
HO"*<< i)-O M e  
O
y ~ N H  NHSES 
^  298
To a stirred solution of the protected diamino-sugar 299 (29.2 g, 58.1 mmol) in dry 
MeOH (290 mL) at 0 °C was added AcCI (12.4 mL, 174 mmol) dropwise over 40 min. The 
reactants were stirred at 0 °C for 1 h, and then allowed to warm to RT for 0.5 h. Solid NaHC03 
was added until pH7 was attained, and the solvents removed in vacuo. The residue was taken 
up in EtOAc (300 mL), and the solution washed with H20  (200 mL). The aqueous layer was 
extracted further with EtOAc (3 x 100 mL). The combined organic layers were washed 
successively with brine (200 mL), and dried over MgS04. After filtration and concentration in 
vacuo, the residue was purified by S i02 flash chromatography initially with 2:3 EtOAc/Petrol to
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remove faster moving by-products, and then with EtOAc to elute the product 298 (20.4g, 85%) 
as an oil. [a]D +35.6 0 (c 0.5, CH2CI2); IR (Neat) 3410 (very br, s), 2954 (s), 1711 (s), 1525 (s), 
1321 (s), 1252 (s), 1137 (s), 1108 (s), 1053 (s), 862 (m), 841 (m), 757 (w); 1H-NMR (500 MHz, 
CDCI3> 298 K) 5 5.97 (d, J = 8.0 Hz, 1 H, -NHSes), 5.75 (br s, 1 H, -NHC02Me), 4.67 (s, 1 H, 
H1), 4.18 (m, 1 H, H3), 4.04 (dd, J = 9.7, 4.2 Hz, 1 H, H4), 3.89 (dd, J=  12.0, 3.3 Hz, 1 H, H6 ),
3.83 (dd, J =  12.0, 3.0 Hz, 1 H, H6 ), 3.68 (s, 3 H, -COzCHa), 3.64 (m, 2 H, H2 + H5), 3.40 (s, 3 
H, -OCH3), 2.96 (m, 2 H, Ses), 2.48 (br s, 2 H, -OH), 0.99 (m, 2 H, Ses), 0.05 (s, 9 H, -TMS); 
13C-NMR (125 MHz, CDCI3, 298 K) 5 158.1 (0=0), 101.1 (C1), 69.0 (C5), 63.4 (C4), 61.7 (C6 ),
55.6 (-OCH3), 54.4 (C2), 53.1 (C3), 52.7 (-COzCHa), 50.1 (Ses), 10.4 (Ses), -2.0 (-TMS). HRMS 
Calcd for C14H3oN20 8SSiNa (M+Na)+: m/z 437.13898. Found: m/z 437.13846.
Methyl 2,3-dideoxy-3-methoxycarbonylamino-6-0-toluenesulphonyl-2-trimethyl-
silylethylsulfonamido-a-o-altropyranoside (301)
HO*"<
O V—(
y - N H  NHSES 
MeO 298
TsCI, Et3N, 
DMAP, CHjClj, 
0°C to RT.
(79%)
H O"-<4 i)-O M e  
O iM( 
y —NH NHSES 
Med ^
To a mixture of the diol 298 (15.5 g 37.4 mmol) and 4-dimethylaminopyridine (457 mg, 
3.74 mol) in dry CH2CI2 (190 mL) was added Et3N (53 mL, 374 mmol). The reactants were 
cooled to 0 °C whereafter TsCI (7.46 g, 39.3 mmol) (freshly recrystallised from C6H6) was added 
portionwise over 1 h. Stirring was continued at 0 °C for a further 3 h, before the cooling-bath 
was removed, and the reaction mixture was allowed to warm to RT, where it was maintained for 
a further 13 h. Saturated aq. NH4CI (200 mL) was then added, and the biphasic mixture 
separated. The aqueous layer was extracted with CH2CI2 ( 2  x 100 mL), and the combined 
organic extracts were washed with brine (50 mL), dried (MgS04) and filtered. The solvent was 
then removed in vacuo and the crude residue purified by S i02 flash chromatography (gradient 
elution 3:2 Petrol:EtOAc to EtOAc) to give 301 (16.9 g, 79%) as a white foam. [a]D +22.2 0 (c 
0.5, CH2CI2); IR (Neat) 3412 (br m), 2955 (m), 1708 (s), 1598 (w), 1522 (s), 1452 (w), 1362 (s), 
1324 (s), 1288 (w), 1253 (s), 1175 (s), 1140 (s), 1099 (s), 1055 (s), 981 (m), 839 (s), 758 (s); 
1H-NMR (400 MHz, CDCI3, 328 K) 5 7.79 (d, J =  8.4 Hz, 2 H, Ts), 7.32 (d, 8.0 Hz, 2 H, Ts),
5.85 (d, J=  8.7 Hz, 1 H, -NHC02Me), 4.85 (d, J=  9.5 Hz, 1 H, -NHSes), 4.60 (s, 1 H, H 1 ), 4.36 
(dd, J =  11.2, 2.1 Hz, 1 H), 4.25 (66, J = 11.2, 5.3 Hz, 1 H, H6 ), 4.16 (m, 1 H,), 3.86-3.74 (m, 3 
H,), 3.67 (s, 3 H, -C 0 2Chb), 3.37 (s, 3 H, -OCH3), 2.96 (m, 2 H, Ses), 2.86 (br s, 1 H), 2.42 (s, 3 
H, Ts), 1.01 (m, 2 H, Ses), 0.06 (s, 9H); 13C-NMR (125 MHz, CDCI3, 298 K) 5 158.2 (C=0),
145.0 (arom.), 132.7 (arom.), 129.9 (arom.), 128.0 (arom.), 100.8 (C1), 69.2 (C6 ), 67.1 (C5),
63.9 (C4), 55.7 (-OCH3), 54.0 (C2), 52.9 (C3), 52.8 (-COzCH3), 50.4 (Ses), 21.6 (Ts), 10.5
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(Ses), -2.0 (-TMS). HRMS Calcd for C2iH 36N2O10S2SiNa (M+Na)+: m/z 591.14783. Found: m/z 
591.14793.
Methyl 2,3-dideoxy-3-methoxycarbonylamino-6-0-toluenesulphonyl-4-0-triethyl-silyl-2- 
trimethylsilylethyl-sulfonamido-a-D-altropyranoside (302)
To a stirred solution of 301 (22.5 g, 39.6 mmol) and 4-dimethylaminopyridine (484 mg, 
3.96 mmol) in dry pyridine (200 mL) was added chlorotriethylsilane (9.96 mL, 59.3 mmol) 
dropwise over 5 min. The reactants were stirred at RT for 19 h, whereafter the solvent was 
removed in vacuo. The residue was taken up in EtOAc (200 mL) and sat. aq. NH4CI (200 mL) 
was added. The organic layer was separated. The aqueous layer was extracted with EtOAc (3 x 
200 mL), and the combined organic layers were washed with brine (50 mL) before being dried 
(MgS04) and filtered. The solvent was removed in vacuo and the crude residue purified by S i02 
flash chromatography (gradient elution 4:1 PetroLEtOAc to EtOAc) to give 302 (24.1 g, 89%) as 
an oil. [ct]D +42.6 0 (c 0.31, CH2CI2); IR (Neat) 3434 (br m), 2955 (s), 1726 (s), 1597 (w), 1517 
(s), 1455 (w), 1366 (s), 1324 (s), 1251 (s), 1176 (s), 1138 (s), 1110 (s), 1059 (s), 1018 (m), 929 
(m), 862 (s), 837 (s), 742 (m), 665 (w); ’H-NMR (500 MHz, CDCI3, 298 K) 8 7.78 (d, J =  8.3 Hz, 
2 H, Ts), 7.34 (d, J=  8.6 Hz, 2 H, Ts), 5.44 (d, 9.6 Hz, 1 H, -NHC02Me), 4.67 (d, J =  9.7 Hz,
1 H, -NHSes), 4.52 (d, J =  2.4 Hz, 1 H, H1), 4.25 (dd, J = 10.9, 1.8 Hz, 1 H, H6), 4.14 (dd, J = 
10.8, 5.6 Hz, 1 H, H6), 3.98 (m, 1 H, H3), 3.82 (m, 1 H, H4), 3.74 (m, 1H, H5), 3.64 (s, 3 H, - 
C 02CH3) superimposed upon 3.62 (m, 1 H, H2), 3.31 (s, 3 H, -OCH3), 2.97 (m, 2 H, Ses), 2.43 
(s, 3 H, Ts), 1.01 (m, 2 H, Ses), 0.88 (t, J =  8.0 Hz, 9 H, Tes), 0.56 (m, 6  H, Tes), 0.05 (s, 9H, - 
TMS); 13C-NMR (125 MHz, CDCI3, 298 K) 5 156.9 (C=0), 145.0 (arom.), 133.0 (arom.), 129.9 
(arom.), 128.0 (arom.), 101.4 (C1), 69.0 (C6 ), 68.3 (C5), 64.4 (C4), 55.7 (-OCH3), 54.3 (C2 ),
52.8 (C3), 52.3 (-CO2CH3), 50.2 (Ses), 21.6 (Ts), 10.6 (Ses), 6.7 (Tes), 4.6 (TES), -2.0 (-TMS). 
HRMS Calcd for C27H5oN20 10S2Si2Na (M+Na)+: m/z 705.23429. Found: m/z 705.23488.
■NH NHSES
EtjSiCI, DMAP, 
Py (89%) TESO'v* i)-OM e
NH NHSES 
MsO ino
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Methyl 6-iodo-3-methoxycarbonylamino-2,3,6-trideoxy-4-0-triethylsilyl-2-
trimethylsilylethylsulfonamido-a-D-altropyranoside (297)
30"< V"OMe 
^ -N H  NHSES
Nal. Me2CO, 
reflux (97%)
MeO
TESOM,v* i)-OMe  
O ¥ - (  
y— NH NHSES
To a stirred solution of 302 (13 g, 19 mmol) in acetone (380 mL) was added Nal (28.5 g, 
190 mmol). The reaction mixture was heated at reflux for 24 h, the solvent removed in vacuo, 
and the residue suspended in EtOAc (400 ml), washed with H20  (200 mL), brine (50 mL) and 
then dried over MgS04. Filtration, and concentration of the filtate in vacuo, gave a residue that 
was purified by Si02 flash chromatography (gradient elution 85:15 to 7:3 Petrol:EtOAc). The title 
compound 297 (11.8 g, 98%) was obtained as a colourless oil. [a]D +40.30 (c 0.27, CH2CI2); IR 
(Neat) 3434 (m), 3267 (m), 2956 (s), 2913 (s), 2879 (s), 2840 (w), 1729 (s), 1517 (s), 1451 (m), 
1324 (s), 1251 (s), 1136 (s), 1026 (s), 851 (s), 800 (m), 742 (s), 699 (w); 1H-NMR (500 MHz, 
CDCI3, 298 K) 5 5.52 (d, J =  9.6 Hz, 1 H, -NHC02Me), 4.82 (d, 10.1 Hz, 1 H, -NHSes), 4.67
(d, 2.0 Hz, 1 H, H1), 4.01 (m, 1 H, H3), 3.75 (m, 1 H, H4), 3.67 (m, 1 H, H2) superimposed
upon 3.65 (s, 3 H, -C0 2CH3), 3.48 (m, 2 H, H5 + H6 ) superimposed upon 3.45 (s, 3 H, -OCH3), 
3.27 (dd, J = 11.1, 8.0 Hz, 1 H, H6 ), 2.99 (m, 2 H, Ses), 1.03 (m, 2 H, Ses), 0.94 (t, J = 8.0 Hz, 9 
H, Tes), 0.65 (m, 6  H, Tes), 0.04 (s, 9 H, Ses); 13C-NMR (125 MHz, CDCI3) 298 K) 5 156.9 
(C=0), 101.5 (C1), 69.3 (C5), 68.5 (C4), 56.0 (-OCH3), 54.6 (C2 ), 53.0 (C3), 52.3 (-COzCHa),
50.3 (Ses), 10.6 (Ses), 7.1 (C6 ), 6 . 8  (Tes), 4.7 (Tes), -2.0 (-TMS). HRMS Calcd for 
C2oH43 lN20 7SSi2Na (M+Na)+: m/z 661.12718. Found: m/z 661.12809.
Aldehyde 296
To a stirred solution of iodide 297 (12.1 g, 19 mmol) in THF:H20 (4:1, 380 mL) was 
added Zn dust (24.9 g, 0.380 mol) (Aldrich 20,998-8) and the mixture heated at reflux for 3 h. 
The suspension was then cooled, diluted with EtOAc (400 mL) and filtered through Celite®, and 
the filtrate thereafter washed with brine (2 x 100 mL), before being dried over MgS04. After 
filtration, the solvent was removed in vacuo and the residue purified by S i0 2 flash
Zn.
THF/HzO (4:1) 
reflux, 3 h
•NH NHSES ■NH NHSES
297 296
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chromatography with 7:3 Petrol:EtOAc to give 296 as a colourless oil (8.43g, 92%). [a]D +10.6 0 
(c 0.4, CH2CI2); IR (Neat) 3334 (br m), 2956 (s), 2913 (s), 2878 (s), 1728 (s), 1644 (w), 1535 
(s), 1458 (s), 1419 (s), 1329 (s), 1250 (s), 1171 (m), 1145 (s), 1101 (s), 1062 (s) 1010 (m), 861 
(s), 840 (s), 744 (s); Mixture of 2 rotamers: a and p (3/1) 1H-NMR (500 MHz, toluene-d8) 363 K) 
5 9.32 (s, 1 H, H1 a), 9.23 (s, 1 H, H1 P), 5.65 (ddd, J =  17.3, 10.4, 7.0 Hz, 1 H, H5 a), 5.60 (m, 
1 H, H5 p), 5.17 (br d, 6.9 Hz, 1 H, -NHSes), 5.05 (ddd, J =  17.2, 1.3 Hz, 1 H, H6 a), 4.99 
(ddd, J=  17.2, 1.3 Hz, H6 P), 4.94 (ddd, J=  10.4, 1.3 Hz, H6 a), 4.90 (m, 1H, H6 P), 4.71 (d, J =
8.0 Hz, 1 H, -NHC02Me), 4.30 (dd, J = 7.2, 3.5 Hz, 1 H, H2 a), 4.25 (m, 1 H, H4 a), 4.15 and 
4.10 (m, 2 H, H2 p + H4 P), 3.99 (m, 1 H, H3 a), 3.44 (s, 3 H, -C 02CH3P), 3.40 (s, 3 H, -C 02CH3 
a), 2.83 (m, 2 H, Ses a), 2.80 (m, 2 H, Ses p), 1.02 (m, 4 H, Ses a,p), 0.89 (t, J =  8.1 Hz, 9 H, 
Tes a), 0.83 (t, J=  7.9 Hz, 9 H, Tes P), 0.55 (q, J=  8.0 Hz, 6 H, Tes a), 0.46 (q, J=  8.0 Hz, 6 H, 
Tes P), -0.15 (s, 9 H, -TMS a), -0.16 (s, 9 H, -TMS p); 13C-NMR (125 MHz, toluene-d8, 363 K) 5
196.9 (C1 a), 195.2 (C1 P), 137.7 (C5), 117.7 (C6), 74.7 (C4), 63.5 (C2 p), 62.8 (C2 a), 55.7 
(C3), 51.5 (-COzCHa), 50.0 (Ses a), 49.4 (Ses P), 10.5 (Ses), 6.2 (Tes a), 6.1 (Tes P), 5.0 (Tes 
a), 4.9 (Tes p), -2.8 (-TMS). HRMS Calcd for C19H4oN20 6SSi2Na (M+Na)+: m/z 481.22237. 
Found: m/z 481.22286.
Cyclopentene-Oxazolidinone 151 and Cyclopentenol 304.
>•••( CHOTESO "
O. —^(  
j —NH NHSES 
MeO 2gg
N-N
N'N/ S^S02Me
265 t
KN(SiMe3)2, THF, 
PhMe, -20 °C, 2.5 h
TESO"
O V - (
y—NH NHSES 
MeO 295
r~ \
MesN^NMes
Me ^ s a /  
______ 276________
C6H6t reflux, 14 h 
(ca 47% over 2 steps)
T E S O - . 3
Sv s K  
j^-NH NHSES
MeO
303
To a stirred solution of sulfone 263 (5.48 g, 24.5 mmol) and aldehyde 296 (8.4 g, 17.5 
mmol) in freshly distilled THF (75 mL) at -20  °C was added potassium hexamethyldisilazide (0.5 
M soln in PhMe, 126 mL, 63.0 mmol) dropwise over 30 min. The mixture was stirred at -2 0  °C 
for 2 h before H20  (50 mL) was added, and the cooling bath removed. Most of the THF was 
removed by evaporation in vacuo, and the product extracted from the aqueous solution with 
EtOAc (400 mL). The combined organic layers were washed with H20  (100 ml), 1M aq. HCI (2 x 
50 mL), sat. aq. NaHC03 (50 mL), brine (100 mL) and dried over MgS04. Filtration, 
concentration in vacuo, and purification of the crude residue by S i02 flash chromatography with 
85:15 Petrol:EtOAc provided 295 as a colourless oil (5.07 g) slightly contaminated by tetrazole 
by-product.
The slightly impure diene 295 and the Grubbs-Hoveyda catalyst 276 (130 mg, 0. 208 
mmol) were dissolved in freshly distilled C6H6 (390 mL) and the reaction mixture heated at reflux 
for 14 h. The solvent was removed in vacuo and the crude residue partially purified by Si02
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flash chromatography with 88:12 PetrolrEtOAc as eluent. Cyclopentene 303 (3.7 g) was 
obtained slightly contaminated with the aforementioned tetrazole derivative.
T F A , 2
T E S O -/%  T^ /H2° (4:1) H O -V ^ a
o y _ ( o,,ctoRT-ih » o H 4
V - n'h  NHSES (ca 56%) J ^ -N H  NHSES
MeO MeO . . .303 304
To a solution of 303 (960 mg, 2.13 mmol) in a mixture of THF (20 mL) and water (5 mL) 
at 0°C was added TFA (1.66 mL, 21.5 mmol) in a dropwise manner. The cold bath was then 
removed, and the mixture was stirred at room temperature. After 1 h, the mixture was cooled 
down to 0°C, and sat. aq. NaHC03 (70 mL) was carefully added to quench the reaction. The 
product of the reaction was extracted with AcOEt (3 x 20 mL). The combined organic layer was 
washed with brine and dried (MgS04). After concentration in vacuo, a white solid is obtained, 
which is washed with ether and dried under vaccum to afford 304 (399 mg, 20% over 3 steps 
from 296) as a white solid. M.p. 179*0; [a]D -150.3 0 (c 0.4, MeOH); IR (KBr) 3396 (s), 3243 
(s), 3069 (m), 2955 (m), 1696 (s), 1558 (s), 1456 (s), 1414 (s), 1366 (w), 1326 (s), 1292 (s), 
1250 (s), 1229 (m), 1184 (m), 1147 (s), 115 (s), 1090 (s), 1058 (m), 1003 (m), 933 (s), 896 (s), 
840 (s), 784 (m), 740 (s), 655 (w), 536 (m) ; 1H-NMR (500 MHz, DMSO-d6) 298 K) 5 7.30 (d, J =
8.2 Hz, 1 H, -NHSes), 7.04 (d, J=  8.9 Hz, 1 H, -NHC02Me), 5.88 (br s, 1 H, H2), 5.76 (d, J=  5.3 
Hz, 1 H, H1), 4.84 (d, J=  5.5 Hz, 1 H, -OH), 4.34 (brs, 1 H, H3), 4.26 (br s, 1 H, H5), 3.76 (ddd, 
J = 8.2, 6.7, 6.5 Hz, 1 H, H4), 3.53 (s, 3 H, -COgChb), 2.91 (m, 2 H, Ses), 0.86 (m, 2 H, Ses), 
0.01 (s, 9 H, -TMS); 13C-NMR (125 MHz, DMSO-d6) 298 K) 8  156.7 (C=0), 136.2 (C1), 133.9 
(C2), 70.9 (C3), 60.9 (C5), 59.39 (C4), 51.3 (-CO2CH3), 48.5 (Ses), 10.1 (Ses), -2.0 (-TMS); 
HRMS Calcd for C12H25N20 5SSi (M+H)+: m/z 337.12534. Found: m/z 337.12494.
T E S O ..,/^ s  K2Cq 3 (yteQH
O )— \  reflux, 3 h
M ed '™  NHSES <Ca79%)
303 151
O -f
Q T
5  NHSES
To a solution of the slightly impure cyclopentene 303 (3.15 g) in MeOH (140 mL) was 
added K2C 0 3 (4.83 g, ca. 34.9 mmol) and the mixture heated at reflux for 2  h before being 
allowed to stand overnight for 11 h. The solvent was removed in vacuo, and the residue was 
taken up in EtOAc (150 mL) and H20  (100 mL). The organic layers were separated and the 
aqueous fraction extracted with EtOAc ( 2  x 50 mL). The combined organic layers were washed 
with H20  (50 mL), brine (50 mL), and dried (MgS04). Filtration and concentration in vacuo gave 
a residue that was purified by Si02 flash chromatography with 3:2 EtOAc:Petrol to give pure 151 
as a foam (1.9 g, 41% over 4 steps from 260). [a]D -6 5 .7 0 (c 0.38, CH2CI2); IR (Neat) 3350 (s),
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3286 (s), 2959 (m), 2897 (w), 1765 (s), 1716 (s), 1538 (w), 1454 (s), 1420 (s), 1321 (s), 1253 
(s), 1212 (w), 1137 (s), 1043 (s), 947 (s), 836 (s), 775 (s); 1H-NMR (500 MHz, DMSO-d6( 298 K) 
5 8.11 (s, 1 H, -NHCO-), 7.36 (s, 1 H, -NHSes), 6.02 (m, with appearance of a large s, 2 H, H5 + 
H6), 5.53 (m, 1 H, H6a), 4.17 (s, 1 H, H4), 4.01 (d, 7.1 Hz, 1 H, H3a), 2.96 (m, 2 H, Ses),
0.87 (m, 2 H, Ses), 0.04 (s, 9 H, -TMS); 13C-NMR (125 MHz, DMSO-d6) 298 K) 5 157.1 (0=0),
135.4 (alkene), 132.0 (alkene), 83.5 (C6a), 64.5 (C4), 60.6 (C3a), 48.2 (Ses), 10.0 (Ses), -1.9 (- 
TMS). HRMS Calcd for C11H21N20 4SSiNa (M+H)+: m/z 305.09912. Found: m/z 305.09997.
BOC-Cyclopentene oxazolidinone 150
/? 1 /? 0—\  Boc20, DMAP, (p ~ \
TEA, CH2 Cl2  ^ C jN B o c
' M  (63%) £— (
NHSES NHSES
151 (-)-ISO
To a stirred solution of oxazolidinone 151 (1.22 g, 4.01 mmol), 4-dimethylaminopyridine 
(123 mg, 1 mmol), and Et3N (0.62 ml, 4.4 mmol) in dry CH2CI2 (80 mL) was added a solution of 
Boc20  (963 mg, 4.41 mmol) in CH2CI2 (1.1 mL) dropwise at RT over 10 min. The reactants were 
stirred at RT for 12 h, whereupon more Boc20  (88 mg, 0.4 mmol) was added, and the stirring 
continued for a further 2 h. H20  (40 mL) was added to the reaction mixture, and the organic 
layer separated. The aqueous layer was extracted with CH2CI2 ( 2 x 1 5  mL), and the combined 
organic layers washed with 1M aq. HCI (10 mL), sat. aq. NaHC03 (10 mL), dried (MgS04), and 
filtered. The solvent was removed in vacuo and the crude residue recrystallised from 
EtOAc/petrol to provide 17 (807 mg, 50%) as a white crystalline solid. The mother liquors were 
concentrated in vacuo, and the residue purified by Si02 flash chromatography with 3:2 
PetroLEtOAc to provide a further quantity of 150 (210 mg, 62% overall). M.p. 162(C; [a]D -88.0  
0 (c 0.22, CH2CI2); IR (KBr) 3283 (s), 2979 (w), 1792 (s), 1724 (s), 1455 (m), 1366 (s), 1338 (s), 
1251 (s), 1168 (s), 1138 (s), 1073 (s), 901 (m), 856 (s); 1H-NMR (500 MHz, CDCI3, 298 K) 5 
6.14 (dd, J =  5.5, 2.1 Hz, 1 H, H5), 6.05 (ddd, J =  5.7, 1.7,1.5 Hz, 1 H, H6), 5.50 (br d, J =  7.4 
Hz, 1 H, H6a), 4.60 (d, J =  7.9 Hz, 1 H, -NHSes), 4.53 (m, 2 H, H3 and H4), 3.10 (m, 2 H, Ses),
1.54 (s, 9H, Boc), 1.03 (m, 2 H, Ses), 0.05 (s, 9 H, TMS); 13C-NMR (125 MHz, CDCI3, 298 K) 8
150.4 (C=0), 150.2 (C=0), 136.5 (C5), 131.8 (C6), 85.0 (Boc), 80.1 (C6a), 65.1 (C3a), 63.6 
(C4), 50.3 (Ses), 27.9 (Boc), 10.5 (Ses), -2.0 (TMS). HRMS Calcd for C16H28N20 6SSiNa 
(M+Na)+: m/z 427.13349. Found: m/z 427.13286.
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5-TMS-Pyrrole-2-carboxamido-/V-SES-Cyclopentene-Boc-Oxazolidinone 171
,NBoc
™S N C0CI 
H 170
e^ N B o c
NHSES
DMAP, Et3 N, 
CH2 CI2, THF 
RT, 14 h (80%)
TM!
O
(-)-150
To a suspension of lithio 2-TMS-pyrrole-5-carboxylate (3.3 g, 20.2 mmol) in freshly 
distilled CH2CI2 (30 mL) at 0 °C was added oxalyl chloride (1.8 mL, 20.4 mmol) followed by 4 
drops of dry DMF. After 10 min, the ice-bath was removed, and the reactants were stirred at RT 
for 2 h. The resulting suspension of 170 and LiCI was taken up via a glass syringe (slightly 
greased) and added dropwise over 1.5 h via syringe pump (flow rate 20 mL/h) to a solution of 
the amide 150 (3.3 g, 8.16 mmol) and DMAP (100 mg, 0. 816 mmol) in dry THF (44 mL) and 
Et3N (5.7 mL, 40.8 mol) at RT. After the addition was complete, TLC (7:3 petrol:EtOAc) analysis 
indicated that none of the starting amide 150 remained. Sat. aq. NaHC03 (23 mL) was added in 
one portion, and the mixture was partitioned between brine (75 mL) and CH2CI2 (150 mL). The 
organic layer was separated, dried over MgS04, and filtered. The solvent was removed in vacuo 
and the residue was purified by Si02 flash chromatography with 4:1 petrol:EtOAc to give 171 
(3.7 g, 80%) as a white foam. [a]D -127 0 (c 0.5, CH2CI2); IR (KBr) 3417 (m), 2959 (m), 2902 
(w), 1817 (s), 1723 (s), 1629 (s), 1528 (w), 1440 (s), 1350 (s), 1277 (s), 1253 (s), 1188 (s), 1140 
(s), 1054 (s), 843 (s), 751 (s), 699 (m); 1H-NMR (500 MHz, CDCI3, 298 K) 5 9.36 (br s, 1 H, NH), 
6.81 (dd, J =  3.8, 2.3 Hz, 1 H, arom), 6.42 (dd, J =  3.8, 2.7 Hz, 1 H, arom.), 6.17 (dd, J = 5.9,
2.1 Hz, 1 H, H5), 6.13 (m, 1 H, H6), 5.62 (m, 2 H, H4 and H6a), 4.98 (dd, 7.4, 1.4 Hz, 1 H, 
H3a), 3.59 (ddd, J=  14.1, 13.8, 4.5 Hz, 1 H, Ses), 3.46 (ddd, 14.1, 13.8, 4.3 Hz, 1 H, Ses), 
1.38 (s, 9 H, Boc), 1.08 (ddd, J =  13.7, 9.6 Hz, 1 H, Ses) superimposed upon 1.01 (ddd, J =
13.7 Hz, 4.7 Hz, 1 H, Ses), 0.26 (s, 9 H, TMS), 0.03 (s, 9 H, Ses); 13C-NMR (125 MHz, CDCI3, 
298 K) 5 162.6 (C=0), 150.9 (C=0), 149.6 (C=0), 140.3 (arom.), 134.5 (alkene), 133.1 (alkene),
126.9 (arom.), 119.2 (arom.), 117.3 (arom.), 84.7 (Boc), 81.4 (C6a), 71.3 (C4), 61.5 (C3a), 52.9 
(Ses), 27.7 (Boc), 9.9 (Ses), -1.4 (TMS), -2.0 (Ses). HRMS Calcd for C24H39N30 7SSi2 (M)+: m/z 
569.20471. Found: m/z 569.20520.
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5-TMS-Pyrrole-2-carboxamido- Cyclopentene-Boc-Oxazolidinone 172
f  CsF, DMF,
•nboc RT5ol«sh5r jNBoc
TMS
(46%)
NH NSES
Protocol A. To a solution of the sulfonamide 171 (348 mg, 0.675 mmol) in dry DMF 
(3.5 mL) was added CsF (103 mg, 0.675 mmol) at RT and the mixture stirred at RT for 19 h 
before being heated at 50 °C for 1 h. After cooling to RT, H20  (50 mL) was added and the 
aqueous solution was extracted with EtOAc ( 6 x 1 5  mL). The combined organic layers were 
washed with H20  (10 mL) and brine (10 mL), dried (MgS04), and filtered. The solvent was then 
removed in vacuo and the residue was purified by S i02 flash chromatography with 3:2 
Petrol/EtOAc to give 172 (169 mg, 68%) as a yellow oil; 171 (58 mg) was also recovered. Data 
for 172: [<x]D -166 0 (c 0.274, CH2CI2); IR (Neat) 3293 (w), 2957 (w), 1807 (s), 1725 (w), 1636 
(m), 1550 (s), 1524 (m), 1365 (s), 1336 (s), 1252 (s), 1200 (s), 1155 (s), 1075 (s), 1041 (m), 842 
(s), 756 (s) cm'1; 1H-NMR (500 MHz, CDCI3, 298 K) 8 9.17 (br s, 1 H, NH), 6.57 (dd, J =  3.6,
2.3 Hz, 1 H, arom.), 6.35 (dd, J = 3.6, 2.7 Hz, 1 H, arom.), 6.31 (d, J=  7.9 Hz, 1 H, NH), 6.05 (s, 
2 H, alkene), 5.61 (ddd, J =  7.7, 1.8, 1.0 Hz, 1 H, H6a), 4.92 (m, 1 H, H3a), 4.68 (dd, 7.6,
1.4 Hz, 1 H, H4), 1.50 (s, 9 H, Boc), 0.23 (s, 9 H, TMS); 13C-NMR (125 MHz, CDCI3, 298 K) 
5 160.7 (C=0), 151.4 (C=0), 149.4 (C=0), 136.7 (alkene), 136.5 (arom), 130.8 (alkene), 128.5 
(arom), 118.3 (arom.), 110.0 (arom.), 84.5 (Boc), 81.2 (C6a), 62.8 (C4), 62.7 (C3a), 27.9 (Boc), 
-1.2 (TMS). HRMS Calcd for Ci9H27N30 5Si (M+H)+: m/z 406.17981. Found: m/z 406.17997.
Larger Scale Protocol B. To a stirred solution of the sulfonamide (3.56 g, 6.25 mmol) 
in dry DMF (30 mL) was added CsF (950 mg, 6.25 mmol) at RT and the mixture stirred at RT for
17.5 h before being heated at 50 °C for 5 h. After cooling to RT, H20  (500 mL) was added and 
the aqueous solution extracted with EtOAc (3 x 200 mL). The combined organic layers were 
washed with H20  (10 mL) and brine (10 mL), dried (MgS04), and filtered. The solvent was then 
removed in vacuo and the residue was purified by Si02 flash chromatography with 3:2 
Petrol/EtOAc to give 172 (1.17 g, 46%) as a yellow oil.
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5-TMS-Pyrrole-2-carboxamido-Cyclopentene-Boc-Oxazolidinone 176
,NBoc
TM!
(-)-172
RT, 2h
NHBoc
TM!
(-)-174
p - f
.NH
NH nh
(-)-173
crude ration: 7:3
N NH
NHBoc
TMS + TMS
(-)-176 
(18% over 3 steps)
305
(7% over 3 steps)
NHBoc
+ (-)-l 73
CsoCOg, MeOH, 
2.5 h, RT
NH NH
NHBoc
+ (-)-173
(-)*175
cat. TPAP, NMO 
MeCN, RT, 2 h
To a solution of the protected oxazolidinone 172 (1.12 g, 2.77 mmol) in THF/H20  (9:1, 
70 mL) was added LiOH.H20  (0.93 g, 22.2 mmol) in one portion. The solution was vigorously 
stirred at RT for 2 h. Excess silica gel was added, and the solvents removed in vacuo. 
Application of the silicated sample to the top of a column containing Si02 followed by elution 
with EtOAc afforded 173 and 174 (1.06 g) as an essentially inseparable mixture. 500 MHz 1H 
NMR analysis of the entire mixed sample of 173 and 174 indicated it was a 7:3 mixture enriched 
in 174.
To a solution of the aforementioned mixture of 173 and 174 (ca. 2.64 mmol) in freshly 
distilled MeCN (53 mL) was added successively NMO (619 mg, 5.28 mmol), 4A MS (ca. 4 g), 
and TPAP (93 mg, 0.264 mmol), and the solution vigorously stirred at RT for 2 h. The solvent 
was then removed in vacuo, the crude residue taken up in EtOAc (50 mL) and the solution 
filtered through a pad of Celite®, and the pad thoroughly washed with more EtOAc. The filtrate 
was concentrated in vacuo, and the residue partially purified by gradient elution S i02 flash 
chromatography (with 7:3 PetroLEtOAc progressing to EtOAc) to give a mixture of 175 and 173 
(530 mg, in ca. 3:1 ratio according to 1H NMR analysis).
The aforementioned mixture of ketone 175 and oxazolidinone 173 (ca. 1.41 mmol) was 
dissolved in MeOH (140 mL) and Cs2C 0 3 (460 mg, 1.41 mmol) was added. The reactants were 
stirred vigorously at RT for 1 h whereafter a further quantity of Cs2C 03 (1.84 g, 4 equiv) was 
added. Stirring was continued for a further 1 h, whereupon TLC analysis indicated that two 
faster-moving products had formed and that the starting oxazolidinone 173 remained. The 
mixture was partitioned between EtOAc (560 mL) and brine (140 mL). The layers were 
separated and the organic layer dried (MgS04), filtered, and concentrated in vacuo. The crude 
residue was purified by Si02 flash chromatography with 7:3 Petrol:EtOAc to give 305 (72 mg,
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7% from 172) initially as a white solid, followed by 176 (189 mg, 18% from 139) as a colourless 
oil, and finally, recovered oxazolidinone 173 (130 mg) as a white solid.
The respective spectral data for 176 and 305 are presented below.
Enaminone/pyrrole 305: IR (KBr) 3226 (s), 2957 (w), 1693 (s), 1662 (s), 1631 (s), 1545 (s), 
1501 (s), 1426 (m), 1372 (s), 1308 (s), 1273 (s), 1248 (s), 1161 (s), 1057 (w), 964 (s), 843 (s), 
736 (w); 1H-NMR (500 MHz, CDCI3, 298 K) S 11.90 (s, 1 H, NH), 9.37 (s, 1 H, NH), 6.97 (dd, J = 
4.5, 2.2 Hz, 1 H, arom.), 6.78 (br s, 1 H, NH), 6.45 (dd, J = 3.4, 2.8 Hz, 1 H, arom.), 3.33 (m, 2 
H, CH2), 2.47 (m, 2 H, Chh), 1.50 (s, 9 H, Boc), 0.26 (s, 9 H, TMS); 13C-NMR (125 MHz, CDCI3, 
298 K) 6 198.6 (C=0), 158.4 (C=0), 154.5 (C=0), 149.5 (alkene), 138.2 (alkene), 129.4 (arom.),
118.9 (arom.), 117.3 (arom.), 112.4 (arom.), 82.2 (Boc), 31.7 (CH2), 28.1 (Boc), 25.4 (CH2), -1.2 
(TMS). HRMS Calcd for C i8H27N30 4Si (M+H)+: m/z 378.18489. Found: m/z 378.18492.
Desired Tricycle 176: [a]D -134° (c0.5 CHCI3); IR (Neat) 3347 (br w), 2977 (w), 1765 (m), 1712 
(m), 1665 (s), 1543 (m), 1366 (m), 1336 (m), 1251 (s), 1164 (s), 842 (s), 754 (s); 1H-NMR (500 
MHz, MeOD, 298 K) 5 6.92 (d, J = 3.8 Hz, 1 H, arom.), 6.43 (d, J = 3.8 Hz, 1 H, arom.), 5.13 
(ddd, J = 9.0, 4.5 Hz, 1 H, H4), 4.79 (br d, J = 4.0 Hz, 1 H, H2), 4.59 (apparent t, J = 4.4 Hz, 1 
H, H3), 2.96 (dd, J=  19.1, 10.2 Hz, 1 H, H5), 2.17 (dd, J=  19.1, 9.1 Hz, 1 H, H5), 1.48 (s, 9 H, 
Boc), 0.36 (s, 9 H, TMS); 13C-NMR (125 MHz, MeOD, 298 K) 5 208.6 (C=0), 162.2 (C=0),
157.9 (C=0), 139.7 (arom.), 126.8 (arom.), 121.1 (arom.), 116.0 (arom.), 81.4 (Boc), 63.7 (C2),
56.2 (C3), 51.4 (C4), 41.6 (C5), 28.6 (Boc), -0.5 (TMS). HRMS Calcd for C18H27N30 4Si (M+H)+: 
m/z 378.18489. Found: m/z 387.18418.
Pyrrole Bromide 177
NHBoc■NHBoc
NBS, THF, 
0°C to RT, 1 hTMS
NHNH (74%)
(-)-177
To a stirred solution of the A/-Boc-a-amino-ketone (-)-176 (110 mg, 0.292 mmol) in 
freshly distilled THF (21 mL) at 0 °C was added A/-bromosuccinimide (62 mg, 351 mmol) in one 
portion. The reactants were stirred at 0 °C for 1 h and then at RT for a further 5 h. Sat. aq. 
NaHC03 (20 mL) and sat. aq. Na2S2Q3 (5 ml) were added to the mixture, and the product 177
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extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (100 
mL), dried (MgS04), and filtered. The solvent was then removed in vacuo, and the crude 
residue purified by Si02 flash chromatography with 3:2 Petrol/EtOAc to give (-)-177 (83 mg, 
74%) as a colourless oil. [a]D -112° in (c 0.66, MeOH); IR (Neat) 3334 (br w), 2979 (w), 1764 
(s), 1711 (s), 1665 (s), 1554 (m), 1423 (s), 1378 (m), 1338 (s), 1251 (m), 1165 (s), 1062 (w), 
751 (s); 1H-NMR (500 MHz, MeOD, 298 K) 5 6.93 (d, 4.1 Hz, 1 H, arom.), 6.35 (d, J =  4.1
Hz, 1 H, arom.), 5.22 (ddd, J=  9.1, 4.8, 4.7 Hz, 1 H, H4), 4.74 ( br d, 1 H, H2), 4.62 (apparent t, 
J = 4.6 Hz, 1 H, H3), 3.02 (dd, J =  19.1, 9.0 Hz, 1 H, H5), 2.13 (dd, 19.1, 9.2 Hz, 1 H, H5),
1.48 (s, 9 H, Boc); 13C-NMR (125 MHz, MeOD, 298 K) 5 208.3 (C=0), 161.5 (C=0), 157.8 
(C=0), 123.9 (arom.), 116.4 (arom.), 114.2 (arom.), 107.5 (arom.), 81.4 (Boc), 63.4 (C2), 55.5 
(C3), 49.8 (C4), 39.8 (C5), 28.6 (Boc). HRMS Calcd for C15H18N30 4 79Br (M+H)+: m/z 384.05588. 
Found: m/z 384.05552.
Preparation of M-Benzyl-Af-methylcarbamoyl chloride (309)81
O T a
KAo COCI2 , DIEA,
6  EtgO. PhMe, 0 °C, 3 h r j ^ V ^ N
(76%) 0^ C|
309
/V-Benzylmethylamine (21.3 mL, 0.165 mL) was dissolved in freshly distilled diethyl 
ether under nitrogen, and the solution was cooled to 0 °C. Redistilled A/,/V-diisopropylethylamine 
(Hunig’s base) (37.5 mL, 0.215 mol) was added, followed by a dropwise addition of a phosgene 
solution in toluene (1.93 M, 120 mL, 0.231 mol). After 3 hours at 0°C, the solution was 
concentrated under vacuum to afford a thick yellow oil, which was triturated with diethyl ether 
(600 mL) for 10 minutes. The suspension was filtered, and the clear yellow filtrate was 
concentrated in vacuo. The residue was purified by Si02 flash chromatography (eluent: 5:95 to 
1:9 AcOEt:Petrol) to give 23.1 g (76 %) of a colourless oil, which crystallised upon storage at 
0°C. IR (neat) 1736 (s), 1495 (w), 1453 (m), 1419 (w), 1382 (m), 1245 (w), 1184 (w), 1076 (m), 
1029 (w), 966 (w), 917 (w), 8 8 8  (w), 737 (w), 702 (m), 6 6 6  (w), 597 (w); 1H-NMR (500 MHz, 
CDCI3 , 298 K) 5 7.36-7.29 (m, 3 H, arom.), 7.25-7.23 (m, 2 H, arom.), 4.69 and 4.55 (s, 2 H, 
CFh), 3.04 and 2.97 (s, 3 H, CH3); 13C-NMR (125 MHz, CDCI3, 298 K) 6  150.4 and 149.5 
(C=0), 135.3 and 135.1 (arom.), 128.9 and 128.9 (arom.), 128.1 and 128.1 (arom.), 127.1 
(arom.), 56.3 and 54.4 (CH2), 37.8 and 36.4 (CH3); HRMS Calcd for CgHnNOCI (M+H)+: m/z 
184.0529126. Found: m/z 184.0525095.
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Preparation of lithium 5-trimethylsilylpyrrole-2-carboxylate (169)68
O Boc20 , DMAP .— . NBS, THF —  1) n-BuLi, Et20 , -78°C —CH3CN II \ \  -78°C to 0 °C / /  \ \  2 ) TMSCI, -78°C to 30°C / /  \\
----------------- ► m'   B r ^ / ' - B r - Jc77T\-----------T M S ^ N^ B r
H (100%) Boc (8 ° %) Boc ( 6 1  %) Boc
165 166 .167
1) o-BuLi, Et2 0 , -78 ■'C
2) C 0 2 (s), -78°C to rt (91%)
j ~ \  i5°°c
T M S ^ ^ C ° 2 Li (100% ) ™ S N ^ C 0 2Li
169 168
N-ferf-Butoxycarbonylpyrrole (165).71 Di-te/t-butyl dicarbonate (66.4 g, 0.304 mol) 
was added to a solution of pyrrole (17.0 g, 0.253 mol) and DMAP (3.1 g, 0.0253 mol) in 
acetonitrile. The mixture was stirred at room temperature for 14 hours (open to the air). The 
solvent was then removed under vacuum, and the resulting dark oil was purified by fractional 
distillation through a Vigreux apparatus under high vacuum (b.p. 115°C / 28 mmHg) to afford
42.1 g (100 %) of a colourless oil. 1H-NMR (500 MHz, CDCI3) 298 K) 5 7.22 (dd, J=  2.4, 2.2 Hz, 
2 H), 6.20 (dd, J =  2.5, 2.2 Hz, 2 H), 1.58 (s, 9 H); 13C-NMR (125 MHz, CDCI3, 298 K) 5 149.9,
119.9, 111.8, 83.5, 27.9.
A/-ferf-Butoxycarbonyl-2,5-dibromopyrrole (166).72 To a stirred solution of N-tert- 
butoxycarbonylpyrrole (30.0 g, 0.180 mol) in freshly distilled THF (360 mL) at -7 8 °C under 
argon was added NBS (63.9 g, 0.359 mol). After the end of the addition, the cold bath was 
removed, and the reaction mixture was allowed to warm to 0°C, at which temperature the 
mixture was kept overnight (12 hours). Solid Na2S 0 3 was added, and the mixture was filtered. 
After concentration of the filtrate under vacuum, the residue was filtrerd on a silica pad, eluting 
with AcOEt:Petrol 1:4, to afford 46.6 g (80 %) of a pale yellow oil which was used immediately 
for the next step. 1H-NMR (500 MHz, CDCI3, 298 K) 5 6.22 (s, 2 H), 1.62 (s, 9 H); 13C-NMR 
(125 MHz, CDCI3, 298 K) 8 147.2, 116.2, 100.3, 86.4, 27.9.
N-ferf-Butoxycarbonyl-2-bromo-5-trimethylsilylpyrrole (167).68 n- BuLi (2.5 M 
solution in hexanes, 57.3 mL,0.143 mol) was added dropwise over 15 minutes under nitrogen to 
a stirred solution of the above dibromopyrrole (46.6 g, 0.143 mol) in freshly distilled diethyl ether 
(286 mL) at -7 8 °C. After the end of the addition, the stirring was continued for 30 minutes at -  
78°C. Freshly distilled TMSCI (23.6 mL, 0.186 mol) was then added dropwise, and the cold bath 
was removed. The mixture was allowed to warm to -3 0 °C, at which temperature was kept for 12
101
Chapter 8: Experimental
hours. The solvent was then removed under vacuum at room temperature. The residue was 
taken up in petroleum spirit (500 mL), and filtered. The filtrate was concentrated under vacuum 
to afford a dark brown oil, which was purified by flash chromatography (eluent: Petrol) to give
27.9 g (61 %) of a colourless oil. This unstable product was used immediately for the next step. 
1H-NMR (500 MHz, CDCI3, 298 K) 8 6.37 (d, J =  3.4 Hz, 1 H), 6.28 (d, J=  3.4 Hz, 1 H), 1.62 (s, 
9 H), 0.23 (s, 9 H); 13C-NMR (125 MHz, CDCI3, 298 K) 5 149.5, 138.8, 122.7, 117.4, 103.3,
85.1,28.0, -0.3.
Lithium A/-ferf-Butoxycarbonyl-5-trimethylsilylpyrrole-2-carboxylate (168).68 n-BuLi 
(2.5 M solution in hexanes, 33.7 mL, 0.0842 mol) was added dropwise over 15 minutes under 
nitrogen to a stirred solution of the above bromopyrrole (26.8 g, 0.0842 mol) in freshly distilled 
diethyl ether (280 mL) at -7 8 °C. After the end of the addition, the stirring was continued for 30 
minutes at -7 8 °C. Solid C 02 chunks were added while the mixture was allowed to rise to room 
temperature. The product was then extracted with water (3 x 150 mL). The combined aqueous 
layer was washed with light petroleum spirit (100 mL), and concentrated in vacuo to afford 22.1 
g (91 %) of a white solid. 1H-NMR (500 MHz, MeOD, 298 K) 5 6.36 (d, J=  3.2 Hz, 1 H), 6.27 (d, 
J = 3.2 Hz, 1 H), 1.57 (s, 9 H), 0.23 (s, 9 H); 13C-NMR (125 MHz, MeOD, 298 K) 5 170.9, 152.5, 
139.6, 136.8, 122.0,114.3, 84.8, 27.9, -0.3.
Lithium 5-trimethylsilylpyrrole-2-carboxylate (169).68 The above solid A/-Boc pyrrole 
(22.1 g, 0.0763 mol) derivative was heated neat at 150°C for a total of 20 minutes by 
successively placing under high vacuum and then a stream of nitrogen (repeated several times) 
giving the deprotected title product (14.4 g, 100 %) as a white solid. IR (KBr) 2272 (br s), 1543 
(s), 1459 (s), 1250 (s), 1219 (s), 1139 (m), 1043 (m), 987 (w), 950 (m), 841 (s), 781 (m), 508 
(w); 1H-NMR (500 MHz, MeOD, 298 K) 8 6.68 (d, J = 3.5 Hz, 1 H), 6.26 (d, J = 3.5 Hz, 1 H), 
0.24 (s, 9 H); 13C-NMR (125 MHz, MeOD, 298 K) 8 169.8, 134.3, 134.1, 118.4, 113.9, -0.9; 
HRMS Calcd for C8H12LiN02SiNa (M+Na)+: m/z 212.06950. Found: m/z 212.069347.
M-Acyl Oxazolidinone 310
To a stirred solution of (-)-150 (3.0 g, 9.86 mmol) in dry THF (95 mL) at -78  °C under N2 
was added a solution of n-BuLi (6.2 mL, 1.6 M in hexanes, 9.92 mmol) dropwise over 5 min,
N -Bn
N-Bnn-BuLi, DABCO, THF, 
-78°C to reflux, 2 1  h 5 4'„ Me NHSESNHSES
O
Cl—^
(88 %)
(-)-150 310
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and 15 min later, carbamoyl chloride 309 (3.6 g, 19.7 mmol) in dry THF (5 mL) was added 
dropwise over 5 min. The cooling bath was removed, the reaction mixture was allowed to warm 
to RT over 15 min, and the reaction vessel was then transferred to an oil bath, where it was 
heated at reflux for 4 h. DABCO (6.6 g, 112.2. mmol) was then added in one portion and the 
heating at reflux was continued for 18 h. The reactants were then cooled to RT, and sat. aq. 
NH4CI (20 mL) and brine (30 mL) were added, and the organic layer was separated. The 
aqueous layer was then extracted with EtOAc (2 x 50 mL), and the combined organic layers 
were dried over MgS04, filtered, and concentrated in vacuo. The residue was dissolved in the 
minimum amount of CH2CI2 needed to fully solubilise it, and applied to a Si02 flash column 
packed with petrol. The product was then gradient eluted with 7:3 PetrokEtOAc through to 1:1 
PetroLEtOAc to give 310 (4.2 g, 94%) as a white solid. M.p. 143*0; [a]D -8 0 .7 0 (c 0.5, MeOH); 
IR (KBr) 2954 (w), 1769 (s), 1685 (s), 1482 (w), 1453 (m), 1420 (w), 1403 (w), 1370 (s), 1324 
(s), 1284 (m), 1254 (m), 1203 (s), 1167 (w), 1135 (s), 1111 (m), 1079 (s), 1042 (s), 1003 (w), 
987 (w), 945 (w), 892 (m), 856 (s), 840 (s), 809 (m), 795 (m), 752 (m), 733 (s), 718 (w), 697 (s); 
1H-NMR (400 MHz, Tol-cfe, 323K) 6 7.12-6.90 (m, 5 H, Ph), 5.54 (dd, J =  5.7, 2.4 Hz, 1 H, H5), 
5.40 (ddd, J = 5.7, 1.6, 1.6 Hz, 1 H, H6), 4.87 (br ddd, J = 7.3, 0.9 Hz, 1 H, H6a), 4.36 (d, J =
7.3 Hz, 1 H, H3a), 4.34 (d, J =  15.4 Hz, 1H, PhCHA 4.28 (d, J=  15.4 Hz, 1 H, PhCH,L 4.26 (s, 
1 H, H4), 3.98 (br s, 1 H, NH), 3.02 (m, 2 H, SES), 2.63 (s, 3 H, NMe), 1.01 (m, 2 H, SES), -0.06 
(TMS); 13C-NMR (125 MHz, Tol-c/g, 363 K, some resonances overlap and are hidden by the 
NMR solvent peaks) 6 154.2 (0=0), 152.3 (C=0), 137.2 (arom.), 136.7 (C5), 131.8 (C6), 128.1 
(arom), 128.0 (arom.), 81.9 (C6a), 64.9 (C4), 64.4 (C3a), 54.0 (CH2), 50.8 (SES), 36.0 (NMe),
11.3 (SES), -1.8 (TMS). HRMS Calcd. for C20H3oN30 5SSi (M+Hf: m/z 452.1677. Found: m/z 
452.16673.
Pyrrole carboxamide 311
p
o - f  o
( 5 r' N^ - en
Me
NHSES
310
j r \
H 170
Et3 N, DMAP, RT, 4 h 
(89 %)
N-Bn
To a vigorously stirred suspension of the lithium carboxylate salt of 5-trimethylsilyl- 
pyrrole-2-carboxylic acid 169 (7.28 g, 38.5 mmol) in dry CH2CI2 (77 mL) under an N2 
atmosphere was added oxalyl chloride (3.4 mL, 38.5 mL) in one portion followed by 4 drops of 
dry DMF. The reactants were stirred at RT for 2 h, and then taken up in a syringe, and added 
via syringe pump (flow rate 20 ml_/h) to a solution of 310 (8.69 g, 19.2 mmol) in dry THF (116 
mL) containing freshly distilled Et3N (13.5 mL, 96.0 mmol) and 4-dimethylaminopyridine (235 
mg, 1.92 mmol). When the addition of 170 was complete, sat. aq. NaHC03 (50 mL) was added. 
The mixture was then partitioned between brine (150 mL) and CH2CI2 (300 mL). The organic 
layer was separated, dried over MgS04, filtered and concentrated in vacuo. The residue was
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taken up in the minimum amount of CH2CI2 needed to fully dissolve it, and applied to a S i02 
flash column packed with petrol. The product was then eluted with a gradient 85:15 to 7:3 
Petrol:EtOAc to give 311 (10.5 g, 89%) as a colourless oil. [a]D -113 0 (c 0.4, MeOH); IR (NaCI 
neat film) 3335 (w), 2955 (w), 1777 (s), 1680 (s), 1537 (w), 1484 (w), 1452 (w), 1404 (w), 1351 
(S), 1251 (s), 1173 (s), 1149 (s), 1054 (m), 952 (w), 918 (w), 842 (s), 803 (w), 757 (m), 700 (w), 
631 (w); 1H-NMR (400 MHz, C6D6, 343 K) 5 9.51 (br s, 1 H, NH pyrrole), 7.35 (dd, J = 3.8, 2.2 
Hz, 1 H, pyrrole), 7.24-7.18 (m, 4 H, Ph), 7.06 (m, 1 H, Ph), 6.35 (dd, J =  3.8, 2.5 Hz, 1 H, 
pyrrole), 5.54 (ddd, 5.7, 1.8, 1.8 Hz, 1 H, H5), 5.51-5.43 (m, 3 H, H6 + H3a + H6a), 5.28 (m, 
1 H, H4), 4.48 (d, J =  15.0 Hz, 1H, PhChU), and 4.40 (d, J =  15.5 Hz, 1 H, PhCHA 3.79-3.71 
(m, 1 H, SES), 3.59-3.49 (m, 1 H, SES), 2.73 (s, 3 H, NMe), 1.27-1.17 (m, 2 H, SES), 0.05 (s, 9
H, TMS), -0.08 (s, 9 H, TMS); 13C-NMR (100 MHz, C6D6, 343 K, some resonances overlap and 
are hidden by the NMR solvent peaks) 6 162.9 (C=0), 154.4 (C=0), 152.8 (C=0), 141.3 (C6),
137.1 (C5), 134.1 (arom), 133.1 (alkene), 130.6 (pyrrole), 129.0 (arom.), 121.7 (pyrrole), 119.6 
(pyrrole), 83.4 (C6a), 70.9 (C4), 62.2 (C3a), 53.7 (CH2), 52.0 (SES), 35.7 (NMe), 10.6 (SES), -
I.6  (TMS), -2.1 (TMS). HRMS Calcd. for C28H4oN406SSi2Na (M+Na)+: m/z 639.2114. Found: 
m/z 639.21130.
Pyrrole carboxamide 308
p
o—^  o
X . N —{  Bu3 SnH, AIBN
^  I  ^N—Bn PhMe, reflux,
TMSV '— \  Me  8  h
NSES (60 %]
0
311
TMS. Me
308
To a degassed solution of the sulfonamide 311 (5.00 g, 8.11 mmol) in freshly distilled 
toluene (42 mL) under N2 was added Bu3SnH (3.4 mL, 12.6 mmol) and the mixture was brought 
to reflux. AIBN (4.40 g, 26.7 mmol) was then added in 32 equal portions [137 mg, (0.1 equiv)] 
approx. every 15 min over 8 h. The mixture was allowed to cool to RT, and the solvent was 
removed in vacuo. The organotin by-products were removed by gradient elution Si02 flash 
chromatography with 9:1 to 8:2 Petrol/EtOAc. The product 308 (2.20 g, 60%) eluted with 7:3 
Petrol/EtOAc and was obtained as a yellow oil. [a]D -289 0 (c 1, MeOH); IR (KBr) 2956 (m), 
2362 (w), 1779 (s), 1696 (s), 1621 (m), 1577 (m), 1549 (w), 1521 (m), 1481 (w), 1455 (m), 1401 
(w), 1354 (s), 1251 (m), 1194 (s), 1147 (w), 1051 (s), 992 (w), 960 (w), 842 (s), 800 (m), 760 
(m); 1H-NMR (500 MHz, CDCI3, 328 K) S 9.19 (br s, 1 H, NH pyrrole), 7.34-7.24 (m, 5 H, Ph),
6.54 (dd, J =  3.5, 2.4 Hz, 1 H, pyrrole), 6.35 (dd, J=  3.3, 3.0 Hz, 1 H, pyrrole), 6.13 (d, J = 7.3 
Hz, 1 H, NHCO of urea), 6.07 (br s, 2 H, H5 + H6), 5.65 (d, J = 7.5 Hz, 1 H, H6a), 4.89 
(apparent d, J = 7.3 Hz, 1H, H3a), 4.73 (d, J =  15.3 Hz, 1 H, CH,PhL 4.51 (d, J =  15.3 Hz, 1H, 
CHpPh). 2.96 (s, 3 H, NMe), 0.25 (s, 9 H, TMS); 13C-NMR (125 MHz, CDCI3, 328 K) 8 160.8 
(C=0), 153.6 (C=0), 153.0 (C=0), 136.5 (arom.), 136.4 (arom.), 136.1 (alkene), 131.7 (alkene),
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128.8 (arom.), 128.7 (arom.), 127.8 (arom.), 127.6 (arom.), 118.4 (pyrrole), 110.1 (pyrrole), 82.8 
(C6a), 63.8 (C3a), 61.7 (C4), 53.7 (CH2), 36.1 (NMe), -1.2 (TMS). HRMS Calcd. for 
CzaHjsN^Si (M+H)+: m/z 453.19592. Found: m/z 453.19528.
Cyclopentenol 313
To a vigorously stirred solution of oxazolidinone 308 (3.55 g, 7.84 mmol) in THF:H20  
(9:1) (100 mL) at RT was added LiOH.H20  (3.29 g, 78.5 mmol) in one portion, and the solution 
stirred at RT for 128 h. The solvents were then removed in vacuo, and the residue was 
partitioned between EtOAc (100 mL) and H20  (100 mL). The layers were separated, and the 
aqueous layer was further extracted with EtOAc (2 x 100 mL). The combined organic layer was 
washed with H20  (50 mL), sat. aq. NH4CI (50 mL), brine (50 mL), and dried over MgS04; it was 
then filtered and concentrated in vacuo. The residue was then purified by Si02 flash 
chromatography using EtOAc as eluent to give 313 (1.32 g, 40%) as a white foam, as well as 
some recovered 308 (1.72 g, yield of the reaction based upon recovered 308 = 77 %). [a]D -
204.1 0 (c 1, MeOH); IR (neat) 3312 (m), 2956 (w), 1633 (s), 1555 (m), 1527 (s), 1453 (w), 1389 
(w), 1339 (w), 1250 (m), 1203 (m), 1148 (w), 1049 (w), 950 (w), 841 (m), 758 (w), 699 (w); 1H- 
NMR (500 MHz, CDCI3) 298 K) 5 9.51 (br s, 1H, pyrrole NH), 7.50 (d, J = 5.9 Hz, 1 H, pyrrole 
CONH), 7.31-7.20 (m, 5 H, Ph), 6.83 (dd, J =  3.6, 2.3 Hz, 1 H, pyrrole), 6.41 (dd, J = 3.6, 2.6 
Hz, 1 H, pyrrole), 6.18 (dd, 6.1, 1.4 Hz, H3), 6.07 (ddd, J =  5.1, 2.4, 2.4 Hz, 1 H, H2), 5.87 
(d, J = 7 .0 Hz, urea NH), 5.08 (m, 1 H, H4), 4.66 (br s, 1 H, H1), 4.51 (d, J =  15.9 Hz, CH,Ph). 
4.47 (d, J =  15.9 Hz, 1H, CH,Ph). 4.19 (dd, J = 13.2, 7.1 Hz, 1 H, H5), 3.58 (br s, 1 H, OH),
2.84 (s, 3 H, NMe), 0.30 (s, 9 H, TMS); 13C-NMR (125 MHz, CDCI3, 298 K) 5 162.3 (C=0), 
159.0 (C=0), 137.6 (arom.), 137.2 (C3), 135.8 (arom.), 133.1 (C2), 129.2 (arom.), 128.6 
(arom.), 127.4 (arom.) 127.2 (arom.), 118.5 (pyrrole), 111.1 (pyrrole), 96.1 (pyrrole C with 
Me3Si), 73.2 (C1), 60.0 (C4), 59.9 (C5), 52.2 (CH2), 34.0 (NMe), -1.1 (TMS). HRMS Calcd. for 
C22H31N40 3Si: (M+H)+: m/z 427.2167. Found: m/z 427.21697.
Cyclopentenone 307
LiOH, THF/H20  
RT, 95 hN -B n N-Bn
(40%)
(77 % based on recovered 308)
O
308 313
N—Bn
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To a stirred solution of alcohol 313 (1.32 g, 3.10 mmol) in DMF (31 mL) was added 
pyridinium dichromate (5.82 g, 15.5 mmol) and the mixture was stirred at RT for 2 h. The 
mixture was then partitioned between EtOAc (500 mL) and H20  (100 mL), and the organic layer 
was separated and washed successively with H20  (6 x 50 mL) and brine (50 mL). After being 
dried over MgS04, the organic fraction was filtered and the solvent was removed in vacuo. The 
residue was then purified by Si02 flash chromatography using EtOAc to give 307 (0.95 g, 73%) 
as a colorless oil. [a]D -242 0 (c 1, MeOH); IR (NaCI neat film) 2956 (m), 1725 (s), 1835 (s), 
1553 (s), 1535 (s), 1452 (w), 1388 (w), 1335 (m), 1250 (m), 1199 (m), 1148 (w), 1117 (w), 1080 
(w), 1049 (w), 979 (w), 842 (s), 798 (w), 759 (m), 699 (w); 1H-NMR (500 MHz, CDCI3, 298 K) 5 
9.33 (br s, 1 H, NH pyrrole), 7.88 (d, J = 6.0 Hz, 1 H, H3), 7.76 (m, 1 H, pyrrole CONH), 7.31- 
7.18 (m, 5 H, Ph), 6.77 (dd, J=  3.3, 2.4 Hz, 1 H, pyrrole), 6.38 (dd, J=  3.4, 2.7 Hz, 1 H, pyrrole), 
6.29 (d, J =  6.1 Hz, 1 H, H2), 5.32 (d, J =  4.4 Hz, 1 H, urea NH), 4.71 (br s, 1 H, H4), 4.54 (d, J 
= 15.8 Hz, 1H, CH,Ph. 4.41 (d, J =  15.8 Hz, CH?Ph). 4.37 (dd, J=  4.3, 4.3 Hz, 1 H, H5), 2.87 (s, 
3 H, NMe), 0.24 (s, 9 H, TMS); 13C-NMR (125 MHz, CDCI3, 298 K) 5 201.3 (0= 0  ketone), 162.3 
(C=0), 160.7 (C3), 158.9 (0=0), 137.1 (arom.), 136.1 (arom.), 131.4 (C2), 128.9 (arom.), 128.8 
(arom.), 127.5 (arom.), 127.3 (arom.), 118.5 (pyrrole), 111.1 (pyrrole.), 62.7 (C5), 59.2 (C4),
52.3 (CH2), 34.3 (NMe), -1.1 (TMS). HRMS Calcd. for C ^ H ^ N ^ S i (M+H)+: m/z 425.2011. 
Found: m/z 425.20174.
Rearranged Enone 314
To a solution of enone 307 (21.0 mg, 49.6 pmol) in dry THF (5 mL) was added DBU 
(100 pi of a stock solution in THF, 49.6 pmol) under nitrogen, and the mixture was stirred at 
room temperature. After 2.5 h, more DBU (100 pL of the stock solution in THF, 49.6 pmol) was 
added, and the mixture was stirred overnight. After 15.5 h, sat. aq. NH4CI (5 mL) was added, 
and the solution was partitioned between brine (5 mL) and AcOEt (30 mL). The layers were 
separated, and the organic layers was dried (MgS04). After concentration under vacuum, the 
residue was loaded onto a preparative TLC plate (eluent: AcOEt/Petrol 1:1) to give 314 (14 mg, 
70%) as an oil. IR (neat) 3295 (w), 2959 (w), 1670 (m), 1822 (s), 1530 (s), 1501 (s), 1452 (w), 
1392 (w), 1358 (m), 1297 (m), 1250 (w), 1220 (w), 1156 (s), 969 (w), 841 (s), 756 (w), 699 (w) ; 
1H-NMR (500 MHz, CDCI3, 298 K) 6 12.69 (s, 1 H, NHCO pyrrole), 9.20 (s, 1 H, NH pyrrole), 
7.36-7.24 (m, 5 H, arom.), 7.06 (dd, J = 3.7, 2.3 Hz, 1 H, pyrrole), 6.77 (s, 1 H, NHCO urea), 
6.45 (dd, J=  3.6, 2.7 Hz, 1 H, pyrrole.), 4.61 (s, 2 H, CHs benzyl), 3.35 (m, 2 H, CH2), 3.02 (s, 3
N -B n
DBU (2 equiv.). THF. 
overnight (70%) N-Bn
314
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H, NCH3), 2.50 (m, 2 H, CH2), 1.50 (s, 9 H, Boc), 0.26 (s, 9 H, TMS); 13C-NMR (125 MHz, 
CDCI3, 298 K) 6 199.1 (C=0), 158.6 (C=0), 155.7 (C=0), 149.1 (alkene), 137.9 (alkene), 136.8 
(arom.), 129.6 (arom.), 128.9 (arom.), 127.8 (pyrrole), 127.6 (arom.), 118.9 (pyrrole), 118.6 
(pyrrole), 112.9 (pyrrole), 52.7 (CH2 benzyl), 35.0 (NCH3), 31.8 (alkene), 25.4 (alkene), -1.2 
(TMS). HRMS Calcd for C22H28N40 3Si (M)+: m/z 424.19306 Found: m/z 424.19447.
Tricyclic Pyrrolocyclopentanone 212 and diep/'-debromoagelastatin A 318 Wa317
O h O O H (
1) NBS (2 equiv.), THF, J l  M—(
T  N -B n 0°C. 2 h, then RT. 1 h \  /  I*
TMS. M  Me ----------------------------------- ► Br, M  u „ '
V "N H  NH 2 ) /-Pr2NEt (5 equiv.),
i j - i  RT’ 18h
O 
(-)-307
+ Other Mono- and Di- 
fa romopyrr ole derivatives
To a solution of the a,p-unsaturated ketone 307 (680 mg, 1.61 mmol) in dry THF (16 
mL) at 0 °C was added /V-bromosuccinimide (NBS) (572 mg, 3.21 mmol) in one portion. The 
mixture was stirred for 2 h at 0 °C and then at RT for 1 h. To the reaction mixture was then 
added Hunig’s base (1.4 mL, 8.03 mmol) dropwise, and the stirring continued overnight (18 h). 
Sat. aq. NH4CI (20 mL) was then added, and the solution was multiply extracted with EtOAc (3 x 
30 mL). The combined organic layers were washed with brine (10 mL) and dried over MgS04. 
After filtration and removal of the solvents in vacuo a residue was obtained that was used 
directly for the next step; the residue was a mixture of components that contained 317 as the 
major product, along with other di- and mono-bromopyrroles.
N -Bn Hz (1 atm.), Pd/C.MeOH, RT. 3h
Me (13% over 4 steps)NH
317
M e. O 
HO.,
'C U
‘M
NH5
318
+ Other Mono- and Di- 
bromopyrrote derivatives
5b,8a-diep/- 
debromoageiastatin A
To a solution of the above product mixture containing 317 (150 mg, ca. 0.294 mmol) in 
methanol (3 mL) was added Pd/C (10% wet, 62 mg, 0.0294 mmol), and the mixture was 
hydrogenated under a atmosphere of H2 (1 atm.) at RT for 3 h. The mixture was then diluted 
with MeOH (15 mL) and filtered on a Celite pad. After concentration in vacuo, the residue was 
purified by Si02 flash chromatography (AcOEt/ MeOH 9:1 then 8:2) to afford 318 (17 mg, 13% 
combined yield over 4 steps) as a white solid. IR (KBr) 3260 (br s), 1680 (s), 1649 (s), 1555 (m),
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1474 (m), 1404 (w), 1369 (w), 1333 (m), 1210 (m), 752 (m); 1H-NMR (500 MHz, MeOD, 298 K) 
8 7.10 (dd, 2.5, 1.6 Hz, 1 H, H1), 6.84 (dd, J =  3.9, 1.5 Hz, 1 H, H3), 6.22 (dd, J =  3.9, 2.7 
Hz, 1 H, H2), 4.68 (dd, J = 5.3, 4.7 Hz, 1 H, H9a), 4.30 (dd, J=  7.3, 5.6 Hz, 1 H, H5a), 4.09 (d, J 
= 7.3 Hz, 1 H, H5b), 3.00 (dd, 15.2, 1.5 Hz, 1 H, H9), 2.51 (s, 3 H, NChh), 2.39 (dd, J=  15.2,
5.1 Hz, 1 H, H9); 13C-NMR (125 MHz, MeOD, 298 K) 5 163.1 (C=0), 161.3 (C=0), 124.2 (C1),
123.7 (C3), 115.6 (C2), 111.6 (C3a), 100.8 (C8a), 59.0 (C5b), 57.8 (C5a), 56.2 (C9a), 38.5 
(C9), 23.8 (NCH3).
0 w P  
X . N —^
H2  (1 aim.), NaOAc (3 equiv.) G  N—Bn
Pd/C, MeOH, RT. 2 h )&-2J M /
(35% over 3 steps)
O 
W-212
A solution of the above product mixture containing 317 was dissolved in MeOH (16 mL) 
and solid NaOAc (396 mg, 4.83 mmol) was added followed by 10% Pd on C (wet) (339 mg, ca. 
0.161 mmol). The mixture was hydrogenated under an atmosphere of H2 at 1 atm for 2 h. The 
suspension was then filtered through Celite, and the filtrate concentrated in vacuo. The residue 
was taken up in EtOAc (50 mL), washed with H20  (5 mL) and brine (5 mL), dried over MgS04, 
filtered, and concentrated in vacuo. Purification of the residue by Si02 flash chromatography 
using EtOAc:MeOH 95:5 afforded 212 (195 mg, 35% over 3 steps) as a colorless oil. [a]D -79.3  
0 (c 0.3, MeOH); IR (NaCI neat film) 3320 (s), 2922 (m), 1756 (s), 1665 (s), 1533 (s), 1470 (m), 
1420 (m), 1391 (m), 1358 (m), 1317 (m), 1267 (m), 1235 (m), 1199 (m), 1139 (m), 1065 (m), 
910 (s), 731 (s), 648 (m); ’H-NMR (500 MHz, CDCI3, 298 K) 8 7.72 (br s, 1 H, pyrrole CONH), 
7.30-7.15 (m, 5 H, arom.), 6.86 (dd, 3.8, 1.4 Hz, 1 H, pyrrole), 6.78 (66, J = 2.5, 1.6 Hz, 1 H, 
pyrrole), 6.25 (dd, J=  3.8, 2.7 Hz, 1 H, pyrrole), 6.10 (d, J=  5.8 Hz, 1 H, CONH urea), 4.84 (dd, 
,7= 5.7, 5.7 Hz, 1 H, H4), 4.55 (m, 1 H, H3), 4.47 (d, 16.0 Hz, 1 H, -CHzPh), 4.30 (d, J = 16.0
Hz, 1 H, -ChbPh), 3.59 (m, 1 H, H2), 3.16 (dd, 18.8, 6.1 Hz, 1 H, H5), 3.01 (d, J =  18.8, 1 H, 
H5), 2.77 (s, 3 H, N-CHh); 13C-NMR (125 MHz, CDCI3 298 K) 8 207.5 (C=0 ketone), 159.9 
(C=0), 157.7 (C=0), 137.0 (arom.), 128.7 (arom.), 127.4 and 127.1 (arom.), 123.4 (pyrrole),
122.8 (pyrrole), 115.2 (pyrrole), 111.2 (pyrrole), 62.3 (C2), 55.8 (C3), 52.1 (CH2), 50.6 (C4),
42.3 (C5), 34.2 (N-CH3); HRMS Calcd. for C19H21N40 3 (M+H)+: m/z 353.16136. Found: m/z 
353.16339.
N -B n
Me
NH
317
♦ Other Mono- and Di- 
bromopyrrole derivatives
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TLC picture at the end of each step in this one-pot reaction sequence (anisaldehyde stain): 
NBS Step Hunig’s Cyclisation Hydrogenation
(-)-8a-0-Methyldebromoagelastatin A
MeO., /o v 
Pd(OH)2, MeOH.
Ho (1 atm.). 24 h \  7s»b
Me O
\  j  /N~Bn Hz (1 atm.), 24 h ^ f
O r "  (36%l jcu?
O 3 0
(-J-212 319
To a solution of (-)-212 (12 mg, 34.1 pmol) in MeOH (2 mL) was added 20% Pd(OH)2 
on carbon (7 mg). The mixture was hydrogenated under a atmosphere of H2 (1 atm) for 15 h at 
RT, then loaded onto a thin-layer chromatography plate (1 mm thick). The product was eluted 
twice with a 82:18 mixture of AcOEt/MeOH to give 319 (3.2 mg, 36%) as a white solid. 1H-NMR 
(500 MHz, CD30D, 298 K) 5 7.03 (dd, J=  2.5, 1.6 Hz, 1 H, H1), 6.88 (dd, J=  3.9, 1.5 Hz, 1 H, 
H3), 6.23 (dd, J=  3.9, 2.5 Hz, 1 H, H2), 4.65 (d(app)t, J = 11.6, 6.0 Hz, 1 H, H9a), 4.00 (dd, J = 
5.4, 2.1 Hz, 1 H, H5a), 3.96 (d, J =  2.1 Hz, 1 H, H5b), 3.09 (s, 3 H, OMe), 2.76 (s, 1 H, NMe), 
2.62 (dd, J =  13.6, 6.3 Hz, 1 H, H9), 2.36 (dd, J =  13.6, 9.4 Hz, 1 H, H9); 13C-NMR (125 MHz, 
CD3OD, 298 K) 5162.9, 161.7, 125.6, 123.0, 115.5, 111.2, 100.2, 68.0, 62.9, 61.8, 55.1, 50.4
40.9, 24.6.
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(-)-Debromoagelastatin A (220)
N -Bn
Pd(OH)2, THF, 
H2 (1 atm.), 24 h
(66%)
(-)-212 (-)-220
To a solution of 212 (165 mg, 0.468 mmol) in freshly distilled THF (4.7 mL) was added 
20% Pd(OH)2 on carbon (65 mg). The mixture was hydrogenated under a atmosphere of H2 (1 
atm) for 23 h at RT, then diluted with methanol (20 mL) and filtered through Celite. The filter pad 
was washed with MeOH to remove all of the products, and the combined filtrate was 
concentrated in vacuo. The residue was purified by Si02 flash chromatography, eluting with an 
85:15 mixture of EtOAc/MeOH to give 220 (81 mg, 66%) as a white solid. [a]D -64.8 0 (c 0.48, 
MeOH); IR (KBr) 3286 (br s), 1652 (br s), 1553 (m), 1474 (m), 1419 (m), 1377 (m), 1302 (m), 
1266 (w), 1210 (w), 1133 (w), 1072 (w), 753 (w); 1H-NMR (500 MHz, CD3OD, 298 K) 5 7.02 
(dd, J=  2.6, 1.6 Hz, 1 H, H1), 6.88 (dd, J = 3.9, 1.6 Hz, 1 H, H3), 6.22 (dd, J=  3.9, 2.6 Hz, 1 H, 
H2), 4.65 (apparent dt, J =  9.7, 6.1 Hz, 1 H, H9a), 4.00 (d, J =  5.4 Hz, 1 H, H5a), 3.80 (s, 1 H, 
H5b), 2.79 (3H, NMe), 2.61 (dd, J =  13.3, 6.4 Hz, 1 H, H9), 2.27 (dd, J =  13.3, 10.3 Hz, 1 H, 
H9); 13C-NMR (125 MHz, CD3OD, 298 K) 8 162.1 (C7), 161.3 (C4), 125.6 (C1), 122.9 (C3a),
115.4 (C3), 111.1 (C2), 95.8 (C8a), 68.0 (C5b), 62.9 (C5a), 55.6 (C9a), 41.6 (C9), 24.2 (N-Me). 
HRMS Calcd. for Ci2H15N40 3 (M+H)+: m/z 263.1145. Found: m/z 263.11333.
(-)-Agelastatin A
To a stirred solution of 220 (69 mg, 0.263 mmol) in MeOH (5 mL) and freshly distilled 
THF (10 mL) at 0°C was added recrystallised A/-bromosuccinimide (NBS) (23.4 mg, 0.132 
mmol). The cold bath was removed immediately after the addition, and the reaction mixture was 
allowed to warm to RT with stirring. After 2 h, a sample of the reaction mixture was concentrated 
and analyzed by 1H NMR; this showed a 56% conversion of (-)-debromoagelastatin A (220) to 
(-)-agelastatin A (1). The mixture was recooled to O'C, and more NBS (18.4 mg, 0.103 mmol) 
was added. The ice bath was removed and the reactants were stirred for a further 2 h at RT.
NBS (0.9 equiv.) 
MeQH/THF (1:2)
(-)-220 (-)-1
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The solution was then concentrated in vacuo, and the residue was purified by Si02 flash 
chromatography, eluting with 8:2 EtOAc/MeOH, to give (-)-agelastatin A (75.4 mg, 84%) as a 
white solid. [a]D -84.2 0 (c 1, MeOH); IR (KBr) 3280 (m), 1652 (s), 1554 (m), 1424 (s), 1377 
(m), 1304 (w), 1269 (w), 1196 (w), 1139 (w), 1091 (w), 935 (w), 749 (w), 663 (w) ; 1H-NMR (500 
MHz, CD3OD, 298 K) 6 6.90 (d, J =  4.1 Hz, 1 H, H3), 6.31 (d, J = 4A Hz, 1 H, H2), 4.58 (m, 1 H, 
H9a), 4.07 (d, 5.5 Hz, 1 H, H5a), 3.88 (s, 1 H, H5b), 2.80 (s, 3 H, N-Me), 2.63 (dd, J=  13.0,
6.5 Hz, 1 H, H9), 2.09 (dd, J = 12.6, 12.6 Hz, 1 H, H9); 13C-NMR (125 MHz, CD3OD, 298 K) 5
161.4 (C7), 161.1 (C4), 124.1 (C3a), 116.0 (C3), 113.8 (C2), 107.2 (C1), 95.6 (C8a), 67.4 
(C5b), 62.2 (C5a), 54.3 (C9a), 40.0 (C9), 24.2 (N-Me). HRMS: Calcd. for C ^ H u N ^ ^ B r  
(M+H)+: m/z 341.0251. Found: m/z 341.0251.
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Appendix 1
X-Ray Diffraction Data for Compounds (-)-150
and (-)-310
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Table 6. Crystal data and structure refinement for (-)-150.
Identification code 
Chemical formula 
Formula weight 
Temperature 
Radiation, wavelength 
Crystal system, space group 
Unit cell parameters
Cell volume 
Z
Calculated density 
Absorption coefficient p. 
F(000)
Crystal colour and size 
Data collection method
0  range for data collection 
Index ranges
Completeness to 0 = 26.00° 
Reflections collected 
Independent reflections 
Reflections with FS-2G 
Absorption correction 
Min. and max. transmission 
Structure solution 
Refinement method 
Weighting parameters a, b 
Data /  restraints / parameters 
Final R indices [F2>2a]
R indices (all data) 
Goodness-of-fit on F2 
Absolute structure parameter 
Largest and mean shift/su 
Largest diff. peak and hole
str0 1 2 1
C 16H 2 8 N 2 0 6SSi 
404.55 
150(2) K
MoKa, 0.71073 A 
orthorhombic,
a = 6.334(2) A a  = 90°
b = 10.812(4) A p = 90°
c = 31.745(12) A y = 90°
2173.9(14) A3 
4
1.236 g/cm3 
0.235 mm- 1  
864
colourless, 0.42 x 0.22 x 0.08 mm3 
Bruker SMART APEX diffractometer 
to rotation with narrow frames 
1.99 to 28.49°
h - 8  to 8 , k -14  to 14,1 -41 to 41 
99.6 %
17159
5096 (Rjnt = 0.0997)
4174
semi-empirical from equivalents 
0.9077 and 0.9814 
direct methods
Full-matrix least-squares on F2  
0.0472, 11.5798 
5 0 9 6 /0 /2 4 4  
R1 =0.1119, wR2 = 0.2249 
R1 =0.1326, wR2 = 0.2344 
1.117 
0.0(2)
0.004 and 0.001 
1.007 and -0.646 e A-3
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Table 7. Atomic coordinates and equivalent isotropic displacement parameters (A2)
for (-)-150. Ueq is defined as one third of the trace of the orthogonalized Ulj tensor.
X y z u eq
S(1) 0.7947(3) 0.70405(13) 0.06118(5) 0.0192(3)
Si(2) 0.5054(4) 1.01360(16) 0.13409(7) 0.0328(5)
0 ( 1 ) 0.9225(8) 0.7780(4) 0.03368(16) 0.0300(12)
0 (2 ) 0.8991(8) 0.6344(4) 0.09357(15) 0.0248(11)
0(3) 0.0409(7) 0.3883(4) 0.03380(15) 0.0230(10)
0(4) -0.0526(8) 0.3146(4) 0.09666(16) 0.0308(12)
0(5) 0.1910(9) 0.4154(4) 0.15746(14) 0.0302(11)
0 (6 ) 0.3825(8) 0.5796(4) 0.13554(15) 0.0276(11)
N (l) 0.6746(9) 0.6072(5) 0.03018(17) 0.0191(11)
N(2) 0.2407(8) 0.4487(4) 0.08846(17) 0.0165(11)
C (l) 0.651(2) 1.1299(8) 0.1671(3) 0.069(4)
C(2) 0.3627(18) 1.0929(9) 0.0911(3) 0.069(3)
C(3) 0.3121(17) 0.9234(8) 0.1663(3) 0.051(2)
C(4) 0.7106(13) 0.9050(5) 0 . 1 1 1 1 (2 ) 0.0291(16)
C(5) 0.6034(10) 0.8030(6) 0.0845(2) 0.0223(13)
C(6 ) 0.5580(9) 0.4996(5) 0.04562(19) 0.0154(12)
C(7) 0.5548(10) 0.4053(5) 0.0104(2) 0.0196(13)
C(8 ) 0.3682(10) 0.3924(5) -0.0066(2) 0.0188(13)
C(9) 0.2045(12) 0.4674(5) 0.0155(2) 0.0232(14)
C(10) 0.3216(10) 0.5227(5) 0.05371(17) 0.0163(12)
C ( l l ) 0.0683(11) 0.3773(5) 0.0755(2) 0.0216(14)
C(12) 0.2762(10) 0.4877(5) 0.1289(2) 0.0240(14)
C(13) 0.1941(16) 0.4504(7) 0.2023(2) 0.0378(19)
C(14) 0.073(2) 0.3443(9) 0.2227(3) 0.063(3)
C(15) 0.0667(19) 0.5693(9) 0.2070(3) 0.061(3)
C(16) 0.4173(15) 0.4625(9) 0.2187(3) 0.049(2)
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Table 8 . Bond lengths [A] and angles [°] for (-)-150.
S ( 1 M X 1 )
S (l)-N (l)
Si(2)—C(2)
Si(2>—C (l)
0 (3 ) -C ( ll)
0 (4 ) -C ( ll)
0(5)-C(13)
N (l) -C ( 6 )
N (2 )-C (ll)
C(4)-C(5)
C(6)-C(10)
C(8)-C(9)
C(13)-C(16)
C(13)-C(14)
1.434(5)
1.626(5)
1.848(10)
1.880(9)
1.340(8)
1.223(8)
1.474(9)
1.463(7)
1.399(8)
1.546(9)
1.539(8)
1.491(9)
1.513(13)
1.526(11)
0 ( l ) -S ( l ) -0 (2 )  117.9(3)
0 (2 )-S (l) -N (l)  108.1(3)
0 (2 )-S (l)-C (5 ) 109.4(3)
C(2)-Si(2)-C(3) 109.0(5)
C (3)-S i(2)-C (l) 111.5(4)
C(3)-Si(2)-C(4) 109.6(4)
C (ll)-0 (3 )-C (9 ) 110.6(5)
C(6 ) -N ( l) -S ( l)  123.1(4)
C( 12)-N (2)-C ( 10) 118.9(5)
C(5)-C(4)-Si(2) 110.5(5)
N (l)-C (6 )-C (7 ) 107.1(5)
C(7)-C(6)-C(10) 102.7(5)
C(7)-C(8)-C(9) 112.1(6)
0(3)-C (9)-C ( 10) 104.8(5)
N(2)-C( 10)-C(6) 112.3(5)
C(6)-C(10)-C(9) 105.9(5)
0 (4 )-C ( ll)-N (2 ) 129.2(6)
0 (6 )-C (12 )-0 (5 ) 126.3(7)
0 (5 )-C ( 12)-N (2) 113.3(6)
0 (5 )-C ( 13)-C( 15) 107.7(7)
0(5)-C (13)-C (14) 102.0(6)
C( 15)-C( 13)-C( 14) 109.0(8)
S (l)-0 (2 ) 1.436(5)
S (l)-C (5) 1.778(6)
Si(2)-C(3) 1.870(9)
Si(2)-C(4) 1.898(7)
0 (3 )-C (9) 1.464(8) 
0(5)-C (12) 1.314(8) 
0(6)-C (12) 1.218(8) 
N(2)-C(12) 1.369(8) 
N(2)-C(10) 1.456(7) 
C(6)-C(7) 1.514(8) 
C(7)-C(8) 1.306(9)
C(9)-C(10) 1.542(8) 
C(13)-C(15) 1.524(12)
0(1 )-S (1)-N (1) 104.7(3)
0(1)-S (1)-C (5) 107.6(3)
N (l)-S (l)-C (5 ) 108.7(3)
C (2)-S i(2)-C (l) 110.0(5)
C(2)-Si(2)-C(4) 109.7(4)
C (l)-S i(2)-C (4) 106.9(5)
C( 12 )-0 (5 )-C ( 13) 120.6(5) 
C( 12)-N (2)-C ( 11) 125.0(5) 
C (ll)-N (2 )-C (10 ) 110.8(5) 
C (4)-C (5)-S (l) 110.9(5)
N (l)-C (6)-C (10) 114.7(5)
C(8)-C(7)-C(6) 112.9(5)
0 (3)-C (9)-C (8) 111.2(5)
C(8)-C(9)-C(10) 104.3(6)
N (2)-C ( 10)-C(9) 102.3(5)
0 (4 ) -C ( ll) -0 (3 )  120.7(6)
0 (3 )-C ( ll) -N (2 )  110.0(5)
0 (6 )-C ( 12)-N(2) 120.3(6)
0(5)-C (13)-C (16) 111.6(7)
C(16)-C(13)-C(15) 112.9(8) 
C(16)-C(13)-C(14) 113.0(8)
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Table 9. Anisotropic displacement parameters (A2) for (-)-150. The anisotropic 
displacement factor exponent takes the form: -27t2[h 2a*2 U n + ...+ 2hka*b*U12]
U 11 U 2 2 U 3 3 U 2 3 U 13 U 12
S(1) 0.0209(7) 0.0087(6) 0.0279(8) 0 .0 0 1 1 (6 ) 0.0017(7) -0.0007(6
Si(2) 0.0522(13) 0.0113(8) 0.0348(11) - 0 .0 0 1 2 ( 8 ) 0.0073(10) 0.0060(9
0 ( 1 ) 0.028(3) 0.016(2) 0.047(3) 0 .0 0 1 (2 ) 0 .0 1 2 (2 ) -0.013(2
0 (2 ) 0.025(3) 0.013(2) 0.036(3) -0.0023(19) -0.009(2) 0.0055(19
0(3) 0.017(2) 0.015(2) 0.037(3) -0.0040(19) -0.003(2) 0.0000(18
0(4) 0.029(3) 0 .0 1 2 (2 ) 0.051(3) 0.006(2) 0 .0 0 2 (2 ) -0.004(2
0(5) 0.044(3) 0.018(2) 0.028(3) 0.0023(19) 0 .0 0 2 (2 ) -0.009(2
0 (6 ) 0.037(3) 0.019(2) 0.027(3) -0.003(2) 0 .0 0 0 (2 ) - 0 .0 1 1 ( 2
N (l) 0.025(3) 0 .0 1 2 (2 ) 0.020(3) 0.003(2) -0.003(2) 0 .0 0 0 ( 2
N(2) 0.009(3) 0.013(2) 0.027(3) 0 .0 0 0 (2 ) 0.003(2) 0.0020(18
C (l) 0.119(11) 0.025(4) 0.064(6) -0.023(4) 0.030(7) -0.038(6
C(2) 0.082(8) 0.050(6) 0.074(7) 0.008(5) 0.005(6) 0.044(6
C(3) 0.062(6) 0.039(5) 0.052(5) -0.001(4) 0.015(5) 0.001(5
C(4) 0.033(4) 0.008(3) 0.047(4) -0.003(3) 0.003(4) -0.005(3
C(5) 0.019(3) 0.012(3) 0.036(4) -0.002(3) 0.001(3) 0.006(3
C(6 ) 0.011(3) 0.006(2) 0.030(3) 0.004(2) 0 .0 0 1 (2 ) - 0 .0 0 2 ( 2
C(7) 0.021(3) 0.014(3) 0.024(3) -0.004(2) 0.000(3) 0.008(2
C(8 ) 0.027(3) 0.008(3) 0.022(3) -0.003(2) 0.001(3) 0.004(2
C(9) 0.033(4) 0.011(3) 0.025(3) 0.003(2) -0.002(3) 0.000(3
C(10) 0.027(3) 0.007(2) 0.015(3) 0 .0 0 1 (2 ) 0.002(3) -0.003(2
C ( l l ) 0.024(3) 0.003(2) 0.038(4) -0.005(2) 0.011(3) 0 .0 0 0 ( 2
C(12) 0.018(3) 0.013(3) 0.041(4) 0.004(3) 0.008(3) 0.002(3
C(13) 0.056(5) 0.024(3) 0.033(4) 0.005(3) 0.014(4) 0.002(4
C(14) 0.106(9) 0.048(5) 0.035(5) 0.010(4) 0.024(6) -0.017(6
C(15) 0.091(9) 0.052(5) 0.039(5) -0.013(4) 0.019(5) 0.016(6
C(16) 0.054(6) 0.050(5) 0.043(5) -0.005(4) -0.010(4) 0.002(4
Table 10. Hydrogen coordinates and isotropic displacement parameters (A2)
for (-)-150.
X y z U
H(1N) 0.632(17) 0.639(10) 0.005(3) 0.080
H(1A) 0.5507 1.1887 0.1792 0.104
H(1B) 0.7528 1.1746 0.1494 0.104
H(1C) 0.7269 1.0872 0.1897 0.104
H(2A) 0.2754 1.1592 0.1029 0.103
H(2B) 0.2724 1.0333 0.0764 0.103
H(2C) 0.4647 1.1281 0.0712 0.103
H(3A) 0.3864 0.8816 0.1893 0.077
H(3B) 0.2426 0.8616 0.1484 0.077
H(3C) 0.2058 0.9796 0.1780 0.077
H(4A) 0.8097 0.9524 0.0932 0.035
H(4B) 0.7926 0.8664 0.1342 0.035
H(5A) 0.5169 0.8417 0.0621 0.027
H(5B) 0.5084 0.7537 0.1027 0.027
H(6 ) 0.6273 0.4645 0.0713 0.018
H(7) 0.6757 0.3602 0.0015 0.024
H(8 ) 0.3400 0.3412 -0.0303 0.023
H(9) 0.1436 0.5329 -0.0031 0.028
H(10) 0.2898 0.6126 0.0574 0 .0 2 0
H(14A) -0.0680 0.3382 0.2099 0.094
H(14B) 0.0584 0.3597 0.2530 0.094
H(14C) 0.1492 0.2666 0.2182 0.094
H(15A) 0.1407 0.6371 0.1928 0.091
H(15B) 0.0505 0.5890 0.2370 0.091
H(15C) -0.0729 0.5581 0.1942 0.091
H(16A) 0.5002 0.3906 0.2099 0.073
H(16B) 0.4148 0.4667 0.2496 0.073
H(16C) 0.4815 0.5380 0.2074 0.073
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Table 11. Torsion angles [°] for (-)-150.
0 ( 1 )-S( 1 )-N ( 1 )-C (6 ) 168.3(5) 0 (2 )-S ( 1 )-N ( 1 )-C (6 ) 41.8(6)
C(5)-S( 1 )-N ( 1 )-C (6 ) -76.9(5) C(2)-Si(2)-C(4)-C(5) -62.6(6)
C(3)-Si(2)-C(4)-C(5) 57.1(6) C( 1)-Si(2)-C(4)-C(5) 178.2(5)
Si(2)-C(4)-C(5)-S( 1) 177.8(3) 0 (  1 )-S( 1 )-C(5)-C(4) -61.8(5)
0(2)-S ( 1 )-C (5)-C(4) 67.5(5) N (l)-S (l)-C (5 )-C (4 ) -174.7(4)
S( 1 )-N ( 1 }-C(6)-C(7) -155.2(4) S( 1 )-N ( 1 )-C (6 )-C ( 10) 91.6(6)
N( 1 )-C (6)-C(7)-C(8) -109.2(6) C( 10)-C(6)-C(7)-C(8) 12.0(7)
C(6)-C(7)-C(8)-C(9) -4 .3(8) C(1 l)-0 (3 )-C (9 )-C (8 ) 103.2(6)
C (ll)-O (3)-C (9)-C (10) - 8 .8 (6 ) C (7)-C (8)-C (9)-0(3) -117.8(6)
C(7)-C(8)-C(9)-C( 10) -5 .4(7) C( 12)-N(2)-C( 10)-C(6) 80.3(6)
C( 11 )-N (2)-C ( 10)-C(6) -124.2(5) C(12)-N(2)-C(10)-C(9) -166.6(5)
C( 11 )-N (2)-C ( 10)-C(9) - 1 1 . 1 (6 ) N (l)-C (6)-C (10)-N (2) -147.7(5)
C(7)-C(6)-C( 10>-N(2) 96.5(5) N (l)-C (6)-C (10)-C (9) 101.4(5)
C(7)-C(6)-C( 10)-C(9) -14.4(6) 0 (3 )-C (9)-C ( 10)-N(2) 1 1 .6 ( 6 )
C (8)-C(9)-C( 10)-N(2) -105.3(5) 0 (3 )-C (9)-C ( 10)-C(6) 129.4(5)
C(8)-C(9)-C( 10)-C(6) 12.5(6) C (9 )-0 (3 )-C (l l)-0 (4 ) -179.9(5)
C (9 )-0 (3 )-C (l 1)-N(2) 2.1(7) C( 12)-N (2)-C ( 11 )-0 (4 ) -17.9(10)
C (10)-N (2 )-C (ll> -0 (4 ) -171.5(6) C( 12)-N(2)-C( 11)-0(3) 159.9(5)
C (10)-N (2)-C (l l) -0 (3 ) 6.2(7) C (13)-0(5)-C (12)-0(6) 8.5(11)
C( 13 )-0 (5 )-C ( 12)-N(2) -173.5(6) C( 11 )-N (2)-C ( 12)-0 (6 ) -155.3(6)
C( 10)-N(2)-C( 12)-0(6) -3.6(9) C (ll)-N (2 )-C (12 )-0 (5 ) 26.5(8)
C( 10)-N (2)-C ( 12 )-0 (5 ) 178.3(5) C( 12)-0(5)-C ( 13)-C( 16) -61.3(9)
C( 12)-0(5)-C ( 13)-C( 15) 63.0(10)i C(12)-0(5)-C(13)-C(14) 177.8(7)
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Table 12. Crystal data and structure refinement for (-)-310.
Identification code 
Chemical formula 
Formula weight 
Temperature 
Radiation, wavelength 
Crystal system, space group 
Unit cell parameters
Cell volume 
Z
Calculated density 
Absorption coefficient p. 
F(000)
Crystal colour and size 
Data collection method
0  range for data collection 
Index ranges
Completeness to 0 = 26.00° 
Reflections collected 
Independent reflections 
Reflections with F~>2a 
Absorption correction 
Min. and max. transmission 
Structure solution 
Refinement method 
Weighting parameters a, b 
Data / restraints / parameters 
Final R indices [ F ^ a ]
R indices (all data) 
Goodness-of-fit on F2  
Absolute structure parameter 
Largest and mean shift/su 
Largest diff. peak and hole
str0187
C2 0H 2 9N 3 O5 S S i 
451.61 
150(2) K
MoKa, 0.71073 A 
monoclinic, P2i
a = 12.4381(10) A a  = 90°
b = 6.2678(5) A |3 = 97.990(2)°
c=  15.0769(12) A y = 90°
1163.98(16) A3 
2
1.289 g/cm3 
0.225 mm- 1  
480
colourless, 0.50 x 0.20 x 0.16 mm3 
Bruker SMART APEX diffractometer 
co rotation with narrow frames 
1.65 to 28.25°
h -15 to 15, k - 8  to 8 ,1 -20  to 14 
98.3 %
6227
4826 (Run = 0.0177)
4731
semi-empirical from equivalents 
0.8957 and 0.9648 
direct methods
Full-matrix least-squares on F2 
0.0574, 0.1856 
482 6 /1 /271
R1 =0.0348, wR2 = 0.0921 
R l=  0.0355, wR2 = 0.0928 
1.023 
0.04(6)
0.000 and 0.000 
0.349 and -0.255 e A '3
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Table 13. Atomic coordinates and equivalent isotropic displacement parameters (A2)
for (-)-310. Ueq is defined as one third of the trace of the orthogonalized U‘j tensor.
X y z u eq
S(1) 0.42020(4) 1.26940(7) 0.87967(3) 0.02652(11)
Si(2) 0.57368(4) 0.79909(8) 0.71157(3) 0.02460(12)
0 ( 1 ) 0.34676(13) 1.4332(2) 0.84217(11) 0.0403(4)
0 (2 ) 0.52451(11) 1.3284(3) 0.92819(10) 0.0417(4)
0(3) 0.11973(11) 0.5624(2) 0.94241(10) 0.0345(3)
0(4) -0.00575(13) 0.5503(3) 0.81970(10) 0.0440(4)
0(5) 0.19758(10) 0.8834(3) 0.70685(9) 0.0380(4)
N (l) 0.35998(11) 1.1361(3) 0.95025(10) 0.0239(3)
N(2) 0.12990(11) 0.8076(3) 0.83683(9) 0.0260(3)
N(3) 0.02074(12) 0.9659(3) 0.71566(11) 0.0293(3)
C (l) 0.63089(17) 1.0121(4) 0.64490(15) 0.0384(5)
C(2) 0.67671(15) 0.5921(4) 0.75149(14) 0.0329(4)
C(3) 0.45622(18) 0.6689(4) 0.64294(17) 0.0460(6)
C(4) 0.52819(14) 0.9275(3) 0.81330(12) 0.0288(4)
C(5) 0.44472(14) 1.1026(3) 0.78890(12) 0.0259(4)
C(6 ) 0.24569(13) 1.0691(3) 0.92851(11) 0.0218(3)
C(7) 0.19284(15) 1.0646(3) 1.01306(13) 0.0293(4)
C(8) 0.17492(16) 0.8681(4) 1.03920(13) 0.0331(4)
C(9) 0.20903(15) 0.7030(3) 0.97685(13) 0.0293(4)
C(10) 0.23321(13) 0.8364(3) 0.89538(11) 0.0224(3)
C ( l l ) 0.07262(16) 0.6328(3) 0.86082(13) 0.0319(4)
C(12) 0.11900(14) 0.8864(3) 0.74684(12) 0.0267(4)
C(13) -0.06321(15) 1.0169(4) 0.77103(14) 0.0366(5)
C(14) 0.00004(15) 1.0331(4) 0.62177(14) 0.0350(5)
C(15) -0.08872(14) 0.9057(4) 0.56602(13) 0.0297(4)
C(16) -0.11977(15) 0.7049(4) 0.59141(14) 0.0325(4)
C(17) -0.20111(16) 0.5931(4) 0.53635(15) 0.0403(5)
C(18) -0.24961(16) 0.6829(5) 0.45656(16) 0.0452(6)
0(19) -0.21650(16) 0.8798(5) 0.43057(15) 0.0449(6)
C(20) -0.13749(15) 0.9935(4) 0.48497(14) 0.0355(5)
Table 14. Bond lengths [A] and angles [°] for (-)-310.
S d H X l) 1.4366(16)
S (l)-N (l) 1.6164(16)
Si(2)-C(3) 1.857(2)
Si(2>—C (l) 1.870(2)
0 (3 )-C (ll) 1.360(2)
0 (4 )-C (ll) 1.197(2)
N(l>-C(6 ) 1.475(2)
N(2)-C(12) 1.432(2)
N(3)-C(12) 1.343(2)
N(3)-C(14) 1.465(2)
C(6)-C(7) 1.514(2)
C(7)-C(8) 1.322(3)
C(9)-C(10) 1.549(3)
C(15)-C(16) 1.385(3)
C(16)-C(17) 1.404(3)
C(18)-C(19) 1.375(4)
0 ( l) -S (l) -0 (2 ) 119.54(10)
0 (2 )-S (l)-N (l) 105.32(9)
0 (2 )-S (l)-C (5) 107.54(9)
C(3)-Si(2)-C(2) 109.05(11)
C(2)-Si(2)-C(l) 112.00(9)
C(2)-Si(2)-C(4) 107.75(9)
C (ll)-0 (3 )-C (9 ) 109.73(15)
C (ll)-N (2 )-C (12) 122.46(15)
C(12)-N(2)-C(10) 119.19(14)
C( 12)-N(3)-C( 14) 118.30(16)
C(5)-C(4)-Si(2) 112.52(13)
N (l)-C (6)-C (7) 109.64(14)
C(7)-C(6)-C(10) 102.67(15)
C(7)-C(8)-C(9) 112.48(17)
O(3)-C(9)-C(10) 105.45(14)
N(2)-C(10)-C(6) 110.60(14)
C(6)-C(10)-C(9) 105.98(14)
0 (4 )-C (l 1)-N(2) 128.24(19)
0(5)-C(12)-N(3) 125.90(17)
N(3)-C(12)-N(2) 114.92(16)
C( 16)-C( 15)-C(20) 119.7(2)
C(20)-C( 15 )-C( 14) 118.0(2)
C(18)-C(17)-C(16) 1 2 0 . 1 (2 )
C(18)-C(19)-C(20) 1 2 0 .6 (2 )
S (l)-0 (2 ) 1.4461(1
S(l)-C(5) 1.7819(1
Si(2)-C(2) 1.864(2)
Si(2)-C(4) 1.8872(1
0(3)-C(9) 1.456(2)
0(5)-C(12) 1.218(2)
N (2 )-C (ll) 1.382(2)
N(2)-C(10) 1.465(2)
N(3)-C(13) 1.460(3)
C(4)-C(5) 1.520(3)
C(6)-C(10) 1.542(3)
C(8)-C(9) 1.498(3)
C(14)-C(15) 1.518(3)
C(15)-C(20) 1.399(3)
C(17)-C(18) 1.388(3)
C(19)-C(20) 1.387(3)
0(1)-S(1)-N(1) 107.51(8)
0(1)-S(1)-C(5) 106.52(9)
N (l)-S (l)-C (5) 110.29(9)
C(3)-Si(2)-C(l) 110.04(11)
C(3)-Si(2)-C(4) 109.80(10)
C(l)-Si(2)-C(4) 108.16(10)
C(6 )-N (l)-S (l) 121.43(12)
C (ll)-N (2)-C (10) 112.37(15)
C(12)-N(3)-C(13) 124.71(16)
C(13)-N(3)-C(14) 116.48(17)
C(4)-C(5)-S(l) 114.94(13)
N(l)-C(6)-C(10) 113.07(14)
C(8)-C(7)-C(6) 112.29(18)
0(3)-C(9)-C(8) 111.91(15)
C(8)-C(9)-C(10) 103.17(16)
N(2)-C(10)-C(9) 99.24(13)
0 (4 )-C (l l)-0 (3 ) 123.05(19)
0 (3 )-C (l 1)-N(2) 108.71(16)
0(5)-C(12)-N(2) 119.13(16)
N(3)-C(14)-C(15) 113.60(17)
C( 16)-C( 15)-C( 14) 122.27(18)
C(15)-C(16)-C(17) 119.7(2)
C(19)-C(18)-C(17) 1 2 0 .0 (2 )
C( 19)-C(20)-C( 15) 1 2 0 .0 (2 )
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Table 15. Anisotropic displacement parameters (A2) for (-)-310. The anisotropic 
displacement factor exponent takes the form: -27t2[h2a*2U n + ...+ 2hka*b*U12]
U 11 U 2 2 U 33 U 2 3 U 13 U 12
S (l) 0.0309(2)
-0.00312(17)
0 .0 2 0 0 (2 ) 0.0309(2) -0.00339(17) 0.01194(16)
Si(2) 0.0235(2)
0.00070(19)
0.0242(3) 0.0266(2) -0.0028(2) 0.00506(17)
0 ( 1 ) 0.0558(9) 0.0238(7) 0.0460(8) 0.0074(7) 0.0233(7) 0.0079(7)
0 (2 ) 0.0361(7) 0.0449(10) 0.0470(8) -0.0182(7) 0.0150(6) -0.0186(7)
0(3 ) 0.0418(7) 0.0269(7) 0.0355(7) 0.0053(6) 0.0080(6) -0.0090(6)
0(4 ) 0.0474(8) 0.0438(9) 0.0411(8) 0.0009(8) 0.0074(7) -0.0229(8)
0 (5 ) 0.0283(6) 0.0566(10) 0.0307(7) 0.0094(7) 0.0096(6) 0.0029(7)
N (l) 0.0223(6) 0.0269(8) 0.0228(7) 0.0008(6) 0.0040(5) -0.0016(6)
N(2) 0.0256(6) 0.0287(8) 0.0241(7) 0 .0 0 1 0 (6 ) 0.0053(5) -0.0069(6)
N(3) 0.0228(7) 0.0351(9) 0.0300(8) 0.0004(7) 0.0035(6) -0.0066(6)
C (l) 0.0420(11) 0.0335(11) 0.0443(12) 0.0056(9) 0.0221(9) 0.0061(9)
C(2) 0.0303(9) 0.0328(11) 0.0367(10) 0.0027(9) 0.0080(8) 0.0046(8)
C(3) 0.0414(11) 
-0.0015(10)
0.0414(13) 0.0501(13) -0.0094(11) - 0 .0 1 1 0 ( 1 0 )
C(4) 0.0278(8) 0.0319(10) 0.0274(9) -0.0018(8) 0.0064(7) 0.0049(8)
C(5) 0.0294(8) 0.0245(9) 0.0253(9) -0.0017(7) 0.0086(7) 0.0015(7)
C(6 ) 0.0207(7) 0.0216(9) 0.0234(8) -0.0003(7) 0.0043(6) 0.0013(6)
C(7) 0.0301(9) 0.0311(10) 0.0282(9) -0.0038(8) 0.0094(7) 0 .0 0 1 1 (8 )
C(8 ) 0.0343(9) 0.0429(12) 0.0238(8) 0.0038(8) 0.0105(8) -0.0017(8)
C(9) 0.0313(9) 0.0255(9) 0.0313(10) 0.0061(7) 0.0050(8) -0.0017(7)
C(10) 0.0225(7) 0.0234(9) 0.0219(8) 0.0005(6) 0.0052(6) -0.0003(6)
C ( l l ) 0.0360(9) 0.0309(10) 0.0310(10) 0.0005(8) 0.0123(8) -0.0071(8)
C(12) 0.0276(8) 0.0269(9) 0.0259(8) -0.0014(7) 0.0043(7) -0.0048(7)
C(13) 0.0293(9) 0.0409(12) 0.0399(11) -0.0089(9) 0.0059(8) -0.0009(9)
C(14) 0.0279(9) 0.0401(12) 0.0355(10) 0.0087(9) -0.0003(8) -0.0090(8)
C(15) 0.0204(8) 0.0378(11) 0.0310(9) - 0 .0 0 2 2 ( 8 ) 0.0043(7) 0 ,0 0 1 2 (8 )
C(16) 0.0293(9) 0.0370(11) 0.0326(10) -0.0048(8) 0.0093(8) -0.0030(8)
C(17) 0.0348(10) 0.0443(13) 0.0447(12) - 0 .0 2 0 1 ( 1 0 ) 0.0163(9) -0.0077(9)
C(18) 0.0243(9) 
- 0 .0 0 2 2 ( 1 0 )
0.0683(17) 0.0429(12) -0.0284(12) 0.0042(9)
C(19) 0.0276(9) 0.0691(17) 0.0364(11) -0.0119(11) -0.0014(8) 0.0156(11)
C(20) 0.0258(9) 0.0467(13) 0.0342(10) -0.0014(9) 0.0046(8) 0.0082(8)
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Table 16. Hydrogen coordinates and isotropic displacement parameters (A2)
for (-)-310.
H(1N)
H(1A)
H(1B)
H(1C)
H(2A)
H(2B)
H(2C)
H(3A)
H(3B)
H(3C)
H(4A)
H(4B)
H(5A)
H(5B)
H(6 A)
H(7A)
H (8 A)
H(9A)
H(10A)
H(13A)
H(13B)
H(13C)
H(14A)
H(14B)
H(16A)
H(17A)
H(18A)
H(19A)
H(20A)
x
0.3962
0.6550
0.6928
0.5749
0.7018
0.6441
0.7385
0.4803
0.4005
0.4260
0.4966
0.5921
0.3753
0.4694
0.2056
0.1746
0.1439
0.2742
0.2973
-0.0410
-0.1315
-0.0734
0.0680
-0.0206
-0.0861
-0.2230
-0.3057
-0.2480
-0.1165
y
1.1028
0.9486
1.0798
1.1194
0.5226
0.4854
0.6594
0.6026
0.7761
0.5594
0.8169
0.9887
1.0355
1.1931
1.1681
1.1889
0.8351
0.6214
0.7833
0.9645
0.9486
1.1719
1.0189
1.1858
0.6432
0.4559
0.6084
0.9384
1.1311
z
1.0028
0.5916
0.6816
0.6265
0.6999
0.7871
0.7885
0.5902
0.6237
0.6787
0.8488
0.8512
0.7631
0.7418
0.8835
1.0438
1.0917
1.0047
0.8684
0.8321
0.7458
0.7724
0.5950
0.6194
0.6458
0.5537
0.4199
0.3749
0.4672
U
0.029
0.058
0.058
0.058
0.049
0.049
0.049
0.069
0.069
0.069
0.035
0.035
0.031
0.031
0.026
0.035
0.040
0.035
0.027
0.055
0.055
0.055
0.042
0.042
0.039
0.048
0.054
0.054
0.043
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Table 17. Torsion angles [°] for (-)-310.
0(1)-S(1)-N(1)-C(6) 44.42(17) 0(2)-S ( 1 )-N ( 1 )-C (6 ) 172.91(14)
C(5)-S( 1 )-N ( 1 )-C (6 ) -71.34(16) C(3)-Si(2)-C(4)-C(5) -62.20(18)
C(2)-Si(2)-C(4)-C(5) 179.15(14) C( 1 )-Si(2)-C(4)-C(5) 57.89(16)
Si(2)-C(4)-C(5)-S( 1) -166.84(10) 0 (  1 )-S( 1 )-C(5)-C(4) 175.38(14)
0(2)-S( 1 )-C(5)-C(4) 46.10(17) N (l)-S (l)-C (5)-C (4 ) -68.25(16)
S( 1 )-N ( 1 )-C(6)-C(7) -148.33(14) S (l)-N (l)-C (6)-C (10) 97.77(16)
N(1)^C(6)-C(7)-C(8) -107.98(19) C(10)-C(6)-C(7)-C(8) 12.5(2)
C(6)-C(7)-C(8)-C(9) -1.5(2) C(1 l)-0 (3)-C (9)-C (8) 96.15(19)
C (ll)-O (3)-C (9)-C (10) -15.3(2) C(7)-C(8)-C(9)-0(3) -123.01(19)
C(7)-C(8)-C(9>-C( 10) - 1 0 . 1 (2 ) C( 11)-N(2)-C( 10)-C(6) -130.59(16)
C( 12)-N(2)-C( 10)-C(6) 75.9(2) C( 11 )-N (2)-C( 10)-C(9) -19.54(19)
C( 12)-N(2)-C( 10)-C(9) -173.04(16) N(l)-C (6)-C(10)-N(2) -153.15(14)
C(7)-C(6)-C( 10)-N(2) 88.80(15) N(l)-C(6)-C(10)-C(9) 100.22(16)
C(7)-C(6)-C( 10)-C(9) -17.83(17) O(3)-C(9)-C(10)-N(2) 20.04(18)
C(8)-C(9)-C(10)-N(2) -97.49(15) 0(3)-C (9)-C ( 10)-C(6) 134.71(14)
C(8)-C(9)-C( 10>-C(6) 17.18(18) C (9)-0(3)-C ( 11 )-0 (4 ) -176.8(2)
C (9)-0(3)-C ( 11 )-N(2) 3.2(2) C( 12)-N(2)-C( 11 )-0 (4 ) -16.1(3)
C (1 0 )-N (2 H :(ll)-O (4 ) -168.6(2) C( 12)-N(2)-C( 11 >-0(3) 164.02(16)
C( 10)-N(2)-C( 11 >-0(3) 11.5(2) C(13)-N(3)-C(12)-0(5) -163.8(2)
C(14)-N(3)-C(12)-0(5) 7.8(3) C(13)-N(3)-C(12)-N(2) 13.5(3)
C( 14)-N(3)-C( 12)-N(2) -174.91(18) C( 11 )-N (2)-C( 12)-0(5) -117.0(2)
C(10)-N(2)-C(12)-O(5) 33.7(3) C(11)-N(2)-C(12)-N(3) 65.5(2)
C( 10)-N(2)-C( 12)-N(3) -143.79(17) C( 12)-N(3)-C( 14)-C( 15) 116.89(19)
C( 13)-N(3)-C( 14)-C( 15) -70.8(2) N(3 )-C( 14)-C( 15 )-C( 16) -21.0(3)
N(3)-C(14)-C(15)-C(20) 161.12(18) C(20)-C( 15)-C( 16)-C( 17) —1.1(3)
C(14)-C(15)-C(16)-C(17) -178.93(18) C(15)-C(16)-C(17)-C(18) 0.4(3)
C( 16)-C( 17)-C( 18)-C( 19) 1.3(3) C( 17)-C( 18)-C( 19)-C(20) -2.3(3)
C( 18)-C( 19)-C(20)-C( 15) 1.7(3) C( 16)-C( 15)-C(20)-C( 19) 0.0(3)
C( 14)-C( 15)-C(20)-C( 19) 177.99(18)
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Appendix 2
1H, 13C, 2D-NMR, HRMS and IR spectra of all 
intermediates discussed in this thesis
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Instrument Resolution: 7,500
Theoretical Mass (C16H28N206SSi):  427 .13349  (M+Na) 
Measured Mass: 427.13286  
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02111203: Scan Avg 336-363 (56.00 - 60.50 min) - Back
Base: 228.00 Int: 468353 Sample: VG 70-SE Positive Ion FAB
75%
70%-
65%
60%-
55%
50%-
45%
40%
35%
30%
25%
20% -
15%
10% -
5%
0% —
130
160
168
15
196
218
150 200
m/z
205
212
Sample: IV-MD-159 
Instrument Resolution: 7,500
Theoretical Mass (C8H12LiN02Si): 212.0695022 (M+Na) 
Measured Mass: 212.0693472 
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Instrument Resolution: 8 ,000
Theoretical Mass (C24H39N307SSi2): 569.20471
Measured Mass: 569 .20520
Error: 0.9ppm
470
NBoc
TMS
569
635  
n i i . i .[.  i,
500 idoo*
1 '
m/z
?1
1250
III-md-84
CDC13, 298 K
NBoc
j l !
“ i— i— i— i— i— i— i— r -i—i—i—i—i—i—i—r-
ppm
III-md-84
CDC13, 298 K
p - f °
X ^^N B oc  
TMS V_/
T r™ ™ T inri 'itt»"i rvn i i i rn fm ri i rnrrj T T T T T r m r j
70 60 50 40 30 20 10 0 ppm
III-md-84
CDC13, 298 K
COSY
NBoc
TMS
ppm
- 1
- 1
- 9
10 9 8 7 6 2 15 4 3 ppm
III-md-84
CDC13, 298 K
HMQC
NBoc
TMS
ppm
10
20
30
40
50
60
70
80
90
- 1 0 0
- 1 1 0
- 1 2 0
- 1 3 0
- 1 4 0
019 8 7 6 24 ppm
I I I - m d - 8 4  
C D C 13, 2 9 8  K 
HMBC
NBoc
TMS
NH NH
ppm
oDo
202 0 -
4 0 - 40
6 0 - 60
8 0 - 80
1 0 0 - - 1 0 0
1 2 0 - - 1 2 0
1 4 0 - - 1 4 0
1 6 0 - - 1 6 0
10 9 8 7 6 ppm
PERKIN ELMER
6 4 .0 1 -
% T
3500 3000 2500 2000
0 3 /0 2 /2 6  13: 12
X: 16 scans, 16 .0cm -l, apod none, f l a t
1500
— i—
1 0 0 0
 [—
cnr1 500
100%
90%
80%
7 0 %
60%
50%
40%
30%
20%
10%
0%
7e+ Sample: VG70-SE Positive Ion FAB
16
X
306
1 0 0 200 300
Sample: lll-MD-84 
Instrument Resolution: 8,000
Theoretical Mass (C19H27N305Si): 406.17981 (M+H) 
Measured Mass: 406.17997 
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Sample: lll-MD-96a 
Instrument Resolution: 8,000
Theoretical M ass (C18H27N304Si): 378 .18489  (M+H) 
Measured Mass: 378.18492  
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Instrument Resolution: 8,000
Theoretical Mass (C18H27N304Si): 378.18489 (M+H) 
Measured Mass: 378.18418 
Error: 1.9ppm
O
TMS
^ X ^ N H B o c
755
■ 6§5  1 7f
III-md-97
MeOD, 298 K
O
NHBoc
NH
' 1 ' ‘ ' 1 I ' 1 ' ‘ I ' ' ‘ ' I 1 ' ■' ■ | - . -  r ■ r—. |
7.5 7.0 6.5 6.0 5.5 5.0 4.5
',_'l 1 ' 1 ' T  1 1 1 ' l    -- ,'' 1 ' ' , ' 1 1 ' I ' ' 1 ' I 1 11 1 i ' ' ' ‘ I
4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
III-md-97
MeOD, 298 K
NHBoc
NH
X
‘ ■ I................................I ...................................l'1"'"1"'1 ' "  ' I ’ I 1 1 r "  I '■' t | -r l" i i —................I , , , , , , , ,  , j ”'-1n-r-r-r—i-n-j
80 70 60' 50 40 30 20 10 ppm
r NHBoc
AjJl
o o
& 0
0
JP
0
ppm
■ 1 . 5  
- 2 . 0  
j- 2 . 5 
- 3 . 0
- 3 . 5
I
- 4 . 0
- 4 . 5
r
- 5 . 0
- 5 . 5
- 6 . 0
- 6 . 5
1 i ■ ■ ■ ■ i 1 ■ 1 ■ i 1 ■ 1 1 i " ' 1 11 i r ■ ■ 1 1 i '■ ■■ ■ ■ i • ■ ■ ■ i ■ ■ • ■ i
5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 ppm
III-md-97
MeOD, 298 K
HMQC
O
NHBoc
NH
ppm
10
20
30
40
50
60
7 0
80
90
- 1 0 0
-110
- 1 2 0
- 1 3 0
[ -1 4 0
6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 ppm
^rro
S3
OQ
ss
NHBoc
NH
40.44 — —  —t------------ ~1----------------1
4000 3500 3000 2500 2000
  T “
cm"1 500
— j
1500 1000
100%
90%
80%
70°/c
60%
50%
40%
30%
20%
1 0 %l
0%
100
166
21
l2Q7
200
322
300
ositive Ion FAB
Sample: lll-MD-97 
Instrument Resolution: 8,000  
378 Theoretical Mass (C15H18BrN304): 384 .05588 (M+H) 
Measured Mass: 384 .05552  
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02111203: Scan 290 (48.33 min) - Back
Base: 136.00 Int: 776043 Sample: VG ;70-SE Positive Ion FAB
105%
Sample: IV-MD-148
Instrument Resolution: 7,500
Theoretical Mass (C9H10CINO): 184.0529126 (M+H)
Measured Mass: 184.0525095
Error: 2.2ppm
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Sample: VG-70SE Positive Cl-Methanease: 40. >e+i
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Sample IV-M D-28  
Positive Electrospray 
Theoretical Mass 639.20223 [M+Na] 
Measured Mass 639.21130 
Error 2.14 ppm
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Theoretical Mass 427.21653 (M + II)  
Measured Mass 427.21697 
Error 1.02 ppm
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02090903: Scan Ava 261-263 (60.72 - 61.18 min
Base: 166.00 Int: 282298 Sample: VG-70SE Ele>ctron Impact
90%
Sample: IV-MD-16a
Instrument Resolution: 6,000
Theoretical Mass (C22H28N403S): 424.19306
Measured Mass: 424.19447
Error: 3.34ppni
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02100104: Scan Avg 47-50 (7.83 - 8.33 min) - Back
Base: 424.00 Int: 2.20841e+006 Sample: VG 70-SE Positive Ion FAB
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Sample: IV-MD-177b 
Theoretical mass 588.89287 (M+H) 
Measured mass 588.89087 
Error 3.40 ppm
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03290404: Scan 200 (36.62 min) - Back
Base: 154.00 Int: 4.6/31 e+006 Sample: VG 70-SE Positive Ion FAB
100%--,
Sample: V-MD-104 
Theoretical Mass: 353.16136 (M+H) 
Measured Mass: 353.16339 (M+H) 
Error: 5.77 ppm
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Sample V-MD-11
Theoretical mass 263.11387 (M+H) 
Measured mass 263.11333 
Error 2.06 ppm
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02130504: Scan 13 (2.83 min) - Back
Base: 58.00 Int: 5 85e+006 Sample: VG 70-SE Positive Cl-Methane
105%
Sample: IV-MD-172
Instrument Resolution: 7,500
Theoretical Mass (C12H13BrN403): 341.0249214
Measured Mass: 341.0251115
Error: 0.55ppm
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